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Chapter 1. Introduction
IMPACT OF DISEASES IN AQUACUTURE
Aquaculture is of major importance in the production of food fish. In theyear
1998, over 30 million metric tons of fish and shellfish were produced worldwide. It has
been estimated that thirty-one percent of the total fish consumed worldwide is farm raised
(Johnson, 2000). In most cases, the production of fish and shellfishuses intensive
aquaculture techniques, which can result in overcrowding, sub-optimal water quality and
stressful conditions. All of these factors can result in enhanced disease transmission and
higher mortality or morbidity during a disease outbreak (Plumb, 1994). Estimatesare
that 10% of total aquaculture production worldwide is lost due to infectious disease
(Leong and Fryer, 1993). In one example, the Chinese shrimp aquaculture industry
reached annual production of2lO,000 metric tons in 1992. Disease outbreaks beginning
in 1993 reduced production by two-thirds annually. The industry is recovering following
changes in husbandry practices and development of new aquaculture species
(Anonymous, 2001).
Bacterial, viral and parasitic diseases also have a major impacton salmonid
aquaculture. The U.S. Trout Farmers Association has released production figures that
show that commercial trout production declined in sales from $78 million in 1997to
$73.5 million in 1998 and losses increased from 6.79 million lbs to 7.84 million lbs inthat period. In 1998, 84% of the trout losses were due to disease (Harvey, 1999). Many
viral infections including infectious pancreatic necrosis virus (IPNV) and infectious
salmon anemia virus (ISAV), and bacterial diseases caused by Aeromonas salmon icida
and Vibrio spp. have had a major impact on Atlantic salmon culture (Evelyn et al., 1998).
For example, in 1995 IPNV disease was observed at 61% of Atlantic salmon farms in
Norway and total losses due to IPNV were estimated at $US 60 million (Christie, 1997).
ISAV has recently caused serious problems for Atlantic salmon aquaculture in Norway,
Scotland, New Brunswick Canada, and Maine (Anonymous, 1999; Anonymous, 2000;
Charron, 2001; Solsletten, 2001). There are numerous other disease problems in
salmonid fisheries and aquaculture (Kent and Poppe, 1998). The work presented in this
thesis focuses mainly on infectious hematopoietic necrosis virus (IHNV) and Yersinia
ruckeri (the causative agent of enteric redmouth, or ERM). Where possible, discussion
will be limited to these pathogens but other examples will be used where appropriate.
Infectious hematopoietic necrosis virus
IHNV is one of the most important diseases of salmon and trout. Each year
between 2 and 20 million fish die as a result of IHNV infection in the Columbia River
basin alone (H.M. Engelking, personal communication). IHNV is a rhabdovirus that
produces a severe hemorrhagic disease in young salmonid fish including Atlantic salmon
(Salmo salar), rainbow trout (Oncorhvnchus mykiss), and Chinook salmon (0.
tshal4ytscha). Adult fish returning to spawn can be infected with IHNV and can spread
the infection by vertical transmission. IHNV infection of young fish, especially fry and
alevins, results in massive destruction of the hematopoietic tissue, exophthalmia, andpetechial hemorrhages that appear on the surface of the affected fish (Bootland and
Leong, 1999). In severe outbreaks, more than 90% of the fish ina pond will die within a
two-to-three week period. The only control strategy available to farmersnow is
avoidance by destroying diseased animals and disinfectingeggs from potential carrier
fish. In the state of Oregon, annual outbreaks of infectious hematopoietic necrosis virus
(IHNV) occur in the feral populations of kokanee salmon (landlocked 0.nerka)at Lake
Billy Chinook (H. M. Engelking, personal communication). In theyear 2001, IHNV
infection was detected in returning adult steelhead (oceanrun 0. mykiss) at the Alsea
Hatchery (Oregon Department of Fish and Wildlife 2000). Recently II-INV has becomea
problem in Atlantic salmon farms on Vancouver Island, British Columbia. In the mid
1990's, losses at some farms were as high as 20% in large fish (1-3 kg) and 80% in
smaller fish (100-300 g) (Traxier et al., 1999).
Yersinia ruckeri
Y. ruckeri isthe causative agent of enteric redmouth disease (ERM), primarilya
disease of salmon and rainbow trout. This pathogencan be a recurrent problem in
hatcheries. Outbreaks of ERM tend to occur under conditions of low dissolvedoxygen,
overcrowding, and elevated water temperatures (15-18 C). This diseasecan be
particularly devastating economically because mortalitiesoccur in market-sized fish
(Ellis, 1988b; Plumb, 1994). In the 1970's, annual outbreaks in Idaho's Hagerman valley
had a severe impact on rainbow trout aquaculture. Annual cost due to disease exceeded
$US 2.5 million (Busch, 1978). In Oregon state hatcheries, outbreaks of Y.ruckerioccur
sporadically. Oak Springs hatchery historically experienced outbreaks of ERM despiteannual vaccination for the disease. In the year 2000,an outbreak was detected in Spring
Chinook(0. tshai'tytscha)at Gnat Creek hatchery (R. Holt personal communication).
ROLE OF VACCINES IN AQUACULTURE
Vaccines are clearly needed in aquaculture to preventor reduce the devastating
losses that can occur due to disease. There are, however,some practical limitations. The
main routes of administration of fish vaccinesare immersion, injection and oral (fed)
vaccination. Generally, immersion or oral vaccination require less investment oflabor;
however, they can be cost prohibitive for larger fish due to the largeamount of vaccine
required. Many diseases affect very early life stages of the animal, when the cash value
of the animal is relatively low. In these cases, the vaccine itselfmust be cheap and easy
to administer in order to be cost effective. Immersion vaccination often inducesa greater
immune response than oral vaccination. Immersion dosage is alsomore easily controlled
than oral vaccine dosage; however, the fish are exposed tomore handling stress during
immersion vaccination. Injection vaccination is the most labor-intensive method, and
induces the greatest stress on the fish. Damage from injectionmay also provide a route
of entry for other disease agents. However, inmany cases injection provides better and
longer lasting immunity than the other routes of vaccination. Injectioncan be cost
effective for high value or larger fish. The economy of injectable vaccinescan also be
increased by using a multivalent vaccine, where a single vaccination provides long
lasting protection against several diseases (Home, 1997; Vinitnantharatet al., 1999). An
important point to remember for any vaccination, humanor veterinary, is that vaccination
does not provide 100% protection from disease. Protection of populations fromdiseaserelies on "herd immunity" where susceptible individuals are so rare in the population that
the chain of transmission is disrupted (White and Fenner, 1986). The protective
immunity generated by vaccination can also be short-lived and booster vaccinations may
be required to maintain an acceptable level of protection from disease (Brackett and
Karreman, 1998). For example, 4-gram rainbow trout vaccinated against Y. ruckeri retain
protection for at least 300 days but rearing to market size may be much longer for some
fish species. Re-vaccination would be required to maintain protection (Ellis, 1 988a).
Currently vaccines are available for only a handful of fish diseases. For many
viral diseases, the only control measure available is avoidance. The majority of bacterial
diseases are treated with antibiotics. In an aquaculture setting this presents the possibility
of creating antibiotic resistant strains of the pathogen, as well as generating resistant
strains of commensal or environmental bacteria. As of July 1998, two companies in the
U.S. were licensed to produce killed bacterin vaccines for aquaculture (USDA Federal
Aquaculture Brief 98-6, 1998). The vaccines listed as approved biologics for fish include
killed bacterin vaccines for Aeromonas salmon icida, Edwardsiella ictaluri, Vibrio
anguillarum, V. ordalii, and 1'. ruckeri. In Canadian Atlantic salmon production,
injectable vaccines are used to protect against A. salmonicida and Vibrio spp. (Brackett
and Karreman, 1998). Atlantic salmon hatcheries in Norway use vaccines against
infectious pancreatic necrosis virus (IPNV), furunculosis (caused by A. salmonicida), and
Vibrio spp. Vaccination against A. salnionicida has greatly reduced the need for
antibiotic treatment in Norwegian aquaculture. In 1990, before introduction of the
injectable A. salmonicida vaccine, approximately 231 grams of antibiotics were used per
kilogram of salmonids produced at farms with A. salmonicida outbreaks. By 1994, fouryears after introduction of the vaccine, antibiotic usage in Norway had dropped to 6.4
grams per kilogram of salmonid production (Vinitnantharat et al., 1999). A multi-valent
vaccine that combines killed bacterins from 3 different bacteria and partially purified IPN
proteins (produced in E. coli) has been shown to reduce mortality from IPNV in field
trials at Norwegian Atlantic salmon farms (Christie, 1997).
Infectious hematopoietic necrosis virus vaccines
Currently there is no commercially available vaccine for IHNV. Many different
experimental vaccines have been tested in laboratory settings and these will be discussed
later in this chapter.
Yersinia ruckerivaccines
h 1976, a vaccine for ERM became the first licensed fish vaccine in the US. This
vaccine consisted of formalin killed Y.ruckeri.Field trials of the vaccine showed up to
89% reduction in the number of mortalities due to ERM. Vaccination also reduced the
need for medication and increased feed conversion rates. Overall, the benefits from
vaccination outweigh the costs (Home and Robertson, 1987; Tebbit et al., 1981). Theuse
of this type of vaccine has greatly reduced the impact of ERM worldwide (Plumb, 1994).
In the state of Oregon, Oak Springs hatchery historically experienced outbreaks of ERM
despite annual vaccination for the disease. Eventually, vaccination in conjunction with
other control measures halted the annual occurrence of ERM at Oak Springs. In theyear
2000, an outbreak was detected in Spring Chinook (0.tshaytscha)at Gnat Creek7
hatchery. This year (2001) the hatchery vaccinated against ERM and has not experienced
an outbreak (R. Holt personal communication).
VACCINES
There are three major types of vaccines against microbial pathogens; killed whole
microorganisms, live attenuated microorganisms, and componentor purified subunit
vaccines.
The first vaccine, Edward Jenner's 1798 smallpox vaccine, wasa live attenuated
vaccine. Pus from cowpox lesions was used to induce the relatively mildcowpox disease
in healthy individuals, thus protecting the patient from smallpox.
Louis Pasteur developed the first inactivated vaccine. Pasteur used dried and
homogenized nerve tissue from rabbits infected with rabies virus to protect dogs, and
later humans, against rabies virus infection.
The diphtheria and tetanus toxoid vaccines are examples of component vaccines.
Injection of formaldehyde-inactivated toxin generates a protective antibodyresponse in
patients. The advent of recombinant DNA technology has providednew methods of
developing and producing specialized types of subunit vaccines including recombinant
protein subunit vaccines and plasmid DNA based vaccines.
Recenfly, some of these methods have been used in combination to create novel
bivalent or multivalent vaccines. For example, an attenuated bacterial vaccine straincan
be engineered to produce and deliver a recombinant protein antigen froma different[,]
pathogen (Noonan et al., 1995). Attenuated bacteria can also be used to deliver a plasmid
DNA vaccine to animal cells (Sizemore et al., 1995).
Most of these types of vaccines have been developed and tested for various
diseases of fish. In the following section, I will discuss these different types of vaccines,
focusing on IHNV and other diseases of fish where possible.
Killed pathogens as vaccines
Killed bacterin vaccines have proven effective against a number of bacterial fish
pathogens. Early successes with killed Y.ruckeriand V. anguillaruni in the 1970's led to
the first commercially available vaccines for aquaculture, approved by the USDA in 1976
(Evelyn, 1997). Both of these vaccines are highly effective when administered by a
variety of methods including bath immersion, oral feeding, or injection (Amend and
Johnson, 1981; Johnson and Amend, 1983). Killed bacterin vaccines for A. salmonicida
are also commercially available. These vaccines are most effective when administered
by injection with an adjuvant (Evelyn et al., 1998). There are no commercially available
killed virus vaccines. However, inactivated virus preparations have proven to be
effective in the case of IHNV and IPNV (Amend, 1976; Dixon and Hill, 1983). As with
the A. salmonicida vaccine, the killed virus preparations must be injected to provide
adequate protection from disease. Amend (1976) injected beta-propiolactone inactivated
IHNV into rainbow trout. Cumulative mortality in the vaccinated groups averaged 4%,
while unvaccinated fish exhibited 70% cumulative mortality (Amend, 1976). Immersion
vaccination with inactivated IPNV did not generate a strong antibody response, however,
when administered by injection, formalin inactivated IPNV generated high titers of virusneutralizing antibody in rainbow trout. Fish injected with formalin-inactivatedIPNV
were also protected from viral challenge (Dixon and Hill, 1983). Despite their efficacy,
killed injectable IHNV and IPNV vaccinesare not economical for most aquaculture
operations due to the high cost of production and high labor costs associated with
injection vaccines. Also, mortalities due to IHNV and IPNV tendto occur in small, low
value fish (less than 1 gram).
Live attenuated organisms as vaccines
Live attenuated vaccines are typically the most efficacious because they mimic
the natural course of infection. A natural route of administration and subclinicalinfection
with the organism can fully mobilize the immune system including bothmucosal and
systemic antibody, as well as cell-mediated immuneresponses. The Sabin poliomyelitis
vaccine is an attenuated viral vaccine that has beenvery successful in human medicine.
However, this vaccine highlights many of the drawbacks of live attenuated vaccines.The
live vaccine is produced in cultured cells,a costly method for vaccine production. In
addition, this means of production, which requires animal derived materials,can lead to
the accidental inclusion of other disease agents (White and Fenner, 1986). Reversionto
virulence or residual virulence has also been documented. hi the United States,a very
small number of children (1 case per 2.4 million doses) receiving the oral attenuated
poliomyelitis vaccine develop paralytic polio (CDC, 1999). Arecent outbreak of polio in
Haiti was attributed to reversion of the oral poliovirus vaccine. The liveattenuated virus
can circulate via fecal-oral transmission in populations with low vaccination rates. In the
Haitian outbreak, the virus probably circulated in the population for about 2years before10
regaining virulence (CDC, 2000). Ideally, to assure the safety and efficacy of an
attenuated vaccine the nature of the attenuation should be irreversible, and severe enough
to allow the organism to replicate only to the point where a protective immune response
is generated.
Attenuated viral vaccines have been examined in fish. McMichael (1974)
developed a serial passage attenuated strain of IHNV. After 41 serial passes on steelhead
salmon cell line STE-I 37, the strain had greatly reduced virulence in kokanee salmon
(landlocked 0. nerka) and provided protection from subsequent injection challenge with
virulent IHNV. Additional work with attenuated IHNV strains by Tebbit (1975)
demonstrated complete protection ofjuvenile sockeye salmon (0. nerka). Chinook
salmon (0. tshawvtscha) were only partially protected from viral challenge (maximum of
72 % survival post challenge). Despite the relative success of this vaccine, residual
virulence of the attenuated strain resulted in vaccination-associated death of up to 20% of
vaccinated salmon fry.
in addition to attenuated viral agents, attenuated bacteria can also be used for
immunization. Over the past decade or so, many groups have examined the efficacy and
safety of attenuated bacterial vaccine strains of veterinary and human pathogens such as
Salmonella spp. (Hoiseth and Stocker, 1981; Smith et al., 1984), Y enterocolitica (Bowe
et al., 1989), Shigellaflexneri (Noriega et al., 1994), Listeria monocvtogenes (Thompson
et al., 1998), Bordetellapertussis (Roberts et al., 1990), V. cholerae (Viret et al., 1999),
and Pasteurella ,nultocida (Homchampa et al., 1992).
Specifically, in aquaculture vaccine research, attenuated mutants of A.
salmonicida have been examined as vaccines for furunculosis of salmon and trout11
(Thornton et at., 1994; Thornton et al., 1991; Vaughan et al., 1993). Thornton and
colleagues investigated the vaccine potential of A. salmonicida strains lacking the normal
paracrystalline surface protein array (A-layer). These A-layer mutants are possibly
unable to avoid the defense mechanisms of the fish and are unable to survive more than
48 hours in the fish. However, this is apparently long enough to generate a protective
immune response (Thornton et al., 1994; Thornton et al., 1991). Vaughan et al. (1993)
generated a mutant strain of A. salmonicida by insertional mutagenesis of the aroA gene.
In laboratory trials, the mutant strain was highly attenuated in Atlantic salmon and brown
trout. Injection of the attenuated strain protected brown trout from subsequent challenge
with virulent A. salmonicida. The vaccine has never been commercially marketed
because the mutant strain carried a kanamycin resistance cassette as a result of the
insertional mutagenesis strategy. In a follow up report, Marsden et al. (1996) reported
the production of an aroA deletion mutant (without the kanamycin resistance gene).
Rainbow trout injected with the attenuated mutant demonstrated vigorous immune
responses. T-cell responses, as measured by in vitro proliferation assays, were much
better with the live vaccine than with killed wild-type A. salmonicida. Similarly, Thune
et al. produced an aroA strain of Edwardsiella ictaluri by insertion of a kanamycin
resistance gene. The mutant strain LSU-E I was avirulent by bath immersion. Channel
catfish (Ictalurus punctatus) exposed to LSU-E I by bath immersion were resistant to
challenge with virulent E. ictaluri (Thune et al., 1999).12
Component and subunit vaccines
Component or subunit vaccines can be divided into at least three categories. 1)
Purified subunit vaccines are fragments of killed or disrupted pathogenic organisms that
have been purified away from the non-immunogenic or hazardous components of the
pathogen. For example, the surface proteins of viruses can be stripped from the virus
particles and used for immunization in their native form. 2) The gene coding foran
immunogenic protein can be cloned via recombinant DNA technology and produced ina
variety of protein production systems, resulting in a "recombinant protein subunit
vaccine". Recombinant protein subunit vaccines can be produced in bacteria, yeast,or
animal cells. The recombinant protein can be purified partially or completely beforeuse
as a vaccine. The human Hepatitis B vaccine, which consists of purified recombinant
Hepatitis B surface antigen produced in yeast, is an example of a recombinant protein
vaccine. 3) Another type of component vaccine based on recombinant DNA technology
is the DNA vaccine. Iii this type of vaccine, the gene for an immunogenic protein is
cloned into a plasmid under control of a eukaryotic promoter. When the plasmid DNA is
injected into muscle tissue, the protein antigen is expressed by the cells of the injected
animal (Wolff et al., 1990). Further, the injected animal can generatean immune
response to the plasmid-encoded antigen (Tang et al., 1992). All of these categories of
subunit vaccine have been investigated in fish.13
Purified subunit vaccines
The glycoprotein of IHNV was purified from whole virus suspensions and used to
vaccinate Kokanee salmon and rainbow trout (Engelking and Leong, 1989). A protective
immune response was generated in fish exposed to the viral glycoprotein. Similar levels
of protection were observed by bath immersion or injection of the vaccine. This type of
vaccine, though effective, is even more expensive to produce than the killed virus
vaccines. However, it provided evidence that the vinon glycoprotein alone was sufficient
to generate an immunoprotective response in fish. The recombinant DNA technologies
provide a more economical production method.
Recombinant protein subunit vaccines
Gilmore et al. (Gilmore and Leong, 1988) used a recombinant protein production
system inF.co/i to produce a 109 amino acid segment of the IHNV glycoprotein asa
fusion with the amino terminus of trpE from plasmid p52G. Expression of the trpE-
IHNVG fusion was inducible by limiting tryptophan in the growth medium and by
adding indoleacrylic acid, an inducer of the trp promoter. The fusion proteincan
constitute more than 10% of the total protein from induced cultures. Ina similar manner,
Xu et al (1991) produced a 184 amino acid segment of the IHNV glycoprotein from
plasmid pXL3 in E. co/i. Immersion of trout fry in crude bacterial lysates of inducedF.
co/i cultures (with either p52G or pXL3) generated protection against challenge with
ll-INV. Despite the success in laboratory trials, transition to industrial scale production
was problematic. Batch to batch variability and the accumulation of the hydrophobic14
fusion protein in large insoluble inclusion bodies made it difficult to produce consistent
vaccine in large vat fermentation procedures (J. Leong unpublished results). E. co/i has
also been used to produce recombinant protein vaccines for other fish viruses including
IPNV (Christie, 1997) and viral hemorrhagic septicemia virus (VHSV) (Lorenzen et al.,
1993). In addition to expression in E. coil, Estepa et al.(1994) attempted to generate a bi-
valent vaccine by expressing VHSV glycoprotein fusions in Y. ruckeri or in the yeast
Saccharomyces cerevisiae. The transformed Y. ruckeri cultures were lysed, and then
fixed with formalin. Proteins expressed by S. cerevisiae were collected by centrifligation.
Both of the expression systems generated some immune response in trout. Trout
immunized with the recombinant protein extracts from S. cerevisiae exhibited survival
rates ranging from 23 to 61%. In contrast, the survival rates ranged from 7 to 15 % in
fish immunized with Y. ruckeri recombinant protein extracts.
All of the bacterially expressed vaccines discussed so far were administered as
crude lysates or partially purified protein fractions. These preparations will contain a
number of non-relevant antigens. It may be beneficial to use a more purified protein for
vaccination, however protein purification from bacterial lysates can be time consuming
and expensive.
Recently a protein production system in Caulobacter crescentus was devised that
overcame some of these limitations (Bingle et al., 1997b). C. crescentus is a non-
pathogenic gram-negative bacterium that elaborates a paracrystalline protein surface (S)-
layer covering the cell surface (Smit et al., 1992). The S-layer protein monomer (RsaA)
of 1,026 amino acids is secreted by a Type I secretion mechanism which relies upon a C-
terminal secretion signal that remains attached to the protein during the secretion process15
(Awram and Smit, 1998; Bingle et al., 1997b). Once RsaA is secreted to the cell surface,
the S-layer forms by a process of self-assembly. About 10-12% of the cell's protein
synthetic capacity is devoted to S-layer production and it is estimated that there are
60,000 interlinked RsaA monomers on the cell surface. Bingle et al. have shown that this
protein could be used to present different epitopes in large quantities on the bacterial
surface or serve as a fusion vector for the secretion of the foreign protein into the culture
medium. Preliminary work was reported on the secretion of a 109 amino acid segment of
the IHNV surface glycoprotein (II{NV-G) fused to the last 242 amino acids of the S-
Layer protein (Bingle et at., 1997a).
One concern with bacterial expression of recombinant proteins, especially viral
glycoproteins, is the fact that glycosylation of proteins is different in bacteria and
animals. Viruses would normally have the glycosylation patterns of animal proteins and
this may be important for their immunogenicity. To this end, the glycoproteins of IHNV
and VHSV have been expressed in Sf9 insect cells from a baculovirus based vector (Cain
et al., 1999; Koener and Leong, 1990; Lecocq-Xhonneux et al., 1994). The protection
afforded by the VHSV glycoprotein from Sf9 cells was measurable but lower than
protection from either inactivated or attenuated VHSV. Protection was observed from
injection and not from immersion vaccination (Lecocq-Xhonneux et al., 1994). In the
IHNV glycoprotein production studies, the recombinant protein appeared to have a short-
term protective effect that disappeared by 9 weeks after primary vaccination (5 weeks
after booster vaccination). The short-term protection was only observed by injection and
may have been non-specific because some protection was observed in the Sf9 cell
negative control (Cain et al., 1999).16
DNA vaccines
Naked plasmid DNA vaccines have proven to be effective for a great number of
human and animal systems (Gurunathan et al., 2000; Haynes, 1999). Development of
DNA vaccines for aquaculture has also been promising (Reviewed by Heppell and Davis,
2000). The first successful DNA vaccine for salmonids was developed by Anderson et a!
(1996). The full-length glycoprotein gene (G) or nucleoprotein gene (N) of IHNV was
inserted into a plasmid under control of the cytomegalovirus (CMV) immediate-early
promoter. The resulting plasmids (pCMV-G and pCMV-N) were injected alone or in
combination. Rainbow trout injected intramuscularly with 10g of pCMV-G or pCMV-
G plus pCMV-N were strongly protected from viral challenge six weeks after
immunization. Fish receiving only pCMV-N were not protected. IHNV neutralizing
antibody titer at 6 weeks post-vaccination seemed to be reduced by co-injection of
pCMV-N. However, total IHNV reactive antibody was much higher in fish that received
pCMV-G plus pCMV-N than in fish receiving pCMV-G alone. The protection afforded
by the IHNV DNA vaccine was much greater than any other IHNV vaccine so far tested.
Similar findings have also been reported for a DNA vaccine encoding the glycoprotein of
VHSV (Boudinot et al., 1998; Lorenzen et al., 1998).
In the early studies of DNA vaccines, high doses of plasmid DNA were
administered (5-50 tg per fish). Recent studies have examined the effect of much lower
doses of DNA (Corbeil et al., 2000; Lorenzen et al., 1999). Corbeil et al. observed
protection against IHNV challenge with as little as 1 ng plasmid DNA per 1 gram fish,
although they concluded that a dose of 100 ng gave optimal protection. In Lorenzen's
VHSV study, 100 ng of plasmid DNA also gave good protection. Doses below 100 ng17
were not tested against VHSV. Neutralizing antibody titer seemed to correlate with
protection in these studies. In at least one experiment, the neutralizing antibody titer
appeared to be similar at 6 weeks post vaccination, regardless of the DNA vaccine dose
(Corbeil et al., 2000). The ability to vaccinate fish with such small quantities of DNA
makes the administration of the injectable vaccine more cost effective. Corbeil et al.
estimate that cost of materials to produce 50 doses of the plasmid DNA vaccine would be
about 1 cent. However, this estimate did not include the cost of labor and injection
supplies that might make DNA vaccines less cost effective.
Recent outbreaks of IHNV in Atlantic salmon net pens has prompted the
examination of the DNA vaccine (pCMV-G) for use in Atlantic salmon smolts (73 grams
avg.) and pre-smolts (57 grams avg.) (Traxler et al., 1999). Fish were vaccinated with 25
tg of plasmid DNA. Both smolts and pre-smolts were protected from viral challenge by
bath immersion or co-habitation. Survivors from the first challenge were still immune 12
weeks after initial challenge. Neutralizing antibody was detected in 27% to 44% of the
vaccinated fish prior to challenge whereas neutralizing antibody was detected in 86% to
88% of the fish surviving viral challenge (Traxler et al., 1999).
Bacterial delivery of recombinant protein vaccines
As described above, many recombinant protein subunit vaccines are produced in
bacterial (usually E. coli) expression systems. Typically, the bacteria are lysed and the
recombinant protein is partially purified. However, if the recombinant protein is
produced in an attenuated vaccine strain of a bacterial pathogen, the resulting bivalent
vaccine can be delivered without inactivation or protein purification. When theattenuated bacteria are degraded in the host animal, the recombinant protein is processed
along with the rest of the bacterial antigens. Essentially the bacteria can serveas an
adjuvant, enhancing the immune response to the recombinant protein. This approach has
been pursued with a number of different bacteria including Salmonella, Shigella and
Listeria (Ikonomidis et al., 1994; Noriega et al., 1996; Schafer et al., 1992). This strategy
has proven somewhat successful in fish vaccination. A. salmonicida strain A440,
deficient in surface A-layer protein synthesis, was used by Noonan et al. (1995) to
produce cloned fragments of IHNV or VHSV glycoproteins, from the expression
plasmids pATIHN or pATVHS. Fish were exposed to live bacteria by spray vaccination
and challenged with virus after 8 to 12 weeks. The fish exposed to live A440 (pATIHN)
were protected from challenge with IHNV but not VHSV. Likewise, the A440
(pATVHS) live vaccine conferred protection against VHSV and not IHNV. The live
vaccines were more protective than formalin killed preparations (4 1-50% relative
survival compared to 20-32% relative survival for the killed bacterin).
Bacterial delivery of DNA to eukaryotic cells
Despite the tremendous efficacy of some DNA vaccines, including the IHNV
glycoprotein vaccine, injection of plasmid DNA has drawbacks. Some plasmid-encoded
antigens do not elicit a vigorous immune response by themselves and may requirean
adjuvant or immunopotentiator. For some applications, including aquaculture, injection
of vaccines can be cost prohibitive (Heppell and Davis, 2000). Many different strategies
have been explored to deliver DNA vaccines to eukaryotic cells and animals without
injection including liposomes, microparticles, and viral vectors (Gurunathan et al., 2000).19
Another strategy is to deliver DNA with live, attenuated bacteria. This approachwas first
discussed in the context of vaccine development by Sizemore Ct al. (1995).Since this
initial report ofin vitroand in vivo gene transfer to mammalian cells by attenuated
mutantShi gel/a flexneri,several other groups have reported on theuse of various bacteria
for gene delivery to eukaryotic cells. These methods and bacterialsystems are described
below. A general model of the steps required for bacterial delivery of DNA ispresented
in Figure 1.1. Each of the systems described below meets these requirementsin slightly
different ways. In general, the animals generatean immune response not only to the
plasmid-encoded antigen, but also to the bacterial delivery vehicle. Thiscan be exploited
in the production of bi-valent or multi-valent vaccines.
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Figure 1.1 A general model of gene transfer to eukaryotic cells byattenuated
bacteria. 1) The bacteria enter the eukaryotic cell, generally by phagocytosisor receptor
mediated endocytosis. 2) Plasmid DNA is released into the cytoplasm of theeukaryotic
cell in one of the following ways; a) the bacteria lyse within the phagosomedue to the
attenuating mutation, bacterial and phagosomal contents, including plasmid DNA(°),
leak into the cytoplasm or b) the bacteriaescape the phagosome and lyse in the cytoplasm
due to the attenuating mutation, releasing plasmid DNA (°)3) Plasmid DNA is
transported to the nucleus. 4) The eukaryotic cellexpresses and processes the plasmid-
encoded antigen(e).(After Dietrich et al., 1999)20
Shiel1a flexneri
Sizemore et al. (1995) used an attenuated Shigellaflexneri to infect tissue culture
cells. S. Jlexneri strain 1 SD has a deletion mutation in the asdAgene, which is required
for synthesis of diaminopimelic acid (DAP), an essential component of the peptidoglycan
of bacterial cell walls. S. flexneri 1 SD, transformed with the beta-galactosidase reporter
plasmid pCMV3, was able to infect BHK and P815 tissue culture cells. Within 24 hours
after infection, high levels of beta-galactosidase activity were detected from lysed
monolayers of tissue culture cells. Flow cytornetry analysis revealed 1-2 % of the
infected cells expressed beta-galactosidase at 24 hours post-infection. Additionally,
intraocular inoculation of guinea pigs resulted in beta-galactosidase expression by cornea!
cells. In their next report, (Sizemore et al., 1997) these researchers further demonstrated
in vivo immune responses to the plasmid-encoded antigen. Mice intranasally inoculated,
and boosted 4 weeks later, with Shigellaflexneri 1 5D (pCMV3) showed T-cell
proliferation and antibody response to beta-galactosidase. These researchers suggest that
S. flexneri 's ability to escape from the phagosomal compartment is important for
successful gene transfer because they observed no gene transfer witha similarly
attenuated strain of Salmonella, which typically does not escape the phagosome
(Sizemore et al., 1997).
Further work with S. flexneri strain 1 SD by Fennely et al. (1999) demonstrated the
ability of this attenuated bacterial vector to deliver DNA and stimulatean immune
response to viral antigens in mice. Eukaryotic expression plasmids encoding the fusion
protein (F), the hemaglutinin (HA) or the nucleoprotein (NP) of measles viruswere
constructed and used to transform strain 1 5D. Intranasal inoculation of mice with S.21
/lexneri 15D carrying measles virus vaccine plasmids p1021::F, p1021::HA,or
p1021: :NP generated measles virus-specific cytotoxic T-Lymphocyte (CTL) response. A
specific antibody response to the viral antigens was also detected. Memory CTL
response to the NP was demonstrated 4 months after primary vaccination, in vitro,
approximately 2% of HeLa cells showed transgene expression 72 hours after infection.
Other mutant strains of S. flexneri have also proven to be effective gene delivery
vehicles. Anderson et al. (2000) used S. flexneri strain CVD 1204, deficient in guanine
nucleotide biosynthesis, to deliver pcDNA3tetC, a eukaryotic expression plasmid
encoding the C-terminal fragment of tetanus toxin (tetC). Immunity to tetanus toxin is
mediated by neutralizing antibody. Guinea pigs immunized and boosted intranasally with
S. flexneri CVD 1204 (pcDNA3tetC) developed serum antibody to tetanus toxin within 4
weeks of primary immunization, however the antibody titer was lower than in the animals
that had been immunized with tetanus toxoid protein. Unfortunately, the level of
neutralizing antibody generated by CVD 1204 (pcDNA3tetC) vaccination was not
sufficient to protect animals against paralysis in a neutralization test with 0.1
international units (]IJ) of tetanus toxin. However, all animals exposed to S. flexneri
CVD 1204 bacteria were protected from challenge with virulent S. Jlexneri.
Escherichia co/i
Shortly after the report by Sizemore et al. (1995), another bacterial delivery
method was reported by Courvalin et al. (1995). Similar to the earlier system, the
bacteria were deficient in DAP synthesis, in this case by deletion of the dapAgene.
Courvalin et al., however, elected to use a non-pathogenic E. co/i as the delivery vehicle.22
The attenuated DAP deficient E. co/i was given the invasion function from the Shi gel/a
flexneri virulence plasmid and was able to infect tissue culture cells with high efficiency.
The DAP deficiency resulted in rapid death of the intracellular bacteria and delivery of
plasmid DNA (encoding the green fluorescent protein (GFP) reporter gene) to HeLa,
CHO, and COS cells. Courvalin et al. estimated the frequency of transfer to be between
0.5 and 3%. This attenuated E co/i system was further refined by replacing the Shi ge//a
virulence functions with the invasin gene from Y. pseudotuberculosis and the listeriolysin
gene from L. rnonocvtogenes (Grillot-Courvalin et al., 1998). In these experiments, they
achieved gene transfer efficiency up to 17% for Cos- 1 cells infected with a multiplicity of
infection (MOl) of 500 bacteria per tissue culture cell. The efficiency was somewhat
lower in the other cell lines (7.1% for 1-leLa cells and 5.8% for CHO cells). In vivo
experiments with these invasive dap-deficient strains have not been reported.
Recently, Shiau et al. reported the use of a non-pathogenic strain of E. co/i to
deliver plasmid DNA to mice (Shiau et al., 2001). A laboratory cloning strain of E. co/i,
TG- 1, was transformed with a DNA vaccine plasmid encoding the pseudorabies virus
glycoprotein D (pUCgD) or with a plasmid encoding rat Prothymosin-a (p6JProT),
which serves as an adjuvant or immune enhancer. These bacteria were used to infect
mouse peritoneal macrophages in vitro at a MOl of 10. After infection, the macrophages
were incubated in the presence of gentamicin and tetracycline. TG- 1 (pUCgD) was able
to direct expression of pseudorabies virus glycoprotein D in a small, unspecified, number
of mouse derived peritoneal macrophages. Mice were also immunized by intramuscular
injection of bacterial suspensions. CTL activity and lymphoproliferative responses were
generated by TG- I (pUCgD). The responses were enhanced by co-administration of TG-23
1(p6JfProT). It remains to be seen if these non-invasiveE.co/i can stimulate an
immune response by mucosal administration as has been demonstrated for other bacterial
vectors.
Recently some attempt has been made to useE.co/i to deliver plasmid DNA to
fish. Fernandez-Alonso et al. (2001) examined microencapsulation, liposomes,
ultrasound, and bacterial delivery methods to promote gene transfer to trout. Delivery of
VHSV glycoprotein DNA vaccine plasmid (G3-pcDNAJIAmp) by immersion-ultrasound
resulted in protection from VHSV challenge (RPS = 50.1 ± 3.2). Bactofection withE.
co/i Top 1OF (G3-pcDNAI/Amp) was not significantly different from controls (RPS=
20.7 ± 14). As with the work by Shiau et al. (2001) these studies used non-invasive
cloning strains ofE.co/i (Top 1OF or XL2). The authors state, "Of the immersion
formulations... bactofection could probably be the cheapest and most practical. However
a suitable bacterial carrier would have to be chosen because E. coli did not produce any
detectable antibody responses or protection in fingerling trout." (Fernandez-Alonsoet al.,
2001)
Salmonel/a
Despite the fact that Salmonellae generally do not escape the phagosome,gene
transfer to professional phagocytes and other cell types by genetically engineered
Salmonellae has been reportedin vitroandin vivo.In the first report, (Darji et al., 1997)
mice were immunized withSa/nione//a typhirnuriurnstrain SL7207 (deficient in histidine
and aromatic amino acid synthesis), carrying eukaryotic expression plasmids encoding
beta-galactosidase (pCMV3), ActA (pCMVactA), or lysteriolysin (LLO) (pCMVhly).24
Mice were fed one or four doses of the attenuated bacteria. Antibody, helper T-cell
proliferation, and CTL responses were observed after oral administration of 1or 4 doses.
The CTL response peaked 5 weeks post immunization in animals receivinga single dose,
but continued to rise in mice receiving 4 doses (study ended 5 weeks after 4thi dose). A
single dose of the LLO DNA vaccine (pCMVhly) protected 3 of 5 immunized mice
against challenge with pathogenicL. monocvtogenes.Four doses conferred protection
against bacterial challenge in 5 of 5 immunized mice.In vitroinfection of macrophage
cell lines did not lead to reporter gene expression, however, infection of primary
peritoneal macrophages resulted in beta-galactosidase expression inup to 30% of the
adherent cells (Darji et al., 1997)
In further work with S.tvphirnuriurnSL7207, Paglia et al. (1998) examined the
generation of tumor immunity using a model tumor antigen system. Micewere
immunized three times at 2-week intervals with SL7207(pCMVf3) and then challenged
with an aggressive fibrosarcoma cell line that had been stably transduced toexpress l-
galactosidase (F1.A1l). Immunized mice showed resistance to challenge with F1.Al1
tumor cells. This bacterial delivery system clearly induced a strong cytotoxic T-cell
response to the plasmid-encoded antigen. Additionally, infection of mice with SL7207
carrying pEGFP-C2 (encoding GFP under control of the CMV promoter) resulted in GFP
expression by splenocytes, including professional antigen presenting cells. Upto 50% of
the dendritic cells and 30% of the macrophages isolated from the spleenwere GFP-
positive (Paglia et al., 1998).
Catic et al. (1999) provided further evidence that the attenuated S.tvphimurium
vaccine delivery methods promoted a broad immuneresponse, stimulating both CD4 and25
CD8 T-cell responses. The eukaryotic expression plasmid pcDNA-OVA, was delivered
by S. typhimurium SL7207 to bone marrow derived macrophages in vitro. The antigens
expressed from pcDNA-OVA were presented by MHC class 1. The plasmid, pcDNA-
OVA, was delivered with higher efficiency when cells were co-infected with the
phagosome escape mutant SL7207 (pJHL-1). The ovalbumin model peptide was
presented in MHC class I as evidenced by OVA specific macrophage activation. In
further work, Dietrich et aL (2001) demonstrated gene transfer by SL7207 also occurs in
human dendritic cells. In vitro infection of human dendritic cells with SL7207 (p3LGFP)
resulted in up to 0.07% GFP positive cells.
Flo et al. (2001) have reported in vivo protection in mice from a viral disease by
oral delivery of attenuated Salmonella. SL7207 carrying vaccine plasmid pgD delivered
herpes simplex virus-2 glycoprotein-D genes to mice after oral feeding (3 doses spaced 2
days apart). Antibody response, IL-2 production, delayed type hypersensitivity, cytokine
profiles, and viral challenge results all indicated a strong immune response. Mice were
protected from viral challenge with 5 or 100 LD50. Despite the protection from viral
challenge, mucosal antibody (igA) was not detected.
Woo et al. (2001) used the same bacterial strain (SL7207) to vaccinate mice with
the hepatitis B surface antigen (sAg) encoded by the eukaryotic expression plasmid
pRc/CMV-HBs(S). In vitro infection with S. lyphimurium strain SL7207 (pRc/CMV-
HBs(S)) results in expression of the Hepatitis B sAg in peritonea! macrophages. In vivo,
mice infected with the attenuated bacteria had lower Ab responses, but higher CTL and
cytokine (IL-4 and IFN-gamma) responses than mice injected with protein vaccine.
Compared to injected plasmid DNA, bacterial delivery induced higher Ab, similar CTLand lower cytokine responses. The authors state that this vaccination methodmay
provide better protection than the currently available recombinant protein subunit
vaccine.
In parallel with the Shigella study carried out by Anderson et al., (2000) the same
group evaluated a strain of Salmonella tvphi as a gene delivery system (Pasetti et al.,
1999). Attenuated Salmonella t,iphi strain CVD 915 (deficient in guanine nucleotide
biosynthesis) carrying plasmid-encoded fragment C of tetanus toxin under eukaryotic
expression control (pcDNA3tetC) or prokaryotic expression (pTETnirl 5), resulted in
antibody response and cell proliferative responses in mice that had been inoculated and
boosted by intranasal exposure to the attenuated bacterial vectors. The immuneresponse
generated by intranasal inoculation with CVD 91 5(pcDNA3tetC) was higher than
immunization with CVD 915 (pTETnirl5) or intramuscular injection of pcDNA3tetC.
Tetanus toxin neutralizing activity was not measured in this study (Pasetti et al., 1999).
It seems that the type of immune response and level of antibody production varies
with the antigens used and perhaps with the type of attenuating mutation. Comparing the
Shigella study by Anderson and the Salmonella study by Pasetti, itappears that different
bacteria can generate very different immune responses to plasmid-encoded antigens in
vivo.
Listeria nionocytogenes
Listeria monocytogenes is used by many researchers as a model intracellular
bacterial pathogen. Numerous studies have used this bacterium to examine immune
response to intracellular pathogens. The first researchers to exploit this highly invasive27
organism for transgene delivery were Dietrich et al. (1998). This group used attenuated
suicide L. nionocvtogenes strain \2 to infect mammalian cells in vitro. This particular
strain is able to efficiently infect mammalian cells and escape the phagosome, however it
is deficient in intra- and inter-cellular mobility due to deletion of the actAgene.
Normally in L. monocvtogenes the actA gene is expressed from the actA promoter(P,.IA),
which is highly upregulated when the bacteria enter the cytosol of the host cell. In order
to induce bacterial lysis after infection of the eukaryotic cell, a Listeria bacteriophage
lysin gene (pivll8) was cloned into a plasmid under control ofPUC(Ato create the lytic
plasmid p3Ll 18. Various reporter genes were cloned into the lytic plasmid under control
of the CMV promoter. Strain A2 transformed with p3LGFP 118 was shown to deliver
plasmid DNA to macrophage cell line P338D. After 24 to 48 hours approximately 0.03%
of the P338D cells were expressing GFP. In contrast, infection with A2 (p3LGFP)
without the phage lysin resulted in only 0.00 1% GFP-positive macrophages. Killing the
intracellular bacteria with penicillin and streptomycin increased efficiency to 0.0 1%
without the phage lysin. The bacteria also directed gene expression of a model antigen,
ovalbumin amino acids 257264 (OVA), in mouse bone marrow-derived macrophages.
The OVA expressing macrophages were specifically lysed by OVA specific T-cells.
Indicating efficient antigen presentation by MHC class I (Dietrich et al., 1998).
Since the initial report, the research group has been very active in exploring the
applications of this technology to other in vitro and in vivo models. Spreng et al. (2000)
confirmed that L. monocyto genes A2 could deliver genes to mouse bonemarrow
macrophages (BMM). Infection of BMM in vitro with A2 (p3LGFP1 18) ata MOI of 50
generated about 0.03 % GFP positive cells by 24-48 hours. In vivo intraperitonealinjection of 2X 1cfu of A2 (p3LGFP 118) resulted in some GFP-positive peritoneal
macrophages. In a report by Gentschev et al. (2001), L.rnonoci'togenes A2 was shown to
infect human blood dendritic cells (DC). Up to 1% of human blood DCwere GFP
positive after in vitro infection with A2 (p3LGFPI 18). Most recently, Dietrichet al.
(2001) ventured into warm-water fish cells, with the goal of developinga vaccine
delivery method for aquaculture. L. monocytogenes A2was shown to infect EPC, A2,
and PSM cells in vitro (derived from Cyprinus carpio, Xiphophorus xiphidiun'i, andX
helleri x X maculatus, respectively). The actA promoterwas active inside the fish cells
at 16, 20, 25, and 30°C. Infection and intracellular expression as wellas activity of the
actA promoter were temperature dependent with highest activity at 30°C. Dietrichet al.
(2001) did not examine gene transfer to fish cells.
Yersinia pseudotuberculosis
In their efforts to explore attenuated bacterial delivery systems Dietrichet al.
(2001) also examined the used of Y. pseudotuberculosis. In vitro infection of human
dendritic cells with an attenuated Y. pseudotuberculosis carrying p3LGFP resulted inup
to 0.07% GFP positive cells.
SUMMARY
Vaccine development for aquaculture can be challenging due tosome of the
limitations in our ability to monitor the immune status and function of the fish. In
mammalian systems, protein vaccines typically inducea humoral or antibody response.29
Antibody response can be measured in larger fish, but becomesvery difficult in the size
fish normally used for IHNV vaccination studies.
Many different attenuated bacteria can be used for genetic vaccine deliveryin
vitro andin vivo,however immune response seems to vary with the species of bacteria,
route of administration, host animal or cell type, and of course the plasmid encoded
antigen. These different bacterial systems have been applieda wide variety of
immunization schemes. In several cases, immune response to the bacterialvector as well
as the plasmid-encoded antigen has been observed. This ability to generate bi-valent or
multi-valent vaccines may prove to be convenient and efficient. Insome cases, the
immune response to the plasmid encoded antigen is improved when presented
simultaneously with the antigens of the bacterial vector (Pasetti et al., 1999; Wooet al.,
2001), in other words the bacterial vector may act as an adjuvant for the plasmid encoded
antigen
Multiple immune parameters should be monitored for evidence of effective
vaccination. In mammals, serum antibody titer rarely tells the whole story. Viral vaccine
efficacy does not always require serum antibody and many viral diseasesare effectively
controlled with cell-mediated responses. Unfortunately in fish studies,we are often
limited to serum antibody measurements, B-cell counts, and resistanceto pathogen
challenge. In small fish (0.5-1 gram) the options are evenmore limited, as it is difficult
to collect more than 10 20 pi of blood or a few thousand lymphocytes from fish of this
size. In these studies we evaluated our vaccines, both DNA and protein based, with viral
and bacterial challenges.30
One of the biggest concerns in using an attenuated bacterial delivery system is
residual pathogenicity of the delivery vector. A crucial balance must be found between
the ability of the vector to stimulate an immune response in vivo and the ability of the
vector to harm the host. This is especially true in aquaculture where overcrowding and
stress can lead to increased susceptibility to disease and efficient disease transmission.
We believe an attenuated bacterial vector can meet the requirements for safety, efficacy,
and ease of use required for aquaculture vaccines.
In this thesis work we examined production of a recombinant protein vaccine
produced by Caulobacter crescentus and we evaluated the potential for attenuated
invasive E. coli to deliver plasmid DNA to fish cells. Further,we produced mutant
strains of Y. ruckeri and tested their ability to infect fish or fish cells and to generate
immunity in the fish to pathogenic Y. ruckeri. The mutant Y. ruckeriwere also tested as
DNA or protein vaccine delivery vehicles to induce a protective response toa viral
antigen, the glycoprotein of IHNV.
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We report the development of an IHNV vaccine produced by a new, low cost
protein production system based on the bacterium Caulobacter crescentus. The subunit
vaccines that were tested contain a 184 amino acid segment of the IHNV glycoprotein in
different fusion arrangements with the C. crescentus S-layer protein. Relativepercent
survival of 26% to 34% was demonstrated in rainbow trout fry fora vaccine that
contained the 184 amino acid segment of the IHNV glycoprotein fused to the C-terminal
one-quarter of the S-layer protein, inclusion of the universal mammalian T cell epitopes
for the measles fusion protein or the tetanus toxin protein did not increase the
effectiveness of the 1}INV-G/S-layer recombinant protein. (113 words).
INTRODUCTION
IHNV is a rhabdovirus that produces a severe hemorrhagic disease inyoung
salmonid fish including Atlantic salmon (Salmo salar), rainbow trout (Oncorhvnchus
mvkiss), and Chinook salmon (Oncorhynchus tshawvtscha). IHNV infection ofyoung
fish, especially fry and alevins, results in massive destruction of the hematopoietic tissue,
exopthalmia, and petechial hemorrhages that appear on the surface of the affected fish
(Bootland & Leong 1999). In severe outbreaks, more than 90% of the fish ina pond will
die within a two-to-three week period. The only control strategy available to farmers
now is avoidance by destroying diseased animals and disinfecting eggs from potential
carrier fish.41
Vaccines for fish viruses have long been sought by the aquaculture industry to
control disease outbreaks at fish rearing facilities. For trout and salmon farms, epizootics
of infectious hematopoietic necrosis virus (IHNV) can be devastating when they result in
the loss of an entire season's production. The U.S. Trout Farmers Association has
released production figures that show that commercial trout production declined in sales
from $78 million in 1997 to $73.5 million in 1998 and losses increased from 6.79 million
lbs to 7.84 million lbs in that period. In 1998, 84% of the trout losseswere due to disease
(Aquaculture Magazine Buyer's Guide '99,p. 34). The major disease-causing pathogen
was IHNV. Thus, there is a critical need to develop a commercially viable vaccine
against IHNV. Although several vaccines have been developed (Leong & Fryer 1993,
Leong et al. 1997), none have been successful in field trials. The critical need for IHNV
vaccines that are safe, easy to produce and administer, and inexpensive ledus to examine
the production of a recombinant IHNV vaccine in Caulobacter crescentus.
C. crescentus is a non-pathogenic gram-negative bacterium that elaboratesa
paracrystalline protein surface (S)-layer covering the cell surface (Smit et al. 1992). The
S-layer protein monomer (RsaA) of 1,026 amino acids is secreted bya Type I secretion
mechanism which relies upon a C-terminal secretion signal that remains attached to the
protein during the secretion process (Bingle et al. 1997a, Awram & Smit 1998). Once
RsaA is secreted to the cell surface, the S-layer forms by a process of self-assembly.
About 10-12% of the cell's protein synthetic capacity is devoted to S-layer production
and it is estimated that there are 60,000 interlinked RsaAmonomers on the cell surface.
Bingle et al. (1997a, b) have shown that this protein could be used to present different
epitopes in large quantities on the bacterial surface or serveas a fusion vector for the42
secretion of the foreign protein into the culture medium. Preliminary workwas reported
on the secretion of a 109 amino acid segment of the IHNV surface glycoprotein (IHNV-
G) fused to the last 242 amino acids of the S-Layer protein (Bingle et al. 1997a). The
present report examines the immunogenicity of different IHNV-G/S-layer fusion proteins
in fish. It also presents some preliminary data on the effects of inserting universal
mammalian T-cell epitopes into these fusion proteins as immunogens in fish.
MATERIALS AND METHODS
Bacterial strains and plasmids
Strains and plasmids used in this study are listed in Table 2.1. Escherichia coil
DH5a was used as a host for all recombinant DNA manipulations. This strain was
routinely grown at 37° C for 18 to 24 h in Luria-Bertani (LB) medium. C.crescentus was
grown at 30° C in peptone-yeast extract medium (PYE) (0.2% peptone, 0.1 % yeast
extract, 0.01 % CaC12, 0.02% MgSO4). When necessary, antibiotics were included in the
media at the following concentrations: Streptomycin (Sm), 50 tg/ml, Ampicillin (Ap),
50 tg/ml, and Chioramphenicol (Cm) 20 tg/ml. Plasmid DNA was isolated from E. coli
using the alkaline lysis method for pUC-based plasmids (Ish-Horowitz & Burke 1981)or
the boiling method for RSF 1010-based plasmids (Holmes & Quigley 1981).
Transformation of both E. coil and C. crescentus was carried out by electroporationas
previously described (Gilchrist and Smit, 1991). Electrotransformantswere selected on
solidified medium (agar concentration 1.2% w/v) containing the appropriate antibiotic(s).43
Table 2.1. Bacterial strains and plasmids used in this study.
Strain or Plasmid RelevantCharacteristics
Source or
Reference
Bacterial Strains
Caulobacter
crescentus
JS4000 SpontaneousRsaK mutant of strain CB2 (ATCC (1)
15252). Formerly CB2A
Escherichia coil
DH5a recK,endA GibcoBRL
Life Tech-
nologies
Plasmids
pUC8 pBR322-derived cloning//acZ-based expression (2)
vector; Ap.
pKT215 RSF1O1O-derivedcloning vector; Cm, Sm. (3)
pWB9KSAC pKT215-derivedexpression vector incorporating (4)
the rsaA promoter; Cm, Sm.
pUC9CXS pUC9 with amodifiedmultiple cloning site. Ap, (4)
Cm.
pUC8: rsaA242C pUC8 carrying a 1.3-kb BamHTIHinclHI (4)
fragment encoding the final 242 C-terminal
amino acids of RsaA, Ap.
pUC8: rsaA336C pUC8 carrying a 1.6-kb BamHL'HindIJI (5)
fragment encoding the final 336 C-terminal
amino acids of RsaA, Ap.
pWB9KSAC:iaAAPrsaAAP carrying a BarnHI linker insertion at a (6)
(MspI69BamI-1I) site corresponding to amino acid 69 of RsaA;
Cm, Sm.
pG8 Source of IHNV G-protein gene (7)
(1) Smit and Agabian (1984); (2) Vieira and Messing (1982); (3) Bagdasarian et al.(1981
(4) Bingle et al.(1997a); (5) Bingle et al. (2000); (6) Bingle et al.(1997b); (7) Xu et al.
(1991).Synthesis of IHNV-G DNA and T-cell epitope DNA
DNA encoding 109 and 184 amino acid segments of the IHNV-Ggene was PCR
amplified with Taq DNA polymerase (Life Technologies, Burlington, ON, Canada) anda
Techne PH3 thermal cycler (Mandel Scientific Co., Guelph, ON, Canada). Plasmid pG8
(Koener et al. 1987) was used as the template (Table 2.1). The primerswere designed so
that the PCR product would contain a 5' X7ioI restriction site anda 3' StuI site, with
respect to the coding sequence and synthesized at the Nucleic Acid/Protein Service
(NAPS) Unit at the University of British Columbia. The PCR productswere digested
with )i7ioI and Stt,I (Life Technologies) and purified byagarose gel electrophoresis
(Sambrook et al., 1989) and a QIAEX II agarose gel extraction kit (Qiagen Inc.,
Chatsworth, CA, USA). The gel purified fragments were then ligated into digested and
gel purified pUC9CXS (Figure Ia) with T4 DNA ligase (Life Technologies) by standard
methods (Sambrook et al., 1989). Because the 184-amino acid segment of IHNV-G
contains an internal StuI site, it was cloned as a partial digest.
Oligonucleotides encoding two different T-cell epitopes were designed and
synthesized (NAPS) such that upon annealing of the complemetary oligonucleotides, the
coding dsDNA would have termini compatible with Xhol and StuI sites. The
oligonucleotides for the tetanus toxin T-cell epitope (aa 830-844 encoding the P2
sequence QYIKANSKFIGITEL) (Valmori et al. 1992) were 5'-
TCGACAGTACATCAAGG CCAACTCGAAGTTCATCGG CATCACCGAGCTGG-
3' and 5'-
CCAGCTCGGTGATGCCGATGAAGTTCGAGTTGGCCTTGATCTACTG-3'. The
oligonucleotides for the measles F protein T-cell epitope (aa 288-3 02 encoding the MVF45
sequence LSEIKGVIVIHRLEGV) (Panina-Bordignon et al. 1989) were 5'-
TCGAGCCCTGTCGGAGATCAAGGGCGTCATCGTCCACCGCCTGGAGGGCG
TCG-3'and 5'-
CGACGCCCTCCAGGCGGTGGACGATGACGCCCTTGATCTCCGACAGGGC-
3'.The annealed oligonucleotides were inserted into )UioIIStuI digested pUC9CXSas
described above.
Fusion protein construction
The insertion of IHNV-G DNA into pUC9CXS (above) provides the fragments
with BamHT termini and a cat gene tag. The gene rsaA, which encodes the RsaA protein,
has been cloned and earlier reports have described the in-frame insertion ofBarnHI
linkers at various sites in a promoterless rsaA gene (rsaAAP) (Bingle et al. 1997a, b).
Several of these BamHI sites were used to receive the IHNV-G/T-cell DNA. Thecat
gene tag was included to select for insertion events as well as monitor the orientation of
the inserted IHNV-G DNA (Bingle et al. 1997a, b); following insertion of the IHNV-
G/T-cell DNA into an rsaABarnHIsite, the cat gene tag was removed.
To create "full-length fusion proteins",BarnHI fragments carrying IHNV-G DNA
and a cat gene tag were excised from plasmid pUC9CXS (Fig. 2.1 a), gel purified and
inserted into theBarnHIsite of pWB9KSAC: rsaAAP(MspI69BarnHI) (Table 2.1, Fig.
2.Ib), corresponding to an insertion at amino-acid 69 of the full-length RsaA protein. In
this construction, expression was driven by the rsaA promoter.
In addition to full-length RsaA, truncated versions of the rsaAPgene have been
created, encoding 242 and 336 C-terminal portions of RsaA (Bingle et al. 1997b, Bingle!11
et al. 2000); these truncated genes were inserted into pUC8 forming pUC8:rsaA242C
and pUC8:rsaA336C (Table 2.1, Fig. 2.lc, d). In these constructs, synthesis of the C-
terminal fragments of RsaA was driven by E. co/i /ac transcription and translation
initiation. As with the "full-length" rsaAAP, DNA encoding the IHNV-G segmentsor the
T-cell epitopes, each tagged with the cat gene was released from pUC9CXS by BamHI
digestion and inserted into theBarnHIsite of pUC8:rsaA242C or pUC8:rsaA336C. After
receiving IJ-fNV-G and/or T-cell epitope inserts, each of the pUC8-based plasmidswas
ligated to pKT2 15 via their commonHindIIIsites for introduction into C.crescentus
(Bingle et al. 1997a, Bingle et al. 2000). Fusion proteins composed ofan N-terminal
IT-TN V-G/T-cell epitope portion and a C-terminal RsaA portionare referred to as "C-
terminal fusion proteins."
The use of pUC9CXS allowed the creationof"BarnHImodules" that could be
placed in any order at any single BwnHI site. After insertion ofone BarnHI module into
an rsaA BamHI site, the cat gene was removed leaving behind a single Bg[ll site (Fig.
2.1). Because of the compatibility between the cohesive ends of BglII andBarnHI,this
BglIT site was used to repeatedly receive additionalBarnHIfragments carrying an internal
Bg/IT site. This approach was used to construct RsaA fusion proteins carrying several
IHNV-G sequences and/or T-cell epitopes (Fig. 2.2). The construction of all plasmids
was confirmed by DNA sequence analysis (NAPS).47
DNA encoding
protein/peptide
of interest
XhoI Stul
Pm cat gene .
BgIIl Bglll
BamHI XhoI Stul BgI II BamHI
IncZ Pm
I I I I pLJC9CXS
GAG GCCTCTAGATCTGGATCC
b, c or d
rsaA Pm/SD
pWB9KSACrsaAP(Mspl69BamHI)
Amino acid 1 69 1026
Hindill HindlU
PrnSD hcZ Pm SD____
pUC8rsaA242C pUC8 rsaA 3360
A I
I
785 1026
A
I
691 1026
8amino acids 8amino acids
LacZ N-terminusRsaA C-terminus LacZ N-terminusRsaA C-terminus
&pUC8 MCS &pUC8 MCS
Figure 2.1. Creation of RsaA fusion proteins, a. To provide compatible termini for
fusion to rsaA, the DNA of interest is first passed through pUC9CXS,a pUC9 derivative
carrying a modified multiple cloning site and a promoterless chioramphenicol resistance
(Cmr P)gene (Bingle et al. 1997a). Expression of the CmTAP gene is directed by the
lacZa promoter (Pm). The DNA of interest is inserted into pUC9CXS in thesame
orientation as theCmT1Pgene. It is then excised as a BamHI fragment and ligated into
the linker site of the appropriate rsaA fusion plasmid, (b, c, or d). The Cm'APgene is
used to select for insertion events with the correct orientation. The CmPgene is then
removed and the plasmid sealed. b. pWB9KSAC:rsaAAP(MspI69BamHI), a pKT215
derived vector with the rsaAEP canying a linker insertion at a site corresponding to
amino acid 69 of RsaA. c. pUC8:rsaA242C, pUC8 carrying a 1.3-kb fragment encoding
the final 242 C-terminal amino acids of RsaA. d. pUC8:rsaA336C, pUC8 carryinga
1.6-kb fragment encoding the final 336 C-terminal amino acids of RsaA. For
introduction into C.crescentus,the pUC based plasmids (c, or d) carrying the DNA of
interest is fused to broad-host-range vector pKT2 15 at their commonHindifi sites. Bold
numbers indicate the amino acid position relative to full-length RsaA.00 70
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B. RsaA(69)/109
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Figure2.2. Diagrammatic representation of RsaA fusion proteins.Numbered boxes
indicate the amino acid position relative to full-length RsaA. The wildtype S-layer is
1026 amino acids in length. The IHNV inserts consist of 109 aminoacids (aa 335-443)
or 184 amino acids (aa 269-452) of the glycoprotein. The RsaA(69)/ 109 (B) and
RsaA(69)/ 184 (C) constructs have IHNV glycoprotein fragmentsinserted at amino acid
69 of the full length RsaA protein (A). The RsaA242C constructs (D-I)carry the C-
terminal 242 amino acids (aa 785-1026) of the RsaA protein. TheRsaA336C constructs
(J-N) carry the C-terminal 336 amino acids (aa 691-1026) of the RsaAprotein. Fusion
proteins used for vaccination studies are shown in bold type. Throughoutthe manuscript,
the fusion proteins will be referred to by the letters assigned in thisfigure (fusions A-N).Recovery of aggregated fusion proteins from the growth medium
Plasmids carrying recombinant genes encoding fusion proteinswere introduced
into C.crescentusJS4000 via electroporation (Gilchrist & Smit 1991).
Electrotransformants were selected on solidified PYE containing Sm (50 jig/ml).
Colonies were transferred to 5m1 liquid PYE medium containing 2 jig/mi of Cm (Bingle
& Smit 1990) and grown overnight at 300 C in a rotary shaker in 5 mL of PYEmedium.
The entire 5 mL culture was then transferred toa 2800 mL Fernbach flask with 1275 mL
ofM11HIGG medium, a modification ofM6HIGG medium (Smit et al., 1981)
containing 5 mM imidazole; 2 mM potassium phosphate, 0.15% glucose, 0.15%L-
glutamate (monosodium salt), 1% modified Hunter's mineral base and 0.58 mMCaCl2
and grown for a further 72-96 h on a G3 gyratory shaker (New Brunswick Scientific,
New Brunswick NJ) at 55 rpm. The aggregated fusion proteinswere recovered from
culture medium by sieving through nylon mesh (diagonalpore dimension 350 jim)
draped over a 12.5 cm diameter Buchner funnel (Bingle et al. 1997a). Theaggregates
were rinsed with water and collected for either SDS-PAGE or vaccine formulation.
Yields of aggregated fusion proteins for six of the vaccine candidateswere
estimated in a similar manner. Aggregates were recovered from the culture fluidsby
filtration of each 1275 ml culture through a 4.5cm diameter nylon mesh disk housed in a
filtration apparatus with an 0-ring seal. The aggregated protein which collectedon the
nylon mesh was washed 3 times with water by centrifugation (about I mm,12, 000 x g),
lyophilized and the dry weight of the fusion proteinswas determined (Table 2.2).50
Table 2.2. Yield of various RsaA:IHNVG fusion protein aggregates from C.
crescentusculture supernatants.
Yield (mg dry weight/L of culture)
Passenger
FusionAverage S.E. mg/Lmol/L
Full length fusions (rsaA promoter)
A245 16 NA NA
B117 4 11 1.0
C57 3 9 0.5
C-terminal fusions (lacZ promoter)
D48 21 NA NA
E86 22 25 2.3
F54 7 22 1.2
J261 32 NA NA
K95 17 22 2.0
L35 14 12 0.7
Fusion protein letters A-L are defined in Figure 2. Standarderror (S.E.) is calculated as
S.E.= standarddeviation/n05.
SDS-PAGE and Western immunoblot analysis
Protein samples were solubilized by mixing with equal amounts of 8Murea in
100 mM Tris-HC1, pH. 8.0, followed by the addition of sample loading buffer. The
samples were then analyzed on a 12% polyacrylamide gel by the discontinuous gel
method of Laemmli (1970). Two identical gelswere prepared. One gel was stained for
total protein in Gel-Code Blue reagent (Pierce Chemical Inc., Rockford, IL, USA) and
dried on cellulose film. The dried gel was scanned witha Molecular Dynamics Personal
Densitometer (Molecular Dynamics, Sunnyvale, CA, USA). Molecular weights of the
protein bands were calculated with FragmeNT Analysis version 1.1 (Molecular
Dynamics) (Fig. 2.3a). The proteins from the second gelwere electrophoretically
transferred to polyvinylidene difluonde (PVDF) membrane for immunoblotting.51
Following transfer, the membrane was blocked with Tris-buffered saline plus 2% BSA
and 0.1% Tween-20 (TBBT). The blot was probed with polyclonal rabbit anti-IHNVat a
1:500 dilution in TBBT for 2 h and washed with TBBT. FITC-conjugated polyclonal
goat anti-rabbit antibody (Sigma-Aldrich, St. Louis, MO, USA) was applied to the
membrane at a 1:2500 dilution in TBBT for 2 h, washed in TBBT and scannedon the
FMBioII fluorescence imaging system (Hitachi Software Engineering America Ltd., San
Bruno, CA, USA) (Fig. 2.3b).
Formulation of vaccines
For the killed IHNV vaccine, type 1 IHN virus was harvested from infected
epithelioma papillosum cyprini (EPC) cells and inactivated with 0.01 M binary
ethyleneimine for 18 h at 25°C. Inactivated virus was emulsified with four parts water
and one part proprietary mineral oil adjuvant (Microtek, Victoria, BC, Canada)to a final
concentration of approximately 3 X 1 0 tissue culture infective dose(TCID50)per ml or
1.5 Xi05 TCID50per 50 tI vaccine dose.
Recombinant protein aggregates were washed twice with sterile distilled water
and then solubilized with an equal volume of sterile 8 Murea. After overnight dialysis
(8000 MW cutoff) against sterile distilled water, the solubilized proteinswere filter
sterilized through a 0.45 pm filter. The proteins were then emulsified with water and
adjuvant (Microtek, Victoria, BC, Canada) to a concentration of 10 picomolesper dose
(calculated from apparent molecular weight of the recombinant proteinon SDS-PAGE
gels) corresponding to 5.6 to 27 ig/ml.52
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Figure 2.3. SDS-PAGE and Western immunoblot analysis of RsaA:IHNVG fusion
proteins. Lanes: 1, Fusion D; 2, Fusion I; 3, Fusion F; 4, Fusion G. Two to three
micrograms total protein was loaded per lane. a. Total protein stain with Gel-Code Blue
(Pierce). b. Immunoblot. Primary antibody was polyclonal rabbit anti-IHNV that had
been preabsorbed with lysed C.crescentuscells.Secondary antibody was FITC
conjugated goat anti-rabbit.53
The fusion H-Alhydrogel
Rfor the IHNV + H vaccine was prepared in a similar
manner except, the protein was mixed with Aihydrogel (Cedar Lane Laboratories,
Toronto, Canada) at a ratio of 20% (v/v) before emulsion with adjuvant and water.
Production of IHNV challenge virus
Chinook salmon embryo (CHSE-2 14) cells were maintained as previously
described (Engelking & Leong 1981) and used to grow IHNV. The type 2 IHNV used
for challenge was isolated from rainbow trout at the Rangen Research Laboratories,
Idaho, USA (Hsu et al. 1986, Drolet et al. 1993). Virus was propagated ata multiplicity
of infection of 0.01 at 170 C for 7 days. Then the culture supernatant was collected and
centrifuged at 2500 x g for 10mmat 4° C to remove cell debris. The clarified
supernatant was distributed into 13 ml tubes and frozen at -80° C. The viral titer was
estimated by determining the plaque titer for a tube of frozen virus (Burke & Mulcahy
1980).
Fish immunization and challenge
Rainbow trout fry were held in aquaria supplied with 12° C specific pathogen-free
well water (2.2 L/min) at the Oregon State University Center for Salmon Disease
Research. The fish were held in a room where photoperiod was controlled by sunlight
and all of the experiments were carried out from January through August. All fishwere
fedad libitunifor the entire experiment. The fish with an average mass of 0.3 to 0.5g
were anesthesized by immersion in 50-100 ppm tricaine-methanesuiphonate (MS-222)54
and vaccinated by intraperitoneal injectionas previously described (Engelking et. al.
1991). Each fish received a dose of approximately 10 picomoles of recombinantprotein
in a volume of 50 iL in the first trial and in subsequent trials the injection volumewas
reduced to 25tlbut the dose was held constant at approximately 10 picomoles of
protein. After vaccination the fish were held for 30 days in 12° C specificpathogen-free
well water. Holding densities during this immune development periodwas
approximately 0.0 1-0.02 kg/rn3. At the end of the 30 day period, the fishwere distributed
into replicate tanks so that replicates withina treatment contained the same number of
fish per tank. The number of fish per replicategroup ranged from 30 to 50. Fish were
then exposed to 1 0 or 1PFU IHNV per mL in static water for a period of 5 h, ata
density of 50 fish per 2 L of water. Water flowwas restored after 5 h and mortalities were
recorded daily for 30 days after virus exposure.
Relative percent survival was calculated using the following formula (Ellis1988):
RPS = [1-(% vaccinated mortality / % control mortality)]x 100.
Statistical methods
Cumulative mortality was recorded for each replicate tank at 30 dayspost
challenge. Data for each trial were first tested for extra-binomial variationbetween
replicates using Fisher's exact test (Ramsey and Schafer, 1997)to determine if use of the
standard binomial model was adequate. Where appropriate, the replicates withineach
treatment were pooled for calculation of a p-value using Pearson's chi-squared analysis
(Ramsey and Schafer, 1997) and pair-wise comparisonswere made between all groups.55
Otherwise, quasi-likelihood analysis was employed to compensate for the extra-binomial
variation between replicate tanks (Ramsey and Schafer, 1997).
Fisher's exact and quasi-likelihood analyses were performed using Statistical
Analysis Systems for Windows, release 8.0 (SAS Inc., Cary, NC). Pearson's chi-squared
analysis was performed using Microsoft Excel 97 (Microsoft Corp., Beilvue, WA).
RESULTS AND DISCUSSION
A subunit vaccine for IHNV consisting of the viral glycoprotein produced from
purified virus (Engelking & Leong 1989) or as a recombinant protein in E. co/i (Gilmore
et al. 1988, Xu et al. 1991) had been shown previously to be highly effective as a vaccine
in rainbow trout. The recombinant protein contained a sequence of 184 amino acids of
IHNV G protein from aa 270 to 453 fused to tryptophan synthetase. Although highly
effective in laboratory trials where only small quantities of the vaccinewere required, the
vaccine produced for large field trials was inconsistent. Efforts to produce theE. co/i
vaccine in large fermentation batches resulted in the unsatisfactory formation of IIINV-
G-TrpE fusion protein inclusion bodies in the bacteria. The work did identifyan
immunodominant domain that was reactive with neutralizing monoclonal antibody (Xu et
al. 1991) and induced protective immunity in fish vaccinated witha 109 amino acid
segment (aa 335-443) of the viral G protein.
The laboratory success of theE. colivaccine indicated that a recombinant protein
would be an effective vaccine for IHNV, if produced in an appropriate expression
system. The secretion of proteins fused to the S-layer protein of C.crescentusoffered an56
attractive alternative for the production of the IFINV vaccine. Several plasmidswere
constructed containing the S-layer protein gene, rsaA, or a fragment of thatgene, fused to
the 109 or 184 amino acid region of the 11-INV G protein gene (Fig. 2.2). These fusion
proteins were examined as possible vaccine candidates.
Yield of aggregated fusion proteins
Earlier reports on the production of the IT-INV-G 109 amino acid segment fusedto
the 242 amino acid C-terminal end of RsaA (fusion E) indicated that the fusion protein
was secreted from C.crescentusat concentrations as high as 10% of the total protein in
stationary phase culture (Bingle et al. I 997a). The current study, aimed to determine if
an increase in passenger protein yield could be brought about by using more of the RsaA
C-terminus (336 amino acids) or even full length RsaA itself.
When the IHNV-G sequences, either encoding the 109 or 184 amino acid insert,
were fused to the full-length RsaA gene near its N-terminus (fusions B and C), a
reduction in the amount of aggregated protein recovered from the culture fluidsas
compared to fusion A was observed (Table 2.2). The size of the IHNV-G insert hadan
impact on the reduction; when the size of the insert was increased by approximatelytwo-
fold from 109 to 184 amino acids, the yield of aggregated fusion protein dropped by
50%. This relationship meant that the yield of the IHNV-G portion of the fusion protein
remained constant when expressed in terms of dry weight. However,on a molar basis
twice as much of fusion B was recovered from the culture fluidsas compared to fusion C.
In comparison to the fusion proteins with full-length RsaA, the yield produced
with only the C-terminus of RsaA (fusions D, E, F, J, K, and L) exhibited considerable57
variation between production batches. This was probably due to the fact that the reduced
amount of RsaA in the fusion protein made it less capable of aggregating. Despite this,
the yields of aggregated RsaA336C fusion proteins (fusions J, K, and L) exhibited the
same general trend, i.e. insertions decreased production and the larger 184 amino acid
insert had a greater effect on the reduction of fusion protein production. Fusions D, E,
and F showed a different yield pattern. The addition of the IHNV-G insert either had
little effect on the yield of aggregated protein on a weight basis (fusion F)or led to an
increase in yield (fusion E). The molar yield of fusion E, however, was approximately
two times that of fusion F (Table 2.2).
We also tested the use of smaller portions of the RsaA C-terminus (166, 134, 119
and 82 amino acids) for the secretion of the 109 and 184 amino acid INHV-G segments
using a suite of plasmids similar in design to those used here (see Bingle et al., 2000).
These experiments showed that while both of the IHNV-G segments could be recovered
in aggregated form from the growth medium when fused to the C-terminal 166, 134, and
119 amino acids of RsaA, yields were much lower than those obtained using the 242 and
336 amino acid portions of RsaA. Thus, the use of these smaller constructs for vaccine
production was abandoned.
SDS-PAGE and immunoblot Analysis of RsaA:IHNV-G fusion proteins
An analysis of the different fusion proteins produced in this study indicated that
the fusion proteins were secreted into the culture medium as nearly pure protein
aggregates (Fig. 2.3). Fusion D migrated as a 26 kDa protein (Fig. 2.3a, lane 1). Fusion I
containing the C-terminal 242 amino acids of RsaA plus two copies of the tetanus toxinand one copy of the measles virus F protein universal T-cell epitopes migrated at 43 kDa
(Fig. 2.3a, lane 2). The fusion F preparation showed two proteins:one migrating at 50
kDa and another migrating at 30 kDa (Fig. 3a, lane 3). The 30 kDa protein consisted of
the RsaA C-terminus bearing a short N-terminal extension consisting of 31 IHNV-G
amino acids (31 /R5aA242C). A similar protein bearing 21 IHNV-G amino acids
(21/RsaA242C) was found in a previous study in which the secretion of fusion Ewas
evaluated (Bingle et al., 1 997a). It was hypothesized that 21 /RsaA242Cwas either a
proteolytic cleavage product of the RsaA:IHNV-G fusion proteinor possibly an internal
translation initiation product originating in the IHNV-G sequence. The possibility of
internal translation initiation was an attractive hypothesis because the N-terminal amino
acid of both 21 /RsaA242C and 31 /RsaA242C lay immediately after thesame methionine
residue and an IHNV-G-derived N terminal cleavage productwas not found in the
aggregated protein recovered from the culture fluids. Resolution of this issuewas
important in the present context because proteolytic cleavage of RsaA fusion proteins
would complicate the use of the C.crescentusS-layer protein secretion system.
To test the idea that the 3 l/RsaA242C was derived from internal translation
initiation, pUC8:rsaA242C (cariying the 184 amino acidsequence of the IHNV-G DNA
inserted at its BamHI site) was digested withEcoRI(Fig. 2.1). The resulting termini were
polished with Klenow fragment of DNA polymerase I (New England Biolabs,
Mississauga, ON, Canada) and the plasmid was circularized by ligating the blunt ends
together. The result of these manipulations was to introducea +1 reading frameshift so
the RsaA:IHNV-G fusion sequence could not be translated from the lacZ ribosome-
binding site. When this modified plasmid was fused to pKT2 15 and introduced into C.59
crescentus,an aggregated protein was produced and found to be composed entirely of
3 1/RsaA242C (manuscript in preparation). This result cannot be explained by proteolytic
cleavage but is consistent with internal translation initiation. Similar resultswere
obtained when plasmid, pUC8:rsaA336, carrying the 184 IHNV-GBarnl-HDNA insertion
was modified as described above. In this case, the internal translation initiation product
possessed a higher molecular mass because a larger portion of the RsaA C-terminuswas
used in the constructed plasmid.
SDS-PAGE analysis of fusion G also yielded two protein bands of 53 kDa and 43
kDa (Figure 3a, lane 4). The 43 kDa band can also be explained by internal translation
initiation in the IHNV-G portion of the fusion protein. Its larger molecularmass can be
accounted for with the additional MVF and P2 sequences.
When an identical gel, containing the same samples as shown in Figure 3a,was
blotted and probed with antibody to IHNV, only those proteins carrying IHNV-G
sequences demonstrated immunoreactivity (Fig. 2.3b). The immunoblot revealed some
higher molecular mass species not readily seen on the stained gels. Theapparent
molecular masses of these proteins suggested that they could be dimers. Although RsaA
possesses no cysteine residues, the 184 amino acid IHNV-G segment does possess one
such residue, which could potentially react with another cysteine residueto produce a
disulfide-linked dimer. This was confirmed by omitting 3-mercaptoethanol fromthe
SDS-PAGE sample-loading buffer. In this case, the higher molecularmass bands were
much more prominent when the reducing agent was omitted (data not shown). Thus the
protein preparations consisted of, at least, monomeric and dimeric F fusion protein,as
well as RsaA242C canying 31 amino acids of IHNV-G resulting from internal translationinitiation. Although only fusions D, F, G, and Iare shown in Figure 3, the functional
construction of each fusion protein used in this reportwas verified by SDS-PAGE and
immunoblot analysis.
Evaluation of the fusion proteins as potential vaccines
A number of different RsaA:IHNV-G fusion proteinswere evaluated in laboratory
trials as vaccines against IHNV. Rainbow trout fiy withan average mass of 0.3 to 0.5 g
were used for this trial because larger fish do not die from virus infection at the levels
required to assess protection. As the fishage, they become more resistant to the lethal
effects of IHNV infection. Also, numerous experiments have shown that fishcan be
protected by vaccination against IHNV at 0.4 to 1gm (Anderson et al., 1996). Early
experiments indicated that we should concentrateour efforts on the RsaA:IHNV-G fusion
proteins containing the 184 amino acid segment of the viral glycoprotein.The fusion
proteins described in Table 3 were evaluatedover the course of three laboratory trials.
The trials were extensive and for every trial, experimental sampleswere run in replicate
tanks of 30 to 50 fish per tank at virus challenge doses of l0to l0 infectious doses/ml
of water (diluted from a virus stock of 2 x 1 0 plaque forming units(PFU) per ml, as
determined by plaque assay)(Burke & Mulcahy 1981). This isa high challenge dose
since virus titers reached at the height of an epizootic in holding pondsrarely reach virus
titers above 0.02-0.2 PFU/ml (Watanabe et al. 1988). The trialswere designed to test the
recombinant vaccines under the most stringent conditions. Adjuvant aloneor PBS was
used as the negative control in each trial. A control vaccine consistingof adjuvant plus
killed IHINV was also included in the study. The dataare presented as cumulative61
percent mortality and relative percent survival (RPS) in Table 2.3 and this permits some
comparison between the different trials. The data from trial I is also shown in Figure 2.4
as cumulative percent mortality for each replicated treatment.
Table 2.3. Relative percent survival (RPS) and cumulative percent mortality (CPM) after
IHNV challenge.
Treatment
Killed IHNV
Killed IHNV + H
A
C
C+H
D
F
F+H
G
M
N
PBS
Adjuvant alone
Trial #1
CPM±SE RPS
53.4±1.124.2
44.0±1.237.5
69.6±14.1 1.2
66.3±1.1 5.9
69.7±5.8 1.2
46.4±5.234.2
46.2±3.834.4
70.5±7.30
Trial #2
CPM±SE RPS
38.6±11.331.5
41.2±12.726.9
43.1±11.323.6
40.6±8.628.1
53.7±3.1 4.8
56.4±3.8 0.0
Trial #3
CPM±SERPS
34.0±2.012.1
28.7±1.825.9
29.3±2.924.1
38.7±6.7 0.0
38.7±5.3 0.0
Relative percent survival (RPS) is calculated as RPS= [1(percent vaccinated
mortality/percent control mortality)] X 100. (Ellis, 1988) In trials I and 2, RPSwas
calculated relative to the adjuvant alone controls. For trial 3, RPS was calculated relative
to the PBS injected controls. Replicate tanks for each treatment group were run in
duplicate for Trial #1 and triplicate for Trials #2 and #3 with 30 to 50 fishper replicate
tank. Letters A-N refer to the fusion protein codes in Figure 2. Standarderror is
calculated as SE= standard deviation/n05.62
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Figure 2.4. Cumulative percent mortality at 30 days post challenge. IHNV challenge
titer =iO4 PFU/ml. Groups labeled with the same superscript were not significantly
different from each other. The fusion A treatment group showed evidence of extra-
binomial variation and was therefore excluded from this analysis.
The level of protection aforded by vaccination witlC. crescentus synthesized IHNV
G/S fusion protein was limited. The differences we observed between vaccinated and
unvaccinated treatment groups were statistically significant in trial 1 only (Fig. 2.4). In the first
trial thercwas little evidence of extrthinomial variation, except in the fusion A treatmentgroup,
therefore this treatment group was not examined further. Of the remaining groups, F, F+H,
Killed IIIINV (IHN), and Killed IHNV+H (IHN+H) were significantly differenifi the adjuvant
alone (ADJ) control (p 0.05) (Fig. 2.4). Extrabinomial variation was evident in the second trial
and quasilikelihood analysis did not show significant treatment effects. The third trial showed
no evidence of extrabinomial variationhowever Pearson's chquared analysis did not reveal
significant treatment effects after pooling of replicates.63
hi all three trials, the adjuvant alone or PBS negative control fish reached
cumulative mortalities ranging from 38.7-70.5% (Table 2.3). The killed IIThW in
adjuvant (positive control) provided some protection (RPS 24.2%) in trial 1 (Table 2.3).
In all three trials, the most efficacious recombinant vaccine was fusion F: trial I,RPS
34.2% (p0.004); trial 2, RPS 3 1.5%; and trial 3, RPS 25.9% (Table 2.3). The inclusion
of the universal mammalian T cell epitopes did not seem to increase the protective
immunity induced by the IHNV-G/RsaA fusion proteins G, Mor N. Rearrangement of
the fusion sequence did not have any effect and may have even decreased the
immunoprotective capacity of fusions M and N. These studies also show that
construction of the fusion protein is important since insertion into a complete rsaAgene
did not produce an IHNV-G fusion protein capable of inducing protective immunity in
trout.
Universal or "promiscuous" T-cell epitopes that enhance the immunogenicity and
overcome genetic restriction of the immune response have received considerable
attention recently as vaccine immunopotentiators. In particular, the human T cell
epitopes for measles virus fusion protein and for tetanus toxin have been used
successfully to augment peptide vaccines for mouse mammary tumor virus (Astori &
Kraehenbuhl 1996) and Human T-lymphotropic virus (Lairmore et al 1995, Kaumayaet
al. 1993). When the universal T-cell epitopes for tetanus toxin and measles virus fusion
protein were tested as enhancers in fish for the recombinant protein IHNV vaccines,we
found no augmentation of protection. The only effect we observedwas with fusion H
suspended in Aihydrogel and mixed with the killed IHNV vaccine in oil-in-water
adjuvant (Table 2.3, Fig. 2.4), the observed protection increased from 24.2% RPS (killedIHNV) to 37.5% RPS (killed IHNV + H) (p= 0.22).The significance of this finding is
unclear and must be repeated with other universal T-cell epitopesand with different
killedlpeptide vaccines.
These studies suggest C.crescentusmediated production of viral proteins for
vaccines may be an alternative to E. coli and yeast protein production.Studies are
continuing on different fusion protein constructs with the entireIHNV-G gene sequence
at the N-terminus of the S-layer protein. Also, the identification of fish specificT- cell
epitopes has been initiated.
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ABSTRACT
Genetic immunization has proven effective in a number of applications including
vaccination of rainbow trout (Oncorhynchus rnvkiss) against the fish pathogen infectious
hematopoietic necrosis virus (IHNV). However injection vaccines, especially in
aquaculture, are not as desirable as oral or immersion dosing schemes. in this report we
present evidence that attenuated invasive Escherichia co/i can infect and deliver plasmid
DNA to salmonid fish cells. Further we discuss the potential of using an invasive fish
pathogen, Yersinia ruckeri, in the development of a bivalent or multivalent vaccine.
INTRODUCTION
Gene transfer to eukaryotic cells has many exciting applications, including gene
therapy, production of transgenic animals, and genetic immunization. Plasmid DNA
based vaccines have been developed and tested for a variety of diseases, including fish
viral diseases (Anderson et al., 1996; Gurunathan et al., 2000; Haynes, 1999; Heppell and
Davis, 2000; Lorenzen et al., 1998). Our laboratory previously developed a highly
effective vaccine against infectious hematopoietic necrosis virus (IHNV) (Anderson et
al., 1996). In previous studies, injection with this DNA vaccine was shown to protect 80-
98% of rainbow trout fry (Oncorhvnchus mykiss) from a normally lethal dose of IHNV.
However, injection of vaccines in fish is labor intensive and can be cost prohibitive.Therefore we are exploring alternative methods of gene transfer to facilitate theuse of
genetic immunization in fish.
Recent developments in mammalian vaccinology have exploited theuse of
attenuated bacteria to deliver plasmid DNA to mammalian cells both in vitro and in vivo
(Courvalin et al., 1995; Darji et al., 1997; Dietrich et al., 1998; Sizemore et al., 1995). In
addition, Dietrich et al. (2001) recently reported the ability of Listeria rnonocvtogenes to
invade cell lines of warm-water fish. We report here the first use of attenuated invasive
bacteria to direct gene transfer to salmonid cells.
To examine gene transfer to salmonid cells, we appropriated the system
developed by Grillot-Courvalin et al.(1 998) based on attenuated invasive E. coli. An E.
coli K12 diaminopimelate auxotroph, (BM2710) expressing the invasingene from Y.
pseudotuberculosis and the listeriolysin gene from Listeria monocytogenes,was shown to
direct transfer of a green fluorescent protein (GFP) reporter plasmid to 1-leLa, COS-7, and
CHO cell lines with varying efficiency (Grillot-Courvalin et al., 1998). The invasin and
listeriolysin genes are carried on a low copy number plasmid pGB2invor pGB2inv-
hly. Gene transfer by bacteria is a multi-step process. In the model proposed by Grillot-
Courvalin et al. (Figure 3.1), the bacteria first invade the eukaryotic cell. Then, due to
nutritional deficiency, the bacteria lyse, releasing their contents into the phagosome. The
phagosomal contents, including plasmid DNA, leak into the cytosol. Phagosoma!
leakage or lysis can be enhanced by bacterial expression of a hemolysin suchas
listeriolysin. Once the plasmid DNA enters the cytosol, the DNA can be transported to
the nucleus and reporter gene expression ensues.70
Figure 3.1. Model of gene transfer by attenuated invasive E. coli. 1: Bacteria invade
the cell by inducing phagocytosis. 2: The nutritional deficiency (i.e. diaminopimelate
auxotrophy) results in death of the bacteria. Bacterial contents, including plasmid DNA,
are released into the phagosome. 3: Phagosomal contents (and plasmid DNA) are
released into the cytosol due to phagosome lysis or leakage. 4: Plasmid DNA enters the
nucleus. 5: The reporter gene is expressed by the host cell.
hi our study, we tested the ability of the attenuated invasive E co/i to infect
chinook salmon embryo (CHSE-214) tissue culture cells as well as rainbow trout
(Oncorhynchus rnvkiss) gill explant cultures and head kidney macrophage cultures. Also,
several wild-type isolates of Yersinia ruckeri were examined for invasiveness using
gentamicin protection assays to identify vaccine strain candidates. This organism is the
causative agent of enteric redmouth disease in salmonids. Future mutagenesis and
attenuation experiments could develop a safe DNA delivery vehicle with potential as a
bivalent or multivalent vaccine.71
MATERIALS AND METHODS
Bacterial strains and plasmids
Strains and plasmids used in this study are listed in Table 3.1. F. coli strain
BM27 10 harboring the reporter plasmid pEGFP-C 1 and the invasion plasmids pGB2,
pGB2inv, and pGB2inv-hly were generously provided by Dr. Sylvie Goussard of
L'Institut Pasteur, Paris, France. BM2710 was routinely cultured at 37°C on LB Lennox
agar plates or broth supplemented with 25 jig/ml meso-diaminopimelic acid (DAP), 50
tg/m1 kanamycin, and 25 tg/ml streptomycin. Yersinia ruckeri strains 11.4, 11.29,
11.47, and 11.73 were provided by Dr. Rocco Cipriano, National Fish Health Laboratory,
Leetown, VA. Y. ruckeri was routinely cultured at room temperature using LB-Lennox
broth or agar plates. Transformation of Y. ruckeri with plasmid DNA was carried by
electroporation (Cutrin et al. 1994)
Infection of CHSE-214 cells with invasive E. co/i or Y. ruckeri
Chinook salmon embryo (CHSE-214) cells were cultured as previously described
(Engelking and Leong, 1981). Twenty-four hours prior to infection, CHSE-2 14 cells
were seeded onto glass coverslips in 6-well plates at to5 cells per well. Bacterial
suspensions ofBM27lO pEGFP-Cl, also carrying one of the invasion plasmids (pGB2,
pGB2inv, or pGB2inv-h1y) were prepared in cell culture medium plus 25 jig/mi DAP.
The monolayers were infected at a multiplicity of infection (MOl) of 100 bacteria per
tissue culture cell. After 2 hours of incubation at room temperature, the monolayers were72
rinsed and the medium supplemented with 100 tg/ml gentamicin. At 24 and 48 hours
post-infection monolayers were fixed with 10% buffered formalin and mounted with
Vectashield (Vector Laboratories) and viewed by epifluorescence microscopy to detect
GFP expression. 4,6-Diamido-2-phenylindole (DAPI) was applied as a counterstain.
Immunocytochemistry was performed on Y. ruckeri infected monolayers using rabbit
anti- Y. ruckeri antibody (supplied by Craig Banner, Oregon Department of Fish and
Wildlife) and Texas Red conjugated goat anti-rabbit secondary antibody (Vector Labs).
Table 3.1. Plasmids and bacterial strains.
Strain or plasmid Description Source
Strains
BM2710 A dap deficient derivative of E. co/i MM294 S. Goussard (1)
11.4 Y. ruckeri from rainbow trout (0. mykiss), Utah, R. Cipriano
1968
11.29 Y. ruckeri from Chinook salmon (0. tshai'tytscha),R. Cipriano
Oregon, 1974
11.47 Y. ruckeri from rainbow trout (0. mykiss), R. Cipriano
Colorado, 1978
11.73 Y. ruckeri from rainbow trout (0. mvkiss) R. Cipriano
DhIrlr1Q
pEGFP-C 1 GFP reporter plasmid with CMV promoter S. Goussard (2)
pGB2 pSC 101 based low copy cloning vector S. Goussard (3)
pGB2inv pGB2 with invasin gene, expressed in bacteria S. Goussard (3)
pGB21inv-hly pGB21inv plus listeriolysin, expressed in bacteriaS. Goussard (3)
1) Courvalin et al. 1995. 2) Clontech, Palo Alto, CA. 3) Grillot-Courvalin et al. 1998.73
Flow cytometry
CHSE-214 cells were seeded into 25cm2tissue culture flasks or 6 well plates and
infected as described above. After infection and rinsing the medium was replaced with
CO2independent medium (Invitrogen) plus 10% fetal bovine serum and 200 jig/mi
gentamicin to kill extracellular bacteria. The monolayers were incubated at 20 C. Five
days after infection, the cells were trypsinized and fixed with 2% methanol-free
formaldehyde in preparation for flow cytometry. The cell suspensions were analyzedon
a Becton-Dickinson FACScalibur. 100,000 to 250,000 events were counted for each
sample.
Macrophage isolation
Head kidney leukocytes were isolated as described by Crippen et al. (2001).
Briefly, individual rainbow trout were killed by an overdose of MS-222. The fishwere
bled from the caudal vein, and then the head kidney was removed toa sterile stomacher
bag. The tissue was mixed with 5 mIs of a 1:1 mixture of Hank's balanced salt solution
and Alsever's solution (HBSS/Alsever's) and homogenized briefly (15-20 sec.) ina
stomacher laboratory homogenizer (Seward Medical). The homogenatewas passed
through a 70 jim nylon cell strainer and rinsed with a further S mis HBSS/Alsever's. The
suspension was divided into two 50 ml polypropylene centrifuge tubes. To eliminate the
red blood cells (RBC), the cell suspensions were subjected to hypotonic lysis by addition
of 8 volumes (40 mls) sterile water. The dilute cell suspensions were mixed by inversion
for about 20 seconds and returned to isotonicity with one volume (5 mls) lOX phosphate74
buffered saline (PBS). The cells were again passed througha cell strainer and rinsed
twice by centrifttgation (700 Xg, 10 minutes) and resuspended in HBSS. Glass cover
slips (18 mm diameter) in tissue culture wellswere seeded with 3 X 10 viable cells.
After 3 hours incubation at 170 C, non-adherent cellswere rinsed away with HBSS and
the adherent cells cultured at 170 C with L- 15 medium supplemented with10% fetal
bovine serum (FBS), 1000 IU/ml penicillin, 1000 tg/ml streptomycin,and 500 lU/mi
fungizone.
Infection of head kidney macrophages with invasive E. coli
One day or 6 days after collection, macrophage cultureswere rinsed to remove
antibiotics and infected with strain BM27 10 carrying plasmid pEGFP-C1 plus pGB2,
pGB2inv, or pGB2inv-h1y. Approximately 1 0 bacteriapercm2were added to each
well. Bacteria were added on a perarea basis because the number of macrophages was
not estimated. After 2 hours of incubation at room temperature, the cellswere rinsed
three times and 100 ig/ml gentamicin was added to the culture medium.
Gill explant culture
Gill explant cultures were preparedas described by Part et al. (1993), with some
modifications. Briefly, fish were anesthetized and injected with sodiumheparin to
prevent blood clotting (approximately 5 units heparin per gram). The gill filamentswere
removed and minced, then incubated at 40 C with shaking in HBSSplus trypsin and
EDTA to dissociate the tissues. Cells were harvested by passing thetissue suspension75
through a 70 m nylon cell strainer. A hypotonic lysis stepwas added to reduce the
number of RBCs (described above). More than 60% of the cells isolated by this method
were viable (measured by trypan blue exclusion). The cells were plated onto glass
coverslips in 6- or 12-well tissue culture plates with L-15 medium supplemented with
10% FBS plus penicillin, streptomycin, and fungizone. After 24 hours the wellswere
rinsed to remove non-adherent cells. The adherent cells were cultured at 170 C with
supplemented L- 15 medium.
Infection of gill explant cultures with invasive E. co/i
Five to 7 days after collection, gill explant cultureswere infected with strain
BM2710 carrying plasmid pEGFP-C1 plus pGB2, pGB2inv,or pGB2inv-h1y as
described above. For the gill explant cultures, 2.5 X 106 bacteriapercm2were added to
each well. Again, bacteria were added on a per area basis because the number of cells
per well was not estimated. At 2 hours and 48 hours post infection, monolayers were
fixed with 10% buffered formalin. Immunocytochemistrywas performed using
biotinylated anti-E. coli antibody followed by Texas Red conjugated avidin.
Gentamicin protection assay
CHSE-214 cells were cultured as previously described (Engelking and Leong
1981) except we used autoclavable minimal essential medium (MEM) (Invitrogen)
supplemented with 5% fetal bovine serum (FBS) and L-glutamine. Gentamicin
protection assays were performed essentially as described by Elsinghorst (1994). Briefly,76
CHSE-214 cells were seeded into 12-well plates at 2 X i0 cells per well. After 24 hours
the monolayers were infected with 2 X 107 bacteria per well. The monolayerswere then
incubated at room temperature for 2 hours (invasion incubation), and then the cellswere
rinsed 3 times with serum-free MEM. The rinse medium was replaced with MEM plus
10% FBS and 100 mg/i gentamicin. The monolayers were again incubated atroom
temperature. This gentamicin-kill incubation was allowed to proceed for 4 or 22 hours.
Replicate wells of infected CHSE-2 14 cells were lysed with 1% SDS immediately after
rinsing, or after 4 and 22 hours gentamicin-kill incubation. Ten-fold serial dilutions of
the cell lysates were plated on LB plates with DAP. The agar plateswere counted after
48-72 hours incubation to determine cfu/ml. The number of bacteria recovered
immediately before addition of gentamicin (timer=0) represents the cell-associated
bacteria. The bacterial counts at 4 and 22 hours post gentamicin treatment represent
intracellular bacteria that are protected from the bactericidal activity of gentamicin.
Invasiveness index was calculated as the percentage of cell associated bacteria that
survived 4 hours gentamicin treatment ((cfu per well at 4 hours/cfu per well at 0 hours) X
100).
RESULTS
Infection of CHSE-214 cells by invasive E. coli
Strain BM27 10 with plasmid pGB2inv-hly was shown to transfer plasmid
pEGFP-C 1 to chinook salmon embryo (CHSE-2 14) cells after a two-hour co-incubation
in tissue culture (Figure 3.2). The resulting reporter gene expressionwas observed 48 to77
72 hours after infection. GFP expression was never detected in wells infected with
BM2710 (pGB2). Very rarely, individual GFP positive cells were observed from wells
infected with BM2710 (pGB2inv). Some of the infected cells in each wellwere
rounded and detaching from the plate. Based on direct observation of infected
monolayers, frequency of GFP positive cells was initially estimated to be approximately
1 positive cell per 10,000 (0.0 1%).
Flow cytometry was used to provide another estimate of transfer frequency.
Forward scatter and side scatter data were collected as well as green and red
fluorescence. Forward and side scatter was used to select the population of single cells
(Figure 3.3a, c, e). The population of single cells was plotted withgreen fluorescence on
the horizontal axis and red fluorescence on the vertical axis (Figure 3.3b, d, f). Normal
cells are somewhat auto-fluorescent and therefore the ratio of green to red fluorescence
should be relatively constant (Figure 3.3b). GFP positive cells will showmore green
fluorescence than red. On the plot GFP positive cells will be shifted down and to the
right of the normal population (Figure 3.3d). Flow cytometry results agreed well with the
visual observations. Approximately 0.02% of the cells infected with BM2710
(pGB2inv-hly) were GFP positive by flow cytometry.Figure 3.2. CHSE-214 cells infected with invasive E. coli. Cells were infected with
strain BM2710 canying pEGFP-C1 plus pGB2 (a), or pGB2inv (b), or pGB2inv-hly
(c). GFP positive cells were only observed in cells that had been infected with BM27 10
canying pGB2inv-hly.Figure 3.2.Figure3.3. Flow cytometry plots, a, b. Negative control uninfected CHSE-214 cells.c,
d. Positive control, CHSE-2 14 cells transfected with pEGFP-C 1 by liposome-mediated
transfection. e, f. CHSE-2 14 cells infected with BM2710 pGB2inv-h1y Forward
scatter and side scatter data were collected as well as green and red fluorescence.
Forward and side scatter was used to select the population of single cells (a,c, e). The
population of single cells was plotted with green fluorescenceon the horizontal axis
(GFP) and red fluorescence on the vertical axis (P1) (b, d, 1). GFP positive cells will
show more green fluorescence than red and will fall within the gate (R5) in plotsb, f, and
d.4)-
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81Infection of head kidney macrophages with invasiveE. coil
Infection of rainbow trout macrophage cultures with BM2710 (pGB2),
(pGB2inv), or (pGB2inv-h1y) did not result in GFP expression by the macrophages
whether infected I day or 6 days after collection. In eachcase, the macrophages did
appear to phagocytose the bacteria that were added to the wells. Typically, with tissue
culture cells some extracellular bacteria remain in the infection wellseven after repeated
rinses and gentamicin treatment. However, the macrophage cultures appearedto be
devoid of extracellular bacteria. Faintly auto-fluorescent vacuoleswere observed in some
macrophages in both infected and uninfected wells. Intact bacteriawere not observed in
fixed macrophages stained with DAPI.
Infection of gill explant cultures with invasive E. coli.
The invasive E. coli were able to infect rainbow trout gill epithelia in vitro (Figure
3.4). The level of invasiveness was about the same for both BM2710 (pGB2inv) and
BM2710 (pGB2inv-hly) (Figure 3.4b, c, e, and f). E. co/i without the invasin didnot
penetrate the gill explant cells (Figure 3.4a, d). Counterstaining with DAPI revealsa
large number of bacteria that were not labeled with the anti-E. co/i antibody. These
unlabelled bacteria do not appear in the wells infected with non-invasive BM27 10
(pGB2). At 48 hours post infection (Figure 3 .4e, f) intact bacteriawere still present in
the gill explant cells. Green fluorescent protein expressionwas not detected in gill
explant cultures.a r]
f
Figure 3.4. Infection of gill explant cultures. Gill epithelial cellswere infected with E.
coli strain BM2710 carrying plasmid pEGFP-C1 plus pGB2 (a, d), pGB2uinv (b, e),or
pGB2inv-hly (c, f). At 2 hours (a, b, c) and 48 (d, e, f) hours post infection,
monolayers were fixed. Immunocytochemistry was performed using biotinylated anti-E.
coli antibody followed by Texas Red conjugated avidin.
Evaluation of Y.ruckerivaccine strain candidates
Rather than using an engineered strain of E. coli to deliver DNA vaccines to fish,
it might be possible to use an attenuated fish pathogen. To this end, several strains of Y.
ruckeriwere evaluated by gentamicin protection assay for the ability to infect CHSE-214cells. These strains were previously reported to be invasive to varying degrees (Romalde
1994). Of the four strains tested, 11.47 had the highest invasion index followed by strain
11.29 (Table 3.2). Transformation of the bacteria with a reporter plasmid pEGFP-C 1 did
not reduce the invasion index relative to the homologous plasmid free strain (Table 3.2).
Invasion index as measured by gentamicin protection assay is subject to variation. The
results are best interpreted as relative invasiveness compared between strains within the
same experiment (Elsinghorst 1994). Immunostaining of fixed monolayers correlated
well with results obtained by gentamicin protection assay (Figure 3.5). Strains 11.29 and
11.47 were found to be more invasive than strains 11.4 and 11.73.
Table 3.2. Evaluation of vaccine strain candidates: Invasion index. CHSE-2 14 cells
were infected withYruckeristrains 11.4, 11.29, 11.47, or 11.73. Invasiveness indexwas
calculated as the percentage of cell associated bacteria that survived 4 hours gentamicin
treatment ((cfu per well at 4 hours/cfu per well at 0 hours) X 100). Experiment 1
compares the relative invasiveness of the four strains. Experiment 2 evaluates the effect
of plasmid transformation on invasion.
Strain Invasion index
Experiment 1Experiment 2
11.4 0.91 -
11.47 11.66 -
11.29 3.48 0.80
11.29(pEGFP-C1) 0.85
11.73 0.11 0.25
11.73(pEGFP-C1) 0.2685
Figure 3.5. Evaluation of vaccine strain candidates: Microscopy. CHSE-214 cells
were infected with strains 11.29 or 11.73. After infection, the monolayers were
incubated with 100 jig/mi gentamicin. Monolayers were fixed 48 hours post-infection
and stained with DAPI. a. Infection with strain 11.29. The white arrow indicates a cell
with a large number of cell-associated bacteria. b. Infection with strain 11.73. Heavily
infected CHSE-214 cells were not observed in this treatment.S
I
SDISCUSSION
We have successfully demonstrated gene transfer to salmonid cells using
attenuated invasive bacteria. The frequency of transfer we observed was somewhat lower
than reported in mammalian systems. The reduced efficiency may be attributed in part to
the general difficulty in transforming CHSE-214 cells. In our lab we typically achieve 1-
5% transfection rates with liposome type transfection reagents, such as Lipofectamine or
Lipofectin (Invitrogen). Another contributing factor may be the lower incubation
temperature of the cells (1720 °C), which could affect the growth rate, and hence the
lysis rate, of the intracellular bacteria. The immunostaining results from gill explant
cultures suggest that expression of the invasin protein promotes very efficient
internalization of the bacteria. The immunostaining, however, did not label all the cell-
associated bacteria. Large numbers of cell associated bacteria remained unlabelled in
wells infected with BM27 10 pGB2inv, or pGB2Qinv-hly, but not those infected with
BM2710 (pGB2), which suggests the gill explant cultures were not contaminated with
unidentified bacteria. A likely explanation is that the fixed epithelial cells were not
adequately permeablized prior to antibody staining. This would lead to the conclusion
that the unlabelled bacteria are intracellular. Another, less likely explanation is that
infection cultures of both BM271O (pGB21inv) and BM2710 (pGB2inv-hly)were
contaminated with another type of invasive or adherent bacteria. Despite the large
numbers of bacteria in the gill epithelial cells, gene transfer was not observed. The
observation that many of the bacteria appeared intact at 48 hours post infection supports
the hypothesis that the rate of bacterial lysis is reduced in these experiments, perhaps due
to the low temperature. The next step in this research is to determine if gene transfer willoccurin vivo.Interestingly, in a recent report, Femandez-Alonso (2001) discussed the
use of laboratory cloning strains of E. co/i for in vivo bacterial exposure. These
researchers report that after exposure to non-invasive E. co/i carryinga GFP reporter
plasmid, caudal fin cells of rainbow trout frywere more fluorescent than unexposed fish.
The fish were exposed 0.15, 1.5, 15, or 150mg of bacterial pellet in 20 mis of water (J.
M. Coil, personal communication). Most of the fish in the highest dose died withinfour
days of bacterial exposure. The highest fluorescencewas detected in fish exposed to 15
mg of bacteria. The results of theirin vivoexperiment with non-invasive bacteria suggest
that an invasive bacteria engineered to lyse after invasionmay be a highly efficient
method to deliver genetic vaccines to fish. However in terms of vaccine development,
the invasive E. co/i system we used raisessome biosafety concerns. Environmental
release of engineered bacteria carrying a plasmid with two virulencegenes from human
pathogens could be cause for alarm, especially in food fish aquaculture. To avoid these
concerns we suggest that an attenuated fish pathogen, such as Y. ruckeri could be
employed in the same manner as the E. co/i. The Y. ruckerimay also have advantages
over the E. co/i system because Y. ruckeri is adapted for growth at lower temperatures.
Fish, especially salmonids, are a natural host for the bacterium. Our initial gentamicin
protection assays roughly concur with the findings of Romalde and Toranzo (1993)in
that Y ruckeri strains were found to be invasive. Inour studies strains 11.29 and 11.47
appeared to be the most invasive. Transformation with ColE 1type plasmids did not
reduce the invasiveness of 11.29 and 11.73, which will be important for the applicationof
these strains as plasmid delivery vehicles. The need for attenuation of these strainsisevident because by 48 hours post infection the infected monolayerswere almost
completely destroyed by the Y. ruckeri.
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Chapter 4. Construction and hi Vitro Characterization of Attenuated Mutant
Yersinia ruckeri
ABSTRACT
We have developed a method of delivering DNA to fish cells with attenuated
bacteria. Using Yersinia ruckeri, a virulent and lethal pathogen of rainbow trout,we have
created several different attenuated mutants by conjugation and homologous
recombination mutagenesis. From a genomic library of Y. ruckeri,we identified target
genes for mutagenesis and created individual deletion mutations in dihydropicolinate-
synthase (dapA), 5-enolpyruvylshikimate-3-phosphate synthetase (aroA),or cyclic-AMP
receptor protein (crp). Double and triple Y. ruckeri mutants were also constructed. We
examined each of the mutants for the ability to invade salmonid cells in culture and
release plasmid DNA encoding green fluorescent protein driven by the cytomegalovirus
promoter. Y. ruckeri deficient in diaminopimelic acid synthesis were able to direct
reporter gene transfer to CHSE-214 cells.
INTRODUCTION
Previous work on vaccination against infectious hematopoietic necrosis virus
(IHNV) has explored many different types of vaccines including live attenuated viruses
(McMichael, 1974; Tebbit, 1975), killed virus preparations (Amend, 1976), and various
recombinant subunit vaccines (Cain et al., 1999; Gilmore and Leong, 1988; Oberg et al.,
1991; Xu etal., 1991). To date the most effective vaccine has been the DNA vaccine
developed by Anderson et a! (1996). DNA vaccines encoding the IHNV glycoproteinunder control of a eukaryotic promoter is highly protective against lethal IHNV challenge
when administered by intramuscular injection (Anderson et al., 1996; Corbeil et al.,
2000).
However, for a disease like IHNV, where many of the mortalitiesoccur in very
young fish, injection vaccination is impractical and expensive. An immersion or oral
vaccine would be preferable (Home, 1997). Several methods of immersion vaccination
have been explored for DNA delivery to fish including liposomes and ultrasound.
However, the most practical and inexpensive approach is probably theuse of bacterial
delivery vectors (Fernandez-Alonso et al., 2001).
A number of researchers have taken the approach of using attenuated bacterial
vectors as delivery vehicles for plasmid DNA-based vaccines or gene therapy. Sizemore
et al. (1995) demonstrated the ability of attenuated Shigella to transfer plasmid DNA to
HeLa cells as well as guinea pig corneal cells. Expression of the plasmid-encoded beta-
galactosidase gene was observed in a small portion of the infected cells. Other
researchers have taken similar approaches with different bacteria including Salmonella,
Listeria, and E. coli (Courvalin et al., 1995; Darji et al., 1997; Dietrich et al., 1998).
In addition to DNA vaccines, attenuated bacteria can also be exploited toexpress
and deliver recombinant protein antigens, as has been demonstrated for Aeromonas
salmonicida. Recombinant protein fragments of IHNV or VHSV glycoproteinswere
shown to be immunogenic in rainbow trout when delivered bya mutant strain of A.
salmonicida (Noonan et al., 1995).
Previously we reported the ability of the attenuated E. co/i system developed by
Grillot-Courvalin et al (1998) to deliver a reporter plasmid to fish cells (Chapter 3).93
While this development is exciting, an engineered E. co/i strain with virulence factors
from human pathogens (invasin from Y. pseudotuberculosis, and listeriolysin from
Listeria monocvtogenes) may be perceived as a biohazard, especially in food fish.
Therefore, we decided to pursue the use of a naturally occurring fish pathogenas a
vaccine delivery vehicle. We chose to use Y. ruckeri as a vaccine delivery vehicle dueto
some similarities with the bacterial systems previously explored in mammals. First, Y.
ruckeri is member of the Enterobacteriaceae, like Salmonella, Shigella, and E. coli.
Second, Y. ruckeri causes an enteric disease (enteric redmouth) in salmon and trout
(Furones et al., 1993), again similar to Salmonella, Shi gel/a, and E. co/i. Third, like the
other bacteria used for vaccine delivery, Y. ruckeri is invasive (Chapter 3; Romalde and
Toranzo, 1993). Finally, Y ruckeri can be transformed with plasmids carrying either the
ColE! or pl5A origin of replication (Cutrin et al., 1994). All of these features ledus to
hypothesize that Y. ruckeri would make a good attenuated vaccine delivery vehicle.
Y. ruckeri is the causative agent of enteric redmouth disease (ERM) in salmon and
trout. Outbreaks of ERM tend to occur under conditions of overcrowding, stress and
elevated water temperatures (Busch, 1978; Ellis, 1988). Thereare two major serotypes of
Y ruckeri (Romalde and Toranzo, 1993). Most disease outbreaks throughout the world
are caused by serotype 01 strains. However, serotype 02 strains have been associated
with disease outbreaks in the state of Oregon and elsewhere (Cipriano et al., 1986;
O'Leary, 1977). The serotypes differ not only in their antigenic properties, but also in
their temperature tolerance, antibiotic resistance, and plasmid profiles (Davies, 1990;
Davies, 1991; De Grandis and Stevenson, 1985; Toranzo et al., 1983; De Grandis and
Stevenson, 1982). Typically, serotype 01 strains carry multiple plasmids includinga 40-50 megadalton plasmid. Serotype 02 strains generally lack the large plasmid, butcan
carry one or more smaller plasmids. Serotype 01 strains that carry the large 40-50
megadalton plasmid are unable to grow at 3 7°C, while those lacking the plasmidcan
grow at the elevated temperature. Serotype 02 strains are also able to grow at 37°C (De
Grandis and Stevenson, 1982). For these mutagenesis and in vitrogene transfer
experiments we used strain 11.29, a serotype 02 strain isolated from chinook salmon
(Oncorhvnchus tshawytscha) during a 1974 epizootic in Oregon (O'Leary, 1977). Strain
11.29 is also referred to in the literature as BC-74 and RS-3 (Ciprianoet al., 1986; De
Grandis and Stevenson, 1982; Schill et al., 1984). This strainwas chosen because it has
no resident plasmids (De Grandis and Stevenson, 1982; Toranzo et al., 1983), is resistant
to polymixin-B (De Grandis and Stevenson, 1985), and is moderately invasive (Chapter
3; Romalde and Toranzo, 1993).
Previous studies indicated that wild type V. ruckeri strainswere able to replicate
inside fish cells (Chapter 3). In order to createa vaccine delivery strain we selected three
target genes for mutagenesis. Each of the three mutations has been used in other
attenuated bacterial systems.
Dihydropicolinate-synthase (dapA) is involved in lysine biosynthesis. This
enzyme pathway also results in synthesis of diaminopimelic acid (DAP), an essential
component of the peptidoglycan cell wall in many bacteria (Patte, 1996). DapA mutants
are unable to grow on solid media without DAP supplementation. DAP is generally
absent inside animal cells, and intracellular dapA mutantsare unable to replicate once
removed from the source of DAP (Courvalin et al., 1995). Other similar mutations that
result in peptidoglycan deficiencies and intracellular bacterial lysis have been explored in95
S.flexneri (Courvalin et al., 1995; Sizemore et al., 1995) and L.nzonocvtogenes
(Thompson et al., 1998).
Many attenuated bacterial systems for human and veterinary vaccination have
used mutations in aroA, which encodes 5-enolpyruvylshikimate-3-phosphate synthetase
(Bowe et al., 1989; Hoiseth and Stocker, 1981; Homchampa et al., 1992; Robertset al.,
1990; Viret et al., 1999). This gene is essential in the biosynthesis of aromatic amino
acids (Pittard, 1996,. The intracellular pools of free amino acidsare presumably very
small, and the intracellular bacteria are starved for aromatic amino acids. AroAmutants
of fish pathogens have been developed and tested as vaccines (Marsdenet al., 1996;
Thune et al., 1999; Vaughan et al., 1993).
A third gene that has been mutated in several attenuated bacterial strains iscrp
encoding cyclic-AMP receptor protein (CRP)(Curtiss and Kelly, 1987; Kennedyet al.,
1999; Zhang et al., 1997). CRP is a global regulator of carbohydrate metabolic pathways
(Saier et al., 1996). Bacterial crp mutants exhibitmany phenotypic traits including, slow
growth, reduced ability to ferment carbohydrates and decreased resistanceto detergents
(Kumar, 1976; Sabourin and Beckwith, 1975).
To assess the potential of attenuated 1'. ruckeri mutants for vaccination against
ERM or as delivery vectors for DNA vaccines, several mutant stains of Y. ruckeriwere
created by allelic exchange mutagenesis. The mutagenic system used in this study is
based on the suicide plasmid, pKNGIO1 (Kaniga et al., 1991) featuringan R6K origin of
replication, strA and strB (conferring streptomycin resistance), and the sacBgene from
Bacillus subtilis. The R6K origin of replication restricts plasmid replicationto pir (R6K
pi protein) host bacteria such as SM1O X-pir or S17-1 A-pir. The suicide plasmidistransferred (by conjugation, electroporation, or chemical transformation) to a pir
recipient strain and transconjugants are selected on the basis of antibiotic resistance.
Transconjugants have generally integrated the entire plasmid, resulting in a partial diploid
mutant. The gene product of sacB, levansucrase, catalyzes the synthesis of toxic levans
from sucrose. Thus, exconjugants (transconjugants that have excised the vector) are
selected by growing transconjugants on agar media plus sucrose. Typically, the entire
vector is excised resulting in either reversion to the wild-type allele or replacement of
wild-type with the mutant allele (Figure 4.1).
This allelic exchange mutagenesis system allows for multiple mutations in a
single strain without retention of antibiotic resistance markers in the genome of the
mutants (Kaniga et a! 1991). Using this system, we created individual deletion mutations
of dihydropicolinate-synthase (dapA), 5 -enolpyruvylshikimate-3 -phosphate synthetase
(aroA), or cyclic-AMP receptor protein (crp) in Y. ruckeri strain 11.29. Double and triple
mutant Y. ruckeri were also constructed. The mutant strains were examined for their
growth characteristics, invasiveness, and ability to transfer a reporter gene to CHSE-214
cells in vitro.7
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Figure 4.1: Homologous recombination mutagenesis. a. The suicide plasmid is
transferred (by conjugation, electroporation, or chemical transformation) toa pir-
recipient strain and transconjugants are selected on the basis of antibiotic resistance. A
single crossover event results in integration of the entire plasmid, resulting ina partial
diploid mutant. b. A second crossover is induced by plating transconjugantson agar
media plus sucrose. Typically, the entire vector is excised resulting in either reversionto
the wild-type allele (c) or replacement of wild-type with the mutant allele (d).MATERIALS AND METHODS
Molecular Biology
Unless otherwise stated, PCR, restriction enzyme digests, enzymatic
manipulations of DNA, electrophoresis and other molecular biology techniques were
carried out by standard methods (Ausubel et al., 1993). Oligonucleotide synthesis was
performed by the Center for Gene Research and Biotechnology, Central Services Lab,
Oregon State University or by Invitrogen (Carlsbad, CA). Restriction and modifying
enzymes were purchased from MBI-Fermentas (Hanover, MD), Promega (Madison, WI),
Invitrogen, or New England Biolabs (Beverly, MA). Enzymes for PCR were purchased
from Promega or Invitrogen. Plasmid DNA purification was performed with Qiagen
(Valencia, CA) miniprep or large-scale plasmid DNA purification kits.
Bacterial strains and plasmids
Strains and plasmids used in this study are listed in Table 4.1. Unless otherwise
stated, E. coli strains were grown at 37°C and Y.ruckeriat room temperature (21-25°C)
in LB-Lennox broth or plates (Ausubel et aL, 1993). Antibiotics and supplements were
included at the following concentrations, where appropriate: ampicillin 100 .ig/ml,
kanamycin 50 tg/ml, streptomycin 50 tg/ml, polymixin-B 200 units/mI, meso-
diaminopimelic acid (DAP) 50 tg/ml, X-gal 40 jig/mi. For phenotypic testing of the
aroAmutants, M9 minimal agar plates were supplemented with the following aromaticcompounds: 65-tM 2,3-dihydroxybenzoate, 70-tM p-aminobenzoic acid, 1 0O-tM
hydroxybenzoate, 20O-iM tryptophan, 22O-.tM tyrosine, and 240-jiM phenylalanine.
Genomic library construction.
For construction of the genomic library, we used a plasmid vector since the
genome size Y.ruckeriis relatively small (approximately 5 megabase-pairs) (Romalde et
al., 1991). Plasmid pCR2.1 was chosen because it carries a kanamycin resistance marker
which eliminates the complication of satellite colonies in transformation of the library.
To produce the vector, a single blue colony was selected from a routine TA cloning
experiment with Invitrogen's Original TA cloning kit. Plasmid DNA was isolated,
digested with EcoRI and re-ligated. This reconstituted the unmodified multiple cloning
site of pCR2.1 (Invitrogen). Qiagen Midi-preps were performed and pCR2.1 plasmid
DNA was isolated. Genomic DNA from Y.ruckeristrain 11.29 was partially digested
with restriction enzymeBsp1431 (Fermentas-MBI) and ligated toBamHIdigested
pCR2. 1. The ligation mixture was used to transform UltraCompetent TOP 10 E. coli cells
(Invitrogen). Transformants were plated on LB plates containing Kanamycin and X-gal.
Approximately sixty-five percent of the resulting colonies contained inserts, based on a
blue/white screening. An estimated 52,000 colonies (33,800 white colonies) were pooled
in 100 mIs of LB broth by scraping the transformation plates. Half of the pooled library
was frozen in 1 ml aliquots. Plasmid DNA was prepared from the remaining 50 mls of
pooled bacterial clones. Restriction digest with 500ng of the pooled library DNA showed
an average insert size of about 3 kb.100
Table 4.1: Bacterial strains and plasmids used in this study
Source or
Description Reference
Strains
BM2710 dap-E.co/i Courvalin et al.,
1995
CC118 Xpir E.co/i R6K cloning strain Herrero et al.,
1990
Si 7-1 Xpir E.co/i RP4 transfer strain
11.29 Type IIYersinia ruckeriisolated from Chinook salmon
(Oncorhvnchus tshai'tytscha)
Plasmids
pCR2. 1 TA-cloning vector
pUT-miniTn5KmTn5 based transposon mutagenesis vector Herrero et al.,
1990
pLOFKm TnlO based transposon mutagenesis vector De Lorenzo et al.,
1990
pKNG 101 Homologous recombination vector with thesacBgene,Kaniga et al., 1991
RP4 origin of transfer, and R6K replication origin
pKNGKm pKNG1O1 with the Kanr cassette from pLOFKm This study
pKNGKm2 pKNG1O1 with the Kanr cassette from pUT- This study
miniTn5Km
p1 129-0 15 3.2 kb Y.ruckerigenomic clone containing the dapA This study
gene
p1 i29-015L\dapp1129-015 with 130 bp deleted from the dapA gene This study
pll29aroA 1.1 kb PCR fragment of the YruckeriaroA ORF in This study
pCR2.l
p1 l29AaroA Inverse PCR product ofpl l29aroA with a 234 bp in- This study
frame deletion
p1 l29Acrp Inverse PCR deletion of 236 bp from Yruckericrp This study
genomic clone
pKNGKm-tdapMutator plasmid with the mutant dapA allele from This study
p1l29-0l5Ldap
pKNGKm2-AaroMutator plasmid with the mutant aroA allele from This study
p1 l29AaroA
pKNGKm2-AcrpMutator plasmid with the mutant crp allele from This study
p1 l29Acrp
pEGFP-N1 Reporter plasmid with enhanced green fluorescent 4
protein driven by the CMV promoter
1) K. N. Timmis, GBF-National Research Center for Biotechnology, Braunschwieg,
Germany. 2) R. Cipriano, U.S. Fish and Wildlife Service, National Fish Health
Laboratory, Leetown, Wv. 3) Invitrogen, Carlsbad, CA. 4) Clontech, Palo Alto, CA.101
Identification of the dapA gene from Y. ruckeri:
Chemically competent BM27 10 cells (Table 4.1) were transformed with 100 ng of
plasmid DNA from the pooled Y. ruckeri genomic library. Transformants were plated on
LB plates with and without DAP. Several colonies that grew in the absence of DAP
supplementation were selected for analysis. Plasmid DNA was extracted from overnight
broth cultures. The clones were subjected to restriction analysis and automated
nucleotide sequencing (OSU Center for Gene Research and Biotechnology, Central
Services Lab). One of the clones, p1 129-015, was completely sequenced and used to
construct a homologous recombination vector. (The nucleotide sequence of this clone
will be submitted to GenBank)
Identification of the aroA gene from Y. ruckeri
Degenerate oligonucleotide primers were designed to the conserved regions of the
aroA genes from E. coli (GenBank accession X00557), Y enterocolitica (GenBank
accession M3 2213), Y. pestis (L463 72), Edwardsiella ictaluri (AF 110153), and
Aeromonas salmonicida (L05002). Primers ME697 and ME698 were used to PCR
amplify the aroA gene from Y. ruckeri 11.29 genomic DNA. A 1.1 kb amplification
product was cloned using the Original TA cloning kit (Invitrogen) to create plasmid
p1 l29aroA. The 1.1 kb PCR product was also directly sequenced. (The nucleotide
sequence of this portion of the aroA open reading frame will be submitted to GenBank.)102
Table 4.2. Oligonucleotide primers used in this study.
Name Sequence Function
ME680 CCCGTGATAAGTTCCCTGTGG dapA screening primer
ME707 ACGCCGATGGACGACAAAG dapA screening primer
ME697 CCACCAGCGAGAAACACAT aroA genomic primer
ME698 TGGAATCCCTGACBTTACA* aroA genomic and screening primer
ME703 GCATATAATCATCVCCCCA* aroA screening primer
ME705 CCGTGCCAGCATTGCCGAGG aroA inverse PCR primer
ME706 GTGTCTCCAGCCAGTTCCTGACCGC aroA inverse PCR primer
ME674 CTGATCAAAGACGAAGAGGGTAAAGA cipgenomic primer
ME679 GGAGATCAGGTTCTGATCTTCCAGCA crp genomic primer
ME724 CAGAAAAGTCAGACCCTCAACCC opgenomic primer
ME725 AGCCAATACTCACTGGTAAGCAGA crp genomic primer
ME695 CTTCACAGGCGGTTTTTG crpinverse PCR primer
ME696 GACGTCAGATTGTTGGCTGTTCC crp inverse PCR primer
ME714 CCAGGGGGATTTCATTGGTG crp screening primer
ME7 15 TTCAGTATGCGACCGACAGTTTC crp screening primer
= C, G, or T; V= A, C, or G
Identification of the crp gene from I'. ruckeri
Oligonucleotide primers were designed to the conserved regions of thecrp gene
from published nucleotide sequences of E. coIl (JO 1598), Pasleurella haemolytica
(L47536), P. multocida (U95380), Salmonella typhimurium (M13773), Haemophilus
inJluenzae (M77207), H. somnus (L47539), Klebsiella aerogenes (M68973), K.
pneumoniae (AJ278967), Vibrio cholerae (U87623), and Shigellaflexneri (M13772).
Using primers ME674 and ME679, a 393 bp region of crp was amplified from the 11.29
genomic DNA and cloned using Invitrogen's Original TA cloning kit to generate plasmid
p1 l29Acrp. The sequence of this fragment was used to design primers for inverse PCR103
and screening of mutants (described below). The complete nucleotidesequence of c,p
was assembled by first sequencing the 3' and 5' ends of thecrpmutator plasmid
described below. Then new genomic primers, ME724 And ME725,were designed
upstream and downstream of thecrpcoding region and used to generate a 1.2 kb
amplification product. This PCR product was directly sequenced togenerate a full-length
consensus sequence ofcrp.(The full-length crp sequence will be submitted to
GenBank.)
Construction of mutator plasmids
pKNGKm and pKNGKm2
We inserted two different kanamycin resistance cassettes at different points in
pKNG 101 to allow the use of donor strain S 17-1 Apir. The kanamycin resistancecassette
from pLOFKm (Herrero et al., 1990) was excised with NotI and insertedat the unique
NotI site of pKNG1O1 to create pKNGKm. This plasmidwas used in construction of the
dapA mutator plasmid (see below). Insertion of the kanamycin resistancecassette at the
NotI site truncates 12 codons from the strB open reading frame. However, itwas
discovered during production of the dapA mutants that the plasmid still confers
streptomycin resistance, probably because the strA coding regionwas intact. Plasmid
pKNGKm2 was designed to disrupt the strA open reading frame, and to introducea
kanamycin resistance cassette for which the entire nucleotidesequence was known. The
kanamycin resistance cassette from pUT-miniTn5 was excised with Xmal and insertedat
the Agel site ofpKNGl0l (Table 4.1).104
Adap mutator piasmid
First, a deletion mutation was made in the dapA gene by digesting pit 29-015
withBshTl(MBI Fermentas) and Sgfl (Promega), filling the ends with T4 DNA
polymerase and re-ligating the blunt ended plasmid DNA. These manipulations resulted
in a 130 bp deletion in the dapA gene and a frameshift. The deletion was confirmed by
PCR with primers flanking the deletion point. The nucleotide sequence of the resulting
plasmid,p1129-Ol5Adap, was also confirmed by automated sequencing (OSU Center for
Gene Research and Biotechnology, Central Services Lab). Additionally, p1129-Ol5Adap
was no longer able to complement the DAP deficiency of E. coli strain BM2710.
To create the dapA allelic exchange vector, the 1.5 kbBarnHI-MluIfragment of
p1 129-0 1 SAdap was ligated to the 6.7 kb BamHI-PauI fragment of pKNGKm. The
ligation was used to transform the transfer strain SI 7-1pir. The resulting mutator
plasmid, pKNGKm-Adap, was used in conjugation experiments to create mutant Y.
ruckeri.
tiaro mutator plasmid
Mutagenic inverse PCR was performed as described by Weiner and Costa (1995).
Briefly, using phosphorylated primers ME705 and ME706 designed to delete 234 base
pairs from the coding region of aroA, plasmid p1 l29aroA was amplified by inverse PCR
with Platinum Pfx polymerase (Invitrogen) to generate a 5 kb PCR product. The PCR
reaction was digested withDpnIto degrade any remaining template DNA.DpnIonly105
cuts methylated DNA and leaves the PCR products intact. The 5 kb product was self-
ligated to produce plasmid p1 1 29AaroA. The I kb ApalIBarnHI fragment of
p11 29AaroA was ligated to ApaIIBamHI digested pKNG-Km2 to create the mutator
plasmid pKNGKm2-AaroA.
Acrp mutator plasmid
A mutant version of the crp gene was generated by mutagenic inverse PCR as
described above. Primers for inverse PCR (ME695 and ME696) were designed to delete
236 base pairs from the coding region of crp. The phosphorylated inverse PCR primers
were used with ELONGase polymerase (Invitrogen) to amplify a portion of the 11.29
genomic library. The reaction products were digested withDpnIseparated by agarose gel
electrophoresis. An 8 kb product of inverse PCR was self-ligated and the ligation was
transformed into Ultra-competent TOP 10E.coli (Invitrogen) to produce plasmid
p1 l29Acrp. The 3.5 kbBamHlISpeIfragment ofpl l29Acrp was ligated into the
BamHIISpeIsites of pKNGKm2 to create the mutator plasmid pKNGKm2-Acrp.
Mutagenesis procedure
DonorE.co/i strain Si 7-1 Xpir and recipient Y.ruckeriwere grown overnight at
37°C and 25°C respectively in Luria-Bertani (LB) broth with appropriate antibiotics. A
100tlaliquot of each overnight culture was pelleted by centnfugation and resuspended
in LB without antibiotics. The resuspended bacteria were mixed and drop-plated on
tryptic soy agar (TSA) plates supplemented with DAP. After 6 hours of conjugation, a106
portion of the conjugation mixture was streaked on TSA supplemented with kanamycin,
polymixin-B, and DAP. Putative transconjugant colonies were streaked for purityon
TSA plus kanamycin. polyrnixin-B and DAP. PCR screeningwas performed on
individual transconjugants to confirm the partial diploid genotype.
Individual transconjugants were then grown for 6 to 18 hours without antibiotic
selection and plated on TSA with 5% sucrose and DAP. Sucrose resistant colonieswere
re-streaked on TSA with sucrose and DAP. Single colonies were then screened by PCR
for the deletion mutation. The phenotype of the mutants was confirmed by replica
plating on appropriate selective media.
PCR and phenotype screening
Confirmation of genotype was carried out in 25tlPCR reactions with Taq DNA
polymerase (Promega) and an MJ Research DNA Engine (MJ Researchmc,Waltham,
MA). Whole bacterial cells were added as template as follows: A plastic pipette tipwas
touched to an individual colony. The colony material was suspended in 50 p1 molecular
grade water and 1tlof the dilute cell suspension was added directly to the PCR reaction.
The dilute suspensions were also drop plated onto selective agar plates for phenotype
analysis. For the dapA gene, amplification with primers ME680 and ME707generates a
wild-type band of 457 bp whereas a 327 bp product is generated from themutant allele.
Similarly, amplification with primers ME698 and ME703 generatesan 863 bp product
from wild-type aroA and 629 bp from the deletion mutant aroA. Mutant and wild type
crp genes are distinguished by amplification with primers ME714 and ME715 producing
a fragment of 398 bp for the wild-type and 130 bp for the mutant alleles. For phenotype107
analysis, the bacteria were drop plated onto M9 minimal medium with andwithout
aromatic supplementation and/or DAP, and LB-kanamycin-DAP plates.
Southern Blot
Genomic DNA from each mutant strain was digested with either EcoRVor Dral
and separated by agarose gel electrophoresis. Approximately 200ng (3.7 X106genome
equivalents) of digested DNA was loaded per lane. EcoRV digested pKNGKm-L\dapand
pKNG-Km2 were also loaded on the gel at approximately 3.7 X106copies (0.35 ng
each). The resolved fragments were transferred to GeneScreen plus membrane(NEN) by
downward capillary transfer under alkaline conditions (Ausubelet al., 1993). The
membrane was probed with Dral digested pKNG-Km2 using the PierceNorth2 South
Direct kit (Pierce Jiic, Rockford IL) according to manufacturer's instructions.To confirm
that the mutants only carried a singlecopy of each target gene, blots were also probed
with PCR amplification products of the wild-type dapA, aroAor crp genes.
Growth curves
Overnight broth cultures of each mutant and the wild type 11.29were diluted in
80 mls of LB broth plus DAP to an0D600of 0.05. The cultures were incubated atroom
temperature with shaking on a gyratory shaker at approximately 200rpm. Absorbance at
600 nm was measured hourly for the first 10 hours and thereafterevery two hours until
the 32-hour time point. A growth curvewas also generated for the dapA single mutant Y.
ruckeriwith and without DAP supplementation in LB broth.In vitro invasion assay
CHSE-214 cells were seeded into 18 mm round coverslips in 12 well tissue
culture plates. After 48 hours the CHSE cells were infected at a MOl of 100 withone of
the mutant strains or wild type V. ruckeri 11.29. The plates were centrifuged in
microplate carriers at 1100 X G for 5 minutes at 4 C. After 2 hours incubationat 20 C
the non-adherent bacteria were removed by 3 washes with serum-free medium.
hitracellular and extracellular bacteria were differentially stainedas described Van Putten
(1994) with minor changes. Briefly, the monolayers were fixed with 2% methanol-free
formaldehyde in PBS. Extracellular bacteria were immunostained with rabbit anti-Y
ruckeri antibody (courtesy of Craig Banner, Oregon Department of Fish and Wildlife)
followed by Texas red conjugated goat anti-rabbit antibody (Vector Labs, Burlingame,
CA), each diluted 1:500 in PBS. The monolayers were then permeablized with 0.15%
Triton N-101 in PBS. Antibody staining was repeated with the polyclonal rabbit anti-V.
ruckeri antibody and FITC conjugated goat anti-rabbit antibody. Monolayerswere
counterstained with 0.25 jig/ml DAPI and viewed on an epifluorescence microscope with
a CCD digital camera.
Gentamicin protection assay
CHSE-2 14 cells were cultured as previously described (Engelking and Leong
1981) exceptCO2Independent Medium (Invitrogen) supplemented with 5% fetal bovine
serum (FBS) was used as the culture medium. Gentamicin protection assays were109
performed essentially as described by Elsinghorst (1994). Briefly, CHSE-2 14 cellswere
seeded into 12-well plates at 2 X l0 cells per well. After 24 hours, the monolayerswere
infected with 2 X107bacteria per well. The monolayers were then incubated atroom
temperature for 2 hours (invasion incubation), and then the cells were rinsed 3 times with
serum-free medium. The rinse medium was replaced withCO2Independent Medium
supplemented with 10% FBS and 100 mg/l gentamicin. The monolayerswere again
incubated at room temperature. This "gentamicin-kill" incubationwas allowed to
proceed for 4 or 22 hours. Replicate wells of infected CHSE-2 14 cellswere lysed with
I % Triton-N 101 (Sigma-Aldrich, St. Louis, MO) in LB broth immediately after rinsing,
or after 4 and 22 hours gentamicin-kill incubation. Ten-fold serial dilutions of the cell
lysates were plated on LB plates with DAP. The agar plateswere counted after 48-72
hours incubation to determine cfu/ml. The number of bacteria recovered immediately
before addition of gentamicin (time=0) represents the cell-associated bacteria. The
bacterial counts at 4 and 22 hours post gentamicin treatment represent intracellular
bacteria that are proiected from the bactericidal activity of gentamicin. Invasiveness
index was calculated as the percentage of cell associated bacteria that survived 4 hours
gentamicin treatment ((cfli per well at 4 hours/cfu per well at 0 hours) X 100).
In vitro gene transfer
CHSE-2 14 monolayers were seeded into 12-well tissue culture plates and infected
with bacteria (MOl100). The plates were centrifuged in microplate carriers at 1100 X
g for 5 minutes at 4°C. After infection and rinsing the medium was replaced with MEM-
5 plus 100 tg/m1 gentamicin to kill extracellular bacteria. The monolayerswere110
incubated at 20°C and examined on an inverted fluorescence microscope 24 hours and 96
hours post infection.
Flow cytometry
CI-ISE-214 monolayers were seeded into 25cm2tissue culture flasks or 6 well plates
and infected as described above. In this case, the flasks were not centrifuged. After
infection and rinsing the medium was replaced withCO2Independent Medium plus 10%
fetal bovine serum and 200 jig/mI gentamicin to kill extracellular bacteria. The
monolayers were incubated at 20°C. Five days after infection, the cells were trypsinized
and fixed with 2% methanol-free formaldehyde in preparation for flow cytometry. The
cell suspensions were analyzed on a Becton-Dickinson FACScalibur. Approximately
100,000 to 250,000 events were counted for each sample.
RESULTS
tdentification of dapA, aroA, and crp and creation of mutant alleles
The nucleotide sequences Y. ruckeri 11.29 dapA, aroA, and crp geneswere
compared to E. co/i and Y. enteroco/itica (Figure 4.2). During the course ofour studies,
Naharro and colleagues submitted to GenBank the nucleotide sequence of the aroAgene
from an unspecified strain of Y ruckeri (GenBank accession AF360730). Thissequence
was also included in Figure 4.2b. For these analyses, only the putative protein coding111
regions were included. The shaded boxes indicate regions that were removed by
restriction digest or inverse PCR to create the mutant alleles for the mutator plasmids.
The dapA gene from 1'. ruckeri is clearly different from both E. co/i (M12844)
and Y. enterocolitica (AJ34500 1) (Figure 4.2a). However, the Y ruckeri dapA is more
similar to Y. enterocolitica than to E. co/i (82% and 72% sequence identities). The aroA
gene from Y. ruckeri 11.29 was also distinct from the Y enterocolitica and E. co/i
sequences. However, there were also some minor differences from the Y ruckeri
sequence AF360730. These differences could reflect strain differences among Y ruckeri
or could be sequencing errors. The 11.29 aroA sequence was 98% identical to
AF360730, 78% identical to Y. enteroco/itica (M33213), and 71% identical to E. co/i
(X00557). The crp sequence obtained for Y. ruckeri 11.29 was also distinct from the E.
coli sequences in GenBank. The sequence of the Y. enteroco/itica cip gene has not been
submitted to GenBank as of this writing but was obtained from the Sanger Center
genome server (www.sanger.ac.uk). The Y. ruckeri cip matched the Y. enterocolitica
sequence with 89% identity. The E. co/i sequence, JO 1598, was 83% identical to the Y.
ruckeri crp.112
Figure 4.2. Nucleotide alignments of the putative coding regions of 3 V. ruckeri
genes. Shaded regions of the Y. ruckeri genes were deleted to create mutant alleles, a.
Alignment of dapA from Y. ruckeri with Y. enterocolitica (GenBank accession #
AJ345001) and E. coil (M12844). b.Partial coding sequence Y. ruckeri 11.29 aroA
gene compared with an unspecified Y. ruckeri (AF360730), Y enterocolitica (M32213),
and E. coil (X00557). c. Comparison of cip from Y. ruckeri 11.29, Y enterocoiitica
strain 8081 (from the Sanger Center Genome server www.sanger.ac.uk), and E. coil
(JO 1598).1129 1ATGTTTACGGAAGTATTGTTGC6ICTG T ACGCCGATGGACGACAAAGG 50
Vent. IATGTT ACUGGAAGDATQGT GCGTTCACGCCGATGGA GA AAAGG 50
E.coli IATGTTCAC000AAGTATTGTC ATTTA TCCGATGG T AAAAAGG 50
1129 51TTGTCGATCGTGUGAG CTTAAAAAACT ATTGATTATCATGTTGCC tOO
Vent.51 TAATGTCTCOTOC AGTTAAUAAACTTATDGATTATCATGT GCCtoo
E.coli51 TAATGTCT 0 T TTGAAAAAACTGATTGATTATCATGTC 100
11.29 1010 GGCACTGCGCOATTGTCTCCGTGGWACGACGGGTGATCTGCCACG 150
Vent. 101GTGGAACT CGGCGAT GTrcGTUGGCAC AC GG GAUTCTGCGAC 150
Ecolu101GCGGTA TTCGGCOATCTT TOTTGGCA CATCOAGTCCGCTACC 150
11.29 151CT GA AT CAT GA C GA A CAT GJG A TOT GOT TT GA T GA C G CT GO A ACT G GCI200
V. ent.151T T 0 A AJC A T 0 A C G AJC A T GbT G A 7 0 TEIG T CT GG A CG C TEIG A A C T 0 0 C200
E.coIi 151TT AATCATGACGAACATGCTGATOTGGTGIATGATGACGCTGGAIICTGGC 200
11.29 201TGATOGCCGCATTCCAGTGATTGCUGGAACCGG 250
Vent.201CGATGGCCGEIATTCCTGT ATTGCCGGAACCGGTCCTAATGCICIACICUG 250
Ecoli201TGATGOflCGCATTCCGOT ATTGCCGGflACCGGROCTA8JCTIACTGCGG 250
11.29251 4CT 1 CA CIT T4 300
fl
11.29 301 350
Vent.301 FTGACGOTGAC CCATA TA AA CGUCC GCA GAAGGEIrUr,,TCAJ 350
E.coli301 ICTOACGOTA C TCTACA TCGTC GTC AGAAGOTTTGTATCAI 350
11.29 351 ...9#CGCUGAAAGTACCOTTCCACAAATCTCTAT4o0
Vent.351 GCATTCA.AGCATGCTGAAA TACC TrTUCC CAAATUCT TATA 400
E.coli351GCATTTCAAAGCICIATCOCTG__GCAT TCCT OCAAATTC G 400
11.29401ATGTGCCIA COCOTACCOG TGCGATATG TGCCG AAC GT CC COT 450
Vent.401ATGTGCCICTC COTAC GO TOCOAT TGTTACCG ACCAT CCCGT 450
E.coIi401ATGTGCCIGCCGTACTGCCTGCGA CCCGGAAACGGTGGG T450
11.29451 TTAOCCAAGATCAAATATTGTTOCG TAIAAAGAAGCUACAOGGAACTT 500
Vent.451TAGC AATTAAAAATATTTCTTTAAAGA GCAACAGGGAACTT 500
E.coli45IC00AG AAAAAATATT CC CAAASAGGCAACAGGGAACTT 500
11.29 501T AC000TAAGTCAGATCCAACTGCTGCTTGATGATGAAGATTTCATCC 550
;A5 _______IkGCITIILaJ1T11IJSJ 550
11.29 551TGCTT GTGGTGACGATOCIJIIJGGT TGACTTTATGCAJTGGTGCC 600
Vent.551TOCTCAGTOG GA GATOCGAGCG TWGACTTTATGCAUTTUGG GO600
E.coli548TCTGA C CTGATGCGAGCOCGCTGGACTTflATCCAATTGG_C T597
11.29 601AAGGTGTTATTTCGGTAACCGC AAC TTGCGGC CG GAAATGG AA650
Vent. ooiCAAGGTGTTATTTC OTGACA C AACT GCTGCGCGA ATGGTT 5650
E.coIi598 TGCTTATTTCC TG CTAACG CGCAGCGCCTG _ TATCGCC A647
11.29 651CTTTGTGCTTT GCG0CTGAAGGICATTTGCCQA1IJCGCCG TTAfl 700
Vent.651CTTTGCGCCCTGGCTGCACAJGGTA CTTTGCQGAGCCACGCTTTGA 700
E.coli648 GATGTG AAACTGGCAGCAGAAGAAC TTTTGCCGAGGCACGCGTTATTA 697
11.29 701A CAACGCTTGATGCCGTTGCATCAOCATTTATTTOTAOAAGCAAATCCA 750
Vent. 701ATCAGCC TTGATGCCGTTGCATCAGCATTTATTTGTAGAACCAAAJCCA 750
E.coIi698 ATCAOC TCTGATGCCJI JACCACAACTATTTGTIIGAflCJlAATCCA 747
11.29 751ATTCCGGTGAAATOGGCICTCTAAO.GCTGCGICTTGIATGGCJAATGAC C800
Vent.751ATTCCGGTGAAATGGGCIT CCAAGUA CTGCGI TTAATGGCGAATGA AC 800
E.coli748 CCCGGTGAAATGGGCI TGTAAGGA CTGGGITCTTGTGOCG_CC T 797
11.2980l FIITGCGTCTGCCAATCACI CC CTGACTCACCCTGC AAACTGGr OTOG 850
Vent.801CTGCGcToCCAATCACICCCA TAC GAC 07A GGTOT 850
E.coIi798GICTGCGICICTGCCAATGACI AC C SOT OTCOTG GACGCA 847
11.29 851 AA 0CC TGAAAACCGCGGTTTCCT0TAA882
Vent.851AAGACOCCCT AA CCJGGTTTCCTCTAA882
E.coli848GA CGGCCCTTGCA GCCGGTTTGCTGTAA879
Figure 4.2a
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CCAT(G c1CTCATCAATCCCACICII 27
Y.ruck. IATCCTuCAATCCCTCACCT
1129 /
CCCATcGTCATCAATCCcAdlCTI 39
CTCIATIIIAATCCCAdT1CTI 50 Vent. /ATCCTGCAATCCCTCACT
E.coli / TCCAATCCCTCACCTTACAACCCATCGCTIdTiATC/OCACITTI47
11.29 28A CCTTC CIAAAAGTCI I cIAACCCTCCTTTACT TITGGCAcI77
Y.ruck. 51 AC IC CIAAAACTCT T CIAACCCTGCTTTACT ITCGCACI /00
Vent. 51A TTT CC IT TAAAACTCT I TAACCGTCCT CT cITCGCA*1 100
E.coPi 48TACT C TT A C CTI TAACCcflCCTTTTC!1TCGdd 97
11.29 78fl 11CCC1AGCCCACAAcflCTTACAACCTCCTACACAGTGATCAI /27
V.ruck. /0!IdTTCC TGA600GACAAcliCIT (ACAACCTCCTACACACTGATCAcI /30
Vent. 10/IIC(TCGCACCCGACAAIkj TC,TAATcTACACACTGATCAcI ISO
E.coli 98 IT CCA C AA ACT TT ACCA TcTGcTIaflJGATCAc1 /47
11.29 /28 IATTCCCCATATCCTcIAATGcI CT AA ICTCGCT(A TT CTIf9/77
V.ruck. IATICCCCATATCCTCIAATCCI CT AA ICICCCTCAI CTIll200
Y.ent. IS!AIICGCCAIAICCITIAAICCIICTAI CATTGCCT AI ICCclii 200
E.coli /48IICGCCATATCCTdAATCdATT (CCTTflCCICCI TACCdII /97
11.29 /78CTCTCCTC!AICCTACCiA TGTCICTTCACCCTTTCC ICCCIC 227
V.ruck. 20/CICTCCICAICCIACCCIA TCTCCTTGACCCIIICC C CCIC 250
Vent. 20/TCTCCICAICCIACCcIC TCTCGTTC TC11CCC CATIC 250
E.coIi /98TI CCAICCTA(1d4C T diAI ATCCC_AA CC ICC IIAC 247
11.29 228 ITCCCAGCAflAAfldCTCCAATTAITTCCTCCd AAIC TICCCACCC 277
V.ruck. 25/TCCCACACAAAAICI CTCCAATTAITTCCICCAAIC IICCCACCGCCAT 300
Vent. 25/ CGCACCCCCAT 319)
E.coli 248 CCCAGAIACCIc4CICCTTcTTCCTCCcTA C CACCCAT 297
11.29 278 .C4C1 327
V. ruck. 30/CCCCCAIICGCGCCCCC AcTCTCCjTGCCAC4ICATAIlCICcICAc1 350
V. ent. 301CCCCCAIICCcCCCCCACICICdTCGCGAAHTCAaA1ITCTTCAi 350
E.coli 298CcflCCITCCCCGCflCd1C1fflTdIdTCCcF1AIdCAIAiTCATATIICTCCICAd 347
1129 38
V. ruck. 351C C C C C ACiCC
Vent. 35!CCCCCA CC C
E.coli 348 CC. CC
11.29 378
V. ruck. 40/ -- cIACGGCC
V.ent. 40/ICCGTCACCGCC
E.coli 39.yTCCd9I1CCCCC
11.29 428
V. ruck.448 [CEj4IIGcCIAIlII
ATCAAACACCCCCCCATCC,CTCAIIICC C C 400
ATCAAACACCCICCQATTCCTCAITICCC TC1 400
ATC,AAAGAICCCCCGATTCCTCAT ICCC IG GC 397
Iii 427
CCACAGATTCATT ATCTCCAACAIcICAAAATTAICC 447
CCACACATTCATTATCTCCACACAAA4TA CC 450
GC ACATIT9LLICTCCAACAIAICAAAATTATCC 447
I liii
_CC(icGclTIIIclCc4c1Cc1IICCTIdlAACId4Acld1CTHGACGd1
V.ent. 45!IClZT- -T1dflATIACCCGd&dCITTTICdTICdCICCTIAIAACIdAddCTIAICACGd 497
E.coIi 448 IT4AckCCC 497
11.29 478 CTCTCICCACCCATICCTdACCCdCITTCAT CCC CT9 527
V.ruck. 498CAOTCTCTCCACCC4TICCTdACCCdCIITCAT CCC CTdd 547
Vent. 498CA TCTTTCCACAIA1TICCTCIACCdA ITITCAI AICI C IC CIIAc 547
E.coli 498IC CTTTCCACCCAJAJTTCCICJACCCdA IIAT AIJICC ICIIU
11.29 528flA CAC C ACcJIA c1CCTATTC*4GCCCATCTCCTCTcfl CC C 577
Y.ruck. 548IdA CAC C ACCIAI ATdCCTATICAidCCCGATCTCCICTddAI CC C 597
V. ent. 54kiTCA CC IA Ic.1AT TICA TA1AIG cJC AT C C IC1(1114C C1 597
E.coli 548UC CC IACI A 1ICCTATTIAIAiCGCGATCTCCTITLJTA C1597
11.29 578IATATTCAITA (.CTCCATCTCATCICCCflCITITCCTCTTCAACTGAC 627
V.ruck. 598TATAI C IATIACTCCATCTCATCICGC6IGITTTCGTCTTCAACTCAC 647
V.ent. 598TATAI CAIIA CITCCATCTGATCIAAACCdTTDCCTCTOC TCICCT 647
E.coli 598TATAI CATA CC ATCTCATd1AAdCd1TTICCTCTTCAIICA 647
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11.29 628ACCAAAATT CCATATT CATATTCfl 6 cI6G6CAI ATACC TI 677
Y.ruck. 648ACCAAAATT CCATAIl CATATTCIAI 6 c4606CAI ATACC TI
Vent. 648ICT AAAATT TC6 TTTTTCATATTAH 6 CIGGGCAI ATAC 6(1 697
E.coIi 648 IC 61 ICA C ATTTGTCA46 c166OC4GlI IC T697
11.29 ICACCOGGIGA TAICIGGI 60 clGAIGcl ITCTGICTIAIIT 727
Y.ruck.698 ICACC GGIGA IAICIC.GI 66 cGATGCIlIICIG cICIIAIIT
Vent. GGIAI TATCIGGI C',0 TIGAIGI IICTG ATCTTATT C747
E.coli 698 UTICCGGGTACTTATTTGGT 60 CIGATGd I 10 TITCTTII 747
11.29 728CTCGCCGCAGCAGCAATCAAAOGCGGAAGTTCGCGIGACI G6CATTG4
V. ruck. 748CTCGCCGCAGCAOCAATCAAAGGCGGAA61 CGCGT Ad GGCAITGc4 797
V ent. 748CTCGCC6CAGdJ3GCFJATCAAA0fJG6AA01 CGCGTAC1 GGCATTGc4 797
E.coli 748C0GCAGCAOCAATCAAAGGCG (A TOT AAA GIOAd C TATTGd 797
11.29 778IAAAAAOTTICAGGOATACCAAIAJTTTC,CIGATGTACTOOAAAAAAI 827
Y.ruck. 798TAAAAAGTTICAGGcIIGATACCAAHTTTGCTGATGTACTOGAAAAAAI 847
Vent. 798TA A AAA ToIAlCAGt4lIciATACCA ITTT6CTGATGTACTOGAaAAAA 847
E.coli 798ACG A CA 1 TcICAGG(ITIGAI_TTCGC1lTTGCTC.ATGTICTGGAAAAAAI 847
11.29 828IGGGCGCICfl CAT CAITTOGGOCOATG4CITAIATCGAI TGCAOCCGIGGT 877
Y.ruck. 848TG0GCG('ICIAITCATCCAITTGGOGCGATCAICITATATCOIGCAGCCGTGGI 897
Vent. 848IGGGCGcITIAIA AT Ac4TGGGcJGAI0ATTATATCGIOCAGCCOTOGT 897
E.colj 848I6l',GC0d1JCATTTGdTC.000CGATGAJITATAITTC ICC C CGTGGT 897
11.29 8780CI ICTATCGATAIGGATATOAACCAIATTCCIIGATOCOOCI(A 927
Y.ruck. 898 IiCI C'CTATCGAIATGGATATOAACCATATTCCICIGAIGCGGCI A 947
Y.ent. 8980 AIIACA TATCGATATGGATAIGAACCAIATTCCII0AIGC0CI A 947
E.coli 8980CTACTATTGATATGGATATGAACCATATICcJTGATOCOGd Al 947
11.29 928GACCAIIGCCAdITGCCGCOCIGTTTGCCAAAOd CC0ACCATTATTCGC 977
V.ruck. 948GACCAITGC 'AdIIGCCGCGCIGIIIGCCAAA0CCGAC ATIATTC0CA 997
Vent 948GACCATIGAdIC CCGCTC.TTTGCA10c1 CCGA T TIAITCtAI
E.coli 948GACCATIOCCAtJ 6Gd IT 1116AAAOtJCACt GGdJC0c 997
11.29 978ATAICTATAACTGGCGAGTAIAAAOAOAcITGACCTIATGCft1AI0GC /027
V.ruck. 998ATAICTATAACTGGCGAGIAIAAAOA AIIGACCITAT (/AIATGGC'°
Vent. 998ATAICTATAACTGGCGAGTc1AAI0AAcI GACCIIAT6 dATGGC
E.coli 998ATAT(1AIAACTGGCGTTIAAAOAOAd CC1 16 tIATC,0A 1047
11.29 /028A IGAACITIAGAAAAGIIIGGCGcHOAAOTGGAAGAI 0 dCAAGATTATA /077
Y.ruck./048A dIOAACTTIAGAAAAGTTIOGCOCIAIGAAOTGGAAGAI 6 CICAAGATTAITA /097
Vent. /048A TIGAAaTc GAAAAGTcIOGCGCIdIOAAOTGGAAGAI 6 c1CAAGATAICAI /097
E.coli /048A AIGAACTGdCRAAAGTCIOOCGCIdGAAGTGGAAGAI 6 dCAI1GATTAI Al /097
11.29 /078ICGIGICG CCCCTGCGCCTGAICG6GAAAIIGACTTAI 1/27
V.ruck./098TCGTGTCG CCCIGCGCCIGATCG6GAAAIIGACTIAI 1147
Vent. /1198IC61 6 CCCTGCOCCTQATCG6GAAAT 6ACTIAT /147
E,coli 1098ICOI ACTC IC AA CTGIT 0Al CA T /147
11.29 1/28cI6AICACC06AI66Cd ____________________________ 1144
V. ruck./148*IGATCACCGGAIGGCGATGI C4JTICICGCI66TGGC6TIATCTGAT ACd /197
Vent. //48 1197
Ecoli /148II6AICACCGGATGGCGA1GTGTTTCTC0CIG6TG6CC.TIIIJ0ATA A 1/97
11.29 1/45 /144
V. ruck.//08CCAGTGACTATICIUGATC1A1AAATCiCACG6CCAAAAdjTTCCCGGACI /247
Vent. 1/98CcGIGACTATDCITGAICcAAATcACGCAAAACATICCcGACT /247
E.coIi 1/98CCAGTOACIaATTCTIGATCdCIAAATGCACOGCCAAAACAITF1CCG6_II /247
11.29 //45 /144
V.ruck./248TTICGACAAC TO TC ITT A TOT 10IA /284
V.ent. TI9GACAACT60CCCIT AGCCATAGCCIA /284
E.coli/x ITTCOAGCAJaCTGG C6 TTAGCCA 0 AGCC /284
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11.29 I AT(1GITCTCUGCAAGCCACAAACAGACCCWACTCTCGAATGGTTCCTGTcI 30
Vent. /A ;cJTrTC1CAAGCCACAAACAGACCCGACTCTCGAATGGTTCCTGT 50
E.coli IA 50
11.29 51TC CIGCCATATCCATAAGTATCCATCGAAGAGTACGCIATICACCAG 100
Vent. 5/TCATTGCCATATCCAAATATCCATCGAAGAGTACGCTAIATTCACCA /00
E.coli SiTCATTGCCAl9JlCATAAGTAJCCATcflAAGAIACGCITIATICAcCAG /00
11.29ioiGTGAAAAAGCCGAAAC CTITACTACATCGTGAAAGGIjTCCGTTGCc3GTT 150
Y.ent./0/GTGAAAAGCCGAAACTTTACTACATCGTGAAAGGCTCCGTTGCGGT 150
E.coli 10/GTGAAAAAGCIGAAAcGCTIaTACTACATCGTIIAAAGGCTCTGT GC GT 150
11.29iiCTGATWAAAGATGAAGAAGGTAAAGAAATGATTCTCTCCTATTT AACC 200
Y.ent./5/CTGATCAAAGATGAAGAAGGTAAAGAATGATTCTCTCCTATCT AACC 200
E.coli/5/CTGATCAAAGAnGAAGAIaGGTAAAGAAATGATnCTCTCCTATCT A IC 200
11.29 20/GG ('IGATTTCATCGdJGAACTTGGATTATTTGAAGAAGGCCAAG1CGIAI 250
Vent.20)GG A1GATTTCATCGGCGAACTTGGATTATTTGAAGAAGGCCAAGAACAI 250
E.coli2(//(3(3 TIGATTTFIATRGGCGAACTI&(1flTTTGAAGA1aGGCCA1GAACGTA] 250
11.29 251 300
Vent.251 IGGCTGGGTC cGCAAAAAcOGCCTGTGAAGTGGCTGAAATTTCTTAd 300
E.coli25!c1AITGGGT cGTGCIAAAAccGCCTGT(3AAGTGGCTGAAATTTCIa 300
11.29 30/ 350
IGAI(3CflTI350 Vent.30) _
GATGCGTITW 350 E.colisoiAAAAAATTflCGCCAATTGAT ICAGGI
11.29 35/ 400
__________________ 4TdIGAGAAAGTGGGT
400 Vent.
GAGAAAGTGGfl400 E.coli35)GTCTGCACAGATC(3C
11.29 450
Vent.40/hCCid CCIGATGTGAdTIG6ACGCAITGCACAAAcGCIGCIIIIAAII 450
E.coli40/ACCT 450
11.29 45/ 500
Vent. ICTGGCAAAACAACCTGATGATGAICACccAGATGGGATGCAGATIA4 500 E.coli 451CTGGCAAAACAACdJGcTATGA TCACCcfaG iATGC4cL 300
11.29 50! GTCAGAIIGTIGGCTGIICCCGCGAAACT550
Vent. 501ATIACCCGCCAGGAAAITGGTCAQAIQGIIGGCIICCCGCGAAACId 550
E.coli30/AATTACCCcflCAGGAAATTGGTCAGATTGTflGGCTGTTcffIIGAAAcI9550
11.2955) [U]T]CGCAT ACTGAAAATGCTLJGAAGATCAAAACCT GATCTCIJ CAC 600
V.ent.55)166CATACTQAAAATGCTGGAAGATCAAAAaCTGATCTCCGCACACI 600
E.coli55!T6GCGCATRCT6AAIATGCTGGAAGATCAIAACCTGATCTCCGCACACI 600
11.29ooj rAAAAGATTGTCGTITACGGCAccC6TTA633 V. ent.60/66 TA A A A C GAIT 6 IC 61 II A C G (3 C A C C C 61 1 A Al 633
E.colj60/GGTAAAAdAGTC6TTTACGGCAcflCGT_TAA1633
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Conjugation and screening
From the mating experiment with S 17-1 &pir pKNGKm-Adap andY ruckeri
11.29, several putative transconjugants were streaked for purity on TSA plates (plus
kanamycin, polymixin-B, and DAP) and verified by PCR. Six out of the eight colonies
screened were true transconjugants as evidenced by presence of both mutant (340 bp) and
wild-type (469 bp) PCR products. Two individual transconjugantswere subcultured for
6 hours in LB broth plus DAP, then plated on TSA-sucrose plates plus DAP and
incubated at room temperature for 48 hours. Sucrose resistant(SUCr)colonies were
picked and streaked for purity on TSA-sucrose-DAP plates. Of the 16 colonies screened
by PCR, 7 showed the 340 bp mutant PCR product (Figure 4.3). Each of the 7 colonies
with the mutant dapA PCR product required DAP for growth onagar plates. All of the
clones were kanamycin sensitive. Clone #10 was selected for further study and
designated 11 .29Adap.
MW 1 3 5 7 9 11 13 15 wt
A 2 4 6 8 10 12 14 16 neg
457 bp (w.t.)
327bp (A)
Figure 4.3. PCR screening of exconjugants from dapA mutagenesis. Colony PCR
with primers ME680 and ME707 amplifies a region of the dapAgene. Sixteen putative
dapA mutants were screened (1-16). Wild-type 11.29 (wt) and p1129-Ol5Adap (A)were
included as controls. A product of 457 bp is generated from the wild type alleleas
opposed to 327 bp for the deletion mutant.118
For the aroA mutation, conjugation of Si 7-1 Xpir, carrying pKNG-Km2Aaro, and
Y.ruckeri11.29 yielded kanamycin resistant transconjugants. Two individual
transconjugants were subcultured for 6 hours in LB broth and platedon TSA-sucrose
plates and incubated at room temperature for 48 hours. Sucrose resistant (5UCr) colonies
were picked and streaked for purity on TSA-sucrose plates. Sixteen individual clones
were selected from the secondary streaks on TSA sucrose plates. PCR and phenotypic
screening of the putative exconjugants (Fig 4.4) yieldedsome interesting results that
illustrate the importance of these screening steps. All 16 putative exconjugant clones
grew on M9 minimal medium plates supplemented with aromatic amino acids (Fig 4.4a).
Of the 16 clones, 8 showed robust growth without aromatic supplementation (aro) (Fig
4.4b) and were sensitive to kanamycin (kans) (Fig 4.4c), indicating reversionto wild type
and excision of the kanamycin resistance cassette. These 8 colonies also showed the wild
type 863 bp PCR product (Fig 4.4d). Five other suc' colonies showedpoor growth on
minimal media with pinpoint colonies occurring after extended incubation (Fig 4.4b).
These same colonies were resistant to kanamycin (kanr) (Fig 4.4c) and had both the
mutant (629 bp) and wild-type (863 bp) alleles by PCR (Fig 4.4d). This indicates that
these colonies had not excised the mutator plasmid. The sucr phenotype of these partial
diploid, kanr clones suggests that expression of the sacBgene was somehow eliminated
without complete excision of the vector. Because the aroA mutator plasmid only carried
coding regions of the aroA gene, any integration of the vector by homologous
recombination would result in the disruption of the genomic aroA by pKNG-Km2Aaro
and an aro phenotype. This is, in fact, what we observed. The pinpoint colonies that
appeared on minimal media (Fig 4.4b) probablyarose from excision of the vector119
sequence and reconstitution of the wild-type aroA gene when these clones were starved
for aromatic amino acids. This hypothesis was not tested further. Of the 3 remaining
aro,kans clones,one (#11) did not amplify in the genotype PCR. Another aro, kans
colony (#6) had a PCR product similar to wild-type. It is possible that this clone acquired
a frameshift or small deletion mutation during excision of the mutator plasmid (again his
hypothesis was not pursued). Only one aro, kan' clone (#14) showed themutant
genotype by PCR (Fig 4.4d). This clone was selected for further study and designated
ii .29Aaro.
For the crp mutation, conjugation of S 17-1 ?pii canying pKNG-Km2Acrp,
yielded numerous kanamycin resistant transconjugants. Two individual transconjugants
were subcultured for 6 hours in LB broth and plated on TSA-sucrose plates and incubated
at room temperature for 48 hours. Sucr colonies were picked and streaked for purityon
TSA-sucrose plates. The putative exconjugants showeda wide range of growth rates and
colony sizes on agar media. Both fast-growing and slow-growing sucr exconjugantswere
selected for screening by PCR. The majority of slow growing colonies (11/16) showed
the mutant genotype (Fig 4.5a), whereas none of the fast growing exconjugants (0/16)
were mutant for crp (Fig 4.5b). Clone 2 was selected for further study and designated
11.29Acrp.120
Figure 4.4. Genotype PCR and phenotype plates of aroA mutants. Sucrose resistant
colonies from the aroA conjugation were drop platedon various media and used as PCR
template to identify aroA deletion mutants. a. M9 minimal medium with aromatic
supplementation. All clones should grow on this medium. b. M9 minimal medium(no
supplementation). Only aro+ clones should grow. c. LB medium plus kanamycin.
Clones that still carry the mutator plasmid will grow but exconjugants shouldnot. d.
Colony PCR for the aroA gene. The wild-type PCR product is 863 bp and themutant
PCR product is 629 bp. Positive control (pos) is E. coli Sl7-1?pir with pKNG-
Km2Aaro and displays both wild type and mutant PCR products. The degenerate
primers ME698 and ME703 amplify both E. coli and Y.ruckeriaroA. Only clone 14
shows the z\aro phenotype and genotype.MW 2 4 6 8 10 12 14 16 neg
Figure 4.4
863 bp (w.t.)
629 bp(it)
121E]
b
MW 2 4 6 8 10 12 14 16 wt
1 3 5 7 9 11 13 15A nei
MW 2 4 6 8 10 12 14 16 wt
1 3 5 7 9 11 13 15A neg
368 bp (w.t.)
130 bp()
368 bp (w.t.)
130 bp(i)
122
Figure 4.5. PCR screening of crp exconjugants. Colony PCRwas performed with
primers ME714 and ME715. The wild-type PCR product (wt) is 368 bp and themutant
band (A) is 130 bp. Both slow growing and normal colonieswere screened. Of the 16
slow growing colonies screened here, 11 displayed the mutant genotype by PCR (a).
None of the colonies with normal growth rates were mutant by PCR (b).
More conjugation experiments were carried out to generate double and triple
mutants. A single dapA mutant, 1 l29Adap, was mutagenized with either the aroAor crp
mutator plasmids to create 1 I29AdapAaro and I l29AdapAcrp double mutants. The aroA
single mutant 11 29Aaro was mutagenized with the crp mutator plasmidto generate
1 l29AaroAcip. Finally, ll29AdapAaro was mutagenized with pKNG-Km2Acrpto
create 1 l29AdapAaroAcrp. Confirmation of genotype by PCR was carried out for each
of these mutants (Figure 4.6).1018 bp
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Figure 4.6. Genotype of Y.ruckerimutants. Each of the mutant strains of Y. ruckeri
11.29 was examined by PCR for the appropriate mutant or wild-type alleles of dapA,
aroA, and crp. Wild-type 11.29 was included for comparison.
Southern Blot
When pKNG-Km2 was used as a probe, no hybridization was observed with
mutant or wild type bacterial genomic DNA (Figure 7a). The only samples that show
significant hybridization signal are the pKNGKm-Adap and pKNG-Km2 lanes. The124
molecular weight marker (HinDIII digest of X-phage DNA) also bound the pKNG-Km2
probe, which is expected since the plasmid carries a portion of the X-phage genome
(Kaniga et al. 1991; Selvaraj et al. 1984).
The blots were also probed with PCR amplification products of the wild-type
dapA, aroA or crp genes. The deleted region of the dapA gene contained a Dral
restriction while the aroA and crp deletions each removed an EcoRV restriction site. The
mutant allele of dapA DNA hybridization with a probe for dapA shows the predicted loss
of the Dral restriction site within the dapA gene (Fig 7b). Further the hybridization with
the dapA probe indicates only a single genomic copy of the gene (with 2 bands in the
wild-type and a single band in dapA mutants). Similarly, hybridization with aroAor crp
probes demonstrated the predicted loss of an EcoRV restriction site in the deletion
mutants (Figure 7c,d). Again, only single copies of the aroA and crp genes were
observed in each strain.
Growth characteristics of mutant 1'. ruckeri
Wild-type Y. ruckeri 11.29 had a growth curve with a short lag phase of about 4
hours followed by rapid log phase growth and reaching stationary phase by 14 hours
(Figure 4.8). Of the three single mutants, only 1 l.29Acip displayed a reduced growth
rate compared to wild-type 11.29, reaching stationary phase after approximately 32
hours. Both 11 .29Adap and 11 .29Aaro had growth curves very similar to the wild-type
strain. The double mutant 11 .29Adaptxaro behaved like wild type, whereas the
11 .29AdapAcrp and 11 .29AaroAcrp double mutants and the 11 .29AdapL\aroAcrp triple
mutant behaved identically to the crp single mutant. Growth in the presence and absence125
of DAP was also examined for the dap single mutant (Figure 4.8b). Surprisingly the
dapA mutant did increase in optical density over the 8-hour timecourse, however on
observation of wet mounts, these bacteria appeared to be spheroplasts.
Invasiveness in vitro
Assessment of invasiveness was performed by differentially staining intra-cellular
and extra-cellular bacteria. The resulting immunofluorescent stain yielded extra-cellular
bacteria labeled with Texas Red and FITC, while intra-cellular bacteriawere labeled with
FJTC only. An example of the differential staining results is shown in Figure 4.9.For
each strain, approximately 200 randomly selected cellswere examined for intra-cellular
bacteria. All of the strains with a defective crp gene (1 l.29Acrp, 1 l.29L\dapAcrp, and
11 .29AdaptxaroAcrp) were restricted in their ability to infect CHSE-2 14 cells. The
remaining strains (11 .29idap, 11 .29Aaro, 11 .29AdapAaro) displayedan invasive
capacity similar to wild-type 11.29 (Table 4.3). Invasiveness of 1l.29AaroAcrpwas not
assessed in this experiment.126
Figure 4.7. Southern blots of mutant F.ruckeri.Genomic DNA from mutant strains
was digested withEcoRVor Dral. HinDIII digested X phage was used as marker (A;).1
EcoRVdigested pKNGKm-Adap, 2EcoRVdigested pKNGKm2,3 =11.29 wild-
type, 4 = 1 l29Adap, 5 = 1 l29Aaro, 6 = I l29Acrp, 7 = 1 l29iXdapAaro, 8 =
11 29Adap&ip, 911 29AaroAcip, 10 = 11 29AdapAaroL\cip. For each gene, the
deletion mutation removes a restriction site, therefore the mutant genotype will showas
a larger single band and wild-type will show a smaller band or doublet. a. pKNGKm2 as
probe to detect residual vector sequence in genomic DNA. Only the pKNGKm-Adap and
pKNGKm2 lanes hybridized. b. DraI digested genomic DNA with a dapA fragmentas
probe. c.EcoRVdigested DNA with aroA probe. d. crp probe ofEcoRVdigested DNA127
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Figure 4.8. Growth curves. Broth cultures of each mutant and the wild type 11.29were
diluted in LB broth to and0D600of 0.05. The cultures were incubated at room
temperature with shaking on a gyratory shaker at approximately 200 rpm. Absorbance
was measured at 600 nm. The symbols for each mutant strain and the wild-type parental
strain are indicated in the figures. a. Growth curves of each mutant strain in LB broth
plus 50 tg/m1 DAP. b. Growth of 11 .29Adap with and without DAP, comparedto wild-
type 11.29 with DAP.a
b
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Figure 4.9. Differential staining of intracellular and extracellular bacteria. Infected
CHSE-214 monolayers were fixed in methanol-free formalin and immunostained with
primary rabbit anti-Y.ruckeriantibody, then with FITC-conjugated secondary antibody.
The monolayers are then permeablized and stained again with primary antibody followed
by a Texas-Red conjugated secondary antibody. Extracellular bacteria are stainedgreen
while intracellular bacteria are red.131
Table 4.3: Invasiveness ofYersinia ruckeristrains: Differential staining.
#of cells
Bacterial Strain examined
11.29 wild-type
11 .29Adap
Ii .29Aaro
1 1.29Acrp
11 .29Adaparo
11 .29Adaptcrp
11 .29AdapAaroAcrp
168
188
206
210
209
200
215
Gentamicin protection assay
Infected CHSE-214 cells
1 to 5 bacteria 6 or more
Total per cell bacteria per cell
number%number%number%
79 47.0 51 30.4 28 16.7
84 44.7 52 27.7 32 17.0
9! 44.2 51 24.8 40 19.4
36 17.1 36 17.1 0 0
94 45.0 55 26.3 39 18.7
49 24.5 48 24.0 1 0.5
37 17.2 37 17.2 0 0
Infected CHSE-2 14 monolayers were lysed and plated to determine CFU/ml
immediately prior to gentamicin treatment, then at 4 and 24 hours after gentamicin
treatment. Invasion index was calculated from viable bacterial counts before and after
gentamicin treatment. Gentamicin protection assay results differed slightly from the
differential staining data shown above. The mutants all had reduced invasion indices
compared to wild-type Y. ruckeri 11.29. The triple mutant (11 .29AdapAaroAcrp) had the
lowest invasion index, followed by the 11 .29AdapAaro double mutant. The single
mutant 11 .29Adap had an invasion index slightly lower than wild-type bacteria.132
Table 4.3. Invasiveness of V.ruckeristrains: Gentamicin protection assay. Invasion
index is calculated as (# of bacteria surviving gentamicin treatment)/(# of bacteria before
gentamicin treatment) X 100 (Van Putten 1994).
Strain Invasion index
11.29 wild-type 2.48
ll29Adap 1.68
1129/xdapAaro 0.65
I l29AdapAaroAcrp 0.08
In vitrogene transfer
CHSE-2 14 monolayers were seeded into tissue culture plates and infected with
mutant bacteria carrying the reporter plasmid pEGFP-N1 as described above. After
infection and rinsing the medium was replaced with MEM-5 plus 100 .tg/ml gentamicin
to kill extracellular bacteria. The monolayers were incubated at 20 C and examinedon an
inverted fluorescence scope 24 hours and 96 hours post infection. At 96 hourspost-
infection GFP positive cells were observed in the wells infected with 11 .29LIdap,
11 .29tdapAaro, and 11 .29AdapAcrp but not in wells infected with 11 .29Aaro,
11 .29Acrp, 11 .29AaroL\crp, or 11 .29L\dapAaroAcrp. Figure 4.10 shows GFP positive
cells 96 hours after infection with 11 .29AdapAcrp.133
Figure 4.10. Reporter gene transfer to CHSE-214 cells. CHSE monolayerswere
infected with mutant Y.ruckeri 11 .29MapAcrpcarrying plasmid pEGFP-N 1. a. Visible
light microscopy of the infected monolayer 96 hours post-infection. b. Thesame field of
view as (a) under IJV illumination. c. Electronic overlap of the two digital images.134
Flow cytometry
The frequency of gene transfer for several of the mutantswas assessed by flow
cytometry. The observed gene transfer frequencies varied widely especially for
11 .29AdapiXaro (Table 4.4), however gene transfer was routinely observed in flasks
infected with 11 .29Adap or 11 .29AdapAaro, and at a reduced level in cells infected with
11 .29AdapAcip. Strain 11 .29AdapAaroAcrp was only used inone flow cytometry
experiment, however, gene transfer was detected at about thesame frequency as with
11 .29AdapAcrp. Uninfected cells or cells infected with 11 .29Adap without the GFP
reporter plasmid were included as negative control in each experiment. No GFP-positive
cells were detected in negative controls. CHSE-214 cells are difficult to trypsinize and
flow cytometric analysis was hampered somewhat by the difficulty in obtaining single
cell suspensions.
Table 4.5: Frequency of gene transfer to CHSE-214 cells infected with attenuated
mutant F.ruckerimeasured by flow cytometry:
% GFP positive
Strain Avg SD Range
ll29Adap 0.0035t 0.0014 0.0020-0.0047
1 129L\dapAaro 0.0044c 0.0030 0.0014 0.0085
1 l29MapAcrp <00010b n.a. <0.00010.0013
ll29AdapAaroAcrp 0.0010" n.a. 0.0010
aEach sample representsat lea100,O()O events
baverage of 3individual experiments
caverage of 4 individual experiments
ddata froma single experiment135
DISCUSSION
We report here the production and in vitro characterization of attenuated mutant 1'.
ruckeri. These mutant strains are potentially useful as live attenuated vaccines against
enteric redmouth disease, caused by Y. ruckeri. Additionally, the strains could be usedas
protein or DNA vaccine delivery vectors to develop multivalent vaccination strategies.
The in vitro growth curves of the mutants indicated that in rich media
supplemented with DAP, the 11 .29Map, 11 .29Aaro, and the double mutant
11 .29AdapAaro grew as well as the parental wild-type bacteria. The dapAor aroA
mutations did not seem to alter the growth rate of any of the mutants. Thecrp mutation
is likely to be solely responsible for the reduced growth rates of strains 11 .29Acrp,
11 .29AdapAcrp, 11 .29L\aroAcrp, and 11 .29tidapAaroAcrp.
Results of the differential staining indicate that the crp mutation also influences
invasiveness of the strains in vitro while the dapA and aroA mutations had little effecton
invasiveness. In contrast, the gentamicin protection results seemed to indicate the
mutations had an additive effect on the invasive capacity of the mutant strains. However,
these results could be explained by reduced intracellular survival of the mutant strains
rather than true differences in invasiveness.
Mutant strains with a dapA mutation are capable of infecting CHSE-2 14 cells and
inducing gene transfer in a small portion of the infected cells. Thegene transfer
frequencies observed here (0.0010 to 0.0085 %) are low compared to those reported for
mammalian systems, however the baseline transfection efficiency of CHSE-2 14 cells is
also considerably lower than mammalian tissue culture cell lines (unpublished
observations). Also, a number of factors probably influence infection andgene transfer136
efficiency, including physiological state and growth phase of the bacteria and tissue
culture cells, the multiplicity of infection, timing of infection and incubation temperature,
as well as timing of observation. These parameters were not rigorously tested in the
experiments described here. Optimization of infection conditions could lead to greatly
increased gene transfer efficiency. The highest efficiency we observed in CHSE cells
was comparable to that observed by Dietrich et al.(1998) for an attenuated Listeria
monocvtogenes in HeLa cells. Grillot-Courvalin et al (1998) reported approximately 2%
of HeLa cells were GFP positive within 48 hours of infection with attenuated invasive E.
co/i at a MOI of 50 bacteria per HeLa cell. Of the many studies on attenuated bacteria as
DNA delivery vectors, few have related in vitro gene transfer efficiency to in vivo
immunogenicity. In vitro infection of human dendritic cells with attenuated Salnione/la
typhimuriuni resulted in gene transfer to as many as 0.07% of the cells (Dietrich et al.,
2001). Other groups have reported in vivo efficacy for this same strain of S. typhimurium
(Flo et al., 2001; Paglia et al., 1998).It remains to be seen whether the frequency of
transfer we observed in these experiments will be immunogenically relevant. Possibly in
vivo transfer to specialized cell types, including antigen presenting cells will result in an
immune response. Immunogenicity, pathogenicity and gene transfer ability of strains
11 .29Adap, 11 .29AdapAaro, and 11 .29AdapAcrp will be evaluated in our rainbow trout
vaccination and challenge model with a DNA vaccine for infectious hematopoietic
necrosis virus (IHNV).137
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Chapter 5. In Vivo Characterization of Attenuated Mutant Yersinia ruckeri
ABSTRACT
To develop practical vaccination method for infectious hematopoietic necrosis
virus (IHNV), we have explored the use of live attenuated Yersinia ruckeri to deliver
protein or DNA vaccines to rainbow trout. The dapA single mutant and dapA aroA
double mutant Y. ruckeri were able to infect rainbow trout fry (Oncorhvnchus rnvkiss) but
did not cause disease, and the bacteria were cleared rapidly from the fish. The dapA
single mutant conferred protection against challenge with a heterologous serotype of Y.
ruckeri. Little evidence of genetic immunization was observed in these trials.
Expression of a fragment of IHNV glycoprotein by Y. ruckeri did not protect the fish
against viral challenge.
INTRODUCTION
IHNV is a rhabdovirus that can cause acute losses in aquaculture settings. Small
trout and salmon are typically most susceptible to disease, however the virus can infect
larger fish (Wolf, 1988). Previous experimental vaccines for IHNV have been basedon
live attenuated viruses (McMichael, 1974; Tebbit, 1975), killed virus preparations
(Amend, 1976), and various recombinant subunit vaccines (Cain et al., 1999; Gilmore
and Leong, 1988; Oberg et al., 1991; Simon et al., 2001; Xu et al., 1991). To date the
most effective vaccine has been the DNA vaccine developed by Anderson et al (1996).
DNA vaccines encoding the IHNV glycoprotein under control of a eukaryotic promoter144
are highly protective against lethal IHNV challenge when administered by intramuscular
injection (Anderson et at., 1996; Boudinot et al., 1998; Corbeil et al., 2000). However,
vaccination of small fish by injection can be cost prohibitive Home (Home, 1997).
Several methods of immersion vaccination have been explored for DNA delivery to fish
including liposomes and ultrasound. Attenuated invasive bacteria also offer an attractive
means to deliver DNA vaccines to fish (Femandez-Alonso et al., 2001; Leong et al.,
1997).
In mammalian systems, number of researchers have used attenuated bacterial
vectors as delivery vehicles for plasmid DNA-based vaccines or gene therapy. Sizemore
et al (1995) demonstrated the ability of attenuated Shigella to transfer plasmid DNA to
HeLa cells as well as guinea pig corneal cells. Expression of the plasmid-encoded beta-
galactosidase gene was observed in a small portion of the infected cells. Other
researchers have taken similar approaches with different bacteria including Salmonella,
Listeria, and E. coli (Courvalin et al., 1995; Darji et al., 1997; Dietrich et at., 1998).
Live attenuated bacteria can also be used to deliver recombinant protein antigens and
may result in a bivalent or multivalent vaccine. For example, Noonan et al. (Noonan et
al., 1995) used an attenuated strain of Aeromonas salmonicida to express fragments of
the IHNV or viral hemorrhagic septicemia virus (VHSV) glycoprotein. Y. ruckerican
also be used to express foreign recombinant proteins (Estepa et at., 1994; L. Bootland,
personal communication).
in a previous report (Chapter 4) we described the development of attenuated
mutants of a serotype 02 strain of Y. ruckeri for use as a vaccine delivery system. Y.
ruckeri is the causative agent of enteric redmouth disease (ERM) in salmon and trout.145
Outbreaks of ERM tend to occur under conditions of overcrowding, stress and elevated
water temperatures (Busch, 1978; Ellis, 1988b). There are two major serotypes of Y.
ruckeri (Daly et al., 1986; Stevenson and Airdrie, 1984). Most disease outbreaks
throughout the world are caused by serotype 01 strains. However, serotype 02 strains
have been associated with disease outbreaks in the state of Oregon and elsewhere
(Cipriano et al., 1986; O'Leary, 1977). Vaccination with serotype 02 strains can becross
protective against challenge with serotype 01 strains (Cipriano and Ruppenthal, 1987).
In our previous report, several of the attenuated strains were able to infect and
induce gene transfer to CHSE-2 14 tissue culture cells (Chapter 4). In this reportwe
examine the in vivo behavior of some of the previously described attenuated Y. ruckeri
strains. Pathogenicity of the attenuated mutant Y. ruckeri was assessed by bath
immersion and intraperitoneal injection in rainbow trout. We also assessed the ability of
the strains to deliver plasmid DNA and recombinant protein antigens and to generatea
protective immune response in rainbow trout. The attenuated strains were also testedas
live vaccines for Y. ruckeri by challenge with a virulent serotype 01 strain of Y. ruckeri.
Attenuated Y. ruckeri were transformed with the DNA vaccine plasmid pIHNV-G
(Kim et al., 2000) or recombinant protein expression plasmid pXL3 (Xu et al., 1991)or
appropriate control plasmids (Table 5.1). Rainbow trout fry (0.51 g each) were
exposed by immersion to varying doses of the bacteria. At various time points, fishwere
examined for bacterial infection and reporter gene expression. After an immune
development phase, groups of fish were challenged with virulent Y. ruckeri or IHNV.Table 5.1. Strains and Plasmids.
Source or
Strain or plasmid Description Reference
Strains
11.29 Yruckerifrom Chinook salmon (0.tshawvtscha),Oregon, 1974
I .29Adap dapA mutant of 11.29
11.29AdapLtaro 11 .29LXdap with an additional aroA mutation
11 .29AdaptIcrp11 .29Adap with an additional crp mutation
RS-48 Y.ruckerichallenge strain
Plasmids
pEGFP-N1 GFP reporter plasmid with CMV promoter
pATH3 Bacterial trpE fusion protein expression vector, trp promoter
pXL3 552 nt of IHNV glycoprotein fused to trpE in pATH3
pLUC Firefly luciferase inserted into pcDNA3 (Invitrogen), CMV
pro' ter
pIHNV-G Coiete fl-INV glycopDtein gene in pcDNA3, CMV promoter
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1) R. Cipriano, U.S. Fish and Wildlife Service, National Fish Health Laboratory,
Leetown, WV. 2) R. Stevenson, University of Guelph, Ontario, Canada. 3) Clontech,
Palo Alto, CA. 4) T. J. Koemer and A. Tzagaloff, Columbia University, NY.
MATERIALS AND METHODS:
Bacterial strains and plasmids
Y. ruckeriwild type and mutant strains were routinely grown at 20 to 25°C in LB
Lennox or Tryptic soy broth, supplemented with 50 ig/ml diaminopimelate (DAP) where
appropriate. Ampicillin was included at 100 j.tg/ml for plasmid maintenance. For
production of pXL3 and pATH3 vaccine cultures strain 11 .29Adap wasgrown in M9
broth supplemented with 0.5% casamino acids, thiamine, ampicillin and DAP. Bacterial
strains and plasmids used in this study are listed in Table 5.1. The reporter plasmid
pLUC was constructed by inserting the2.7 kbBamHIIHindIIIfragment (containing the147
luciferase gene) of pGL2 basic (Promega, Madison, WI) intoBa,nHI/HindIIIdigested
pcDNA3 (Invitrogen, Carlsbad, CA).
SDS-PAGE and Western immunoblot analysis
Protein samples were solubilized by mixing with equal amounts of 8M urea in
100 mM Tris-HC1, pH. 8.0, followed by the addition of sample loading buffer. The
samples were then analyzed by discontinuous gel electrophoresis through a 10%
polyacrylamide gel using the method of Laemmli (Ausubel et al., 1993). Two identical
gels were prepared. One gel was stained for total protein with colloidal coomassie blue
stain and dried on cellulose film. The dried gel was scanned with a Molecular Dynamics
Personal Densitometer (Molecular Dynamics, Sunnyvale, CA). Molecular weights of the
protein bands were calculated with FragmeNT Analysis version 1.1 (Molecular
Dynamics) (Fig. 3a). The proteins from the second gel were electrophoretically
transferred to polyvinylidene difluoride (PVDF) membrane for immunoblotting.
Following transfer, the membrane was blocked with Tris-buffered saline plus 2% BSA
(TBS-BSA). The blot was probed with polyclonal rabbit anti-IHNV at a 1:500 dilution in
TBS-BSA for 2 h and washed with TBS plus 0.1% tween-20. FITC-conjugated
polyclonal goat anti-rabbit antibody (Vector Labs, Burlingame, CA) was applied to the
membrane at a 1:500 dilution in TBS-BSA for 2 h, washed in TBS plus 0.1% tween-20
and scanned on the FMBioII fluorescence imaging system (Hitachi Software Engineering
America Ltd., San Bruno, CA)Ir
Experimental animals
Rainbow trout fry(Oncorhvnchusmykiss) were obtained from Roaring River
hatchery, Oregon Department of Fisheries and Wildlife. Frywere held in aquaria
supplied with 12°C specific pathogen-free well water (2.2 L/min) at the OregonState
University Center for Salmon Disease Research. The fishwere held in a room where
photoperiod was controlled by sunlight.
Preliminary vaccination experiments
Separate bacterial vaccination experiments were performed with dilutions of
bacteria at optical densities (0D600) of 0.003 or 0.333 (correspondingto approximately
i0 ori09cfu/ml). These small-scale experiments were used to establishexposure
conditions and sample collection and handling protocols for the large-scale vaccination
experiment.
For the low dose exposure, fish were held in static water with aerationat a density
of 0.015 kg/liter (thirty ig fish per 2 liters). Stationary phase bacterial culturewas
diluted to achieve a finalOD600of 0.003, corresponding to approximatelyi07cfu/ml.
Fish were monitored for signs of stress throughout theexposure. Water flow was
restored after 2 hours. The fish were exposed to six treatmentsas follows: 1)
11 .29Adap(pIHNV-G), 2)11 .29idap(pLUC), 3)11 .29AdapAaro(pIHNV-G), 4)
11 .29AdapAaro(pLUC), 5)11 .29Adap&rp(pIHNV-G), and 6)11 .29AdapAcrp(pLUC).
hi addition, a control group of 30 fish was mock exposed. These fishwere used to assess149
pathogenicity of the mutant strains and to test luciferase assay protocols. In addition, the
fish were used to test viral challenge dose for the large-scale trial.
For the high dose bacterial exposure 30ish per group were exposed to
11 .29Adap(pEGFP-N 1), 11 .29AdapAaro(pEGFP-N 1) or ii .29AdapAaro(pLUC) atan
0D600of 0.333, corresponding to approximatelyi09cfu per ml. Saturated overnight
cultures were diluted into 500 mis of water. A control group of 30 fish was mock
exposed in a 1:10 dilution of LB broth. For high dose exposure, water flow was restored
after 1.5 hours due to severe stress. These fish were examined for bacterial persistence
and pathogenicity of the Y.ruckerimutants.
Luciferase assay of low dose bacterial exposure
Three days post exposure, 3 fish from each group were dissected for luciferase
assay. Gill, skin, liver, muscle, kidney, and digestive tract tissues were collected from
each fish and frozen separately on dry ice in microfuge tubes with 100 p1 of passive iysis
buffer (Promega). The samples were stored at -80°C. To assay the luciferase activity in
the samples, the tissues were thawed and homogenized with a plastic microfuge pestle
(Kontes). Twenty p1 aliquots of the homogenized sample were placed into a black opti-
lux 96-well microtiter plate with clear bottom (Falcon). One hundredtlof Luciferase
assay reagent was added to each well, and the samples were read on a Wallac Lumi-count
scintillation counter. Luminescence in each well was measured for 2 seconds, then the
entire plate was read a second time for 5 seconds per well. Bacterial suspensions of
11 .29Adap(pLUC) were used as a positive control.150
Bacterial persistence in bacterially exposed fish
Fourteen days post-vaccination, 3 fish from each treatment in the 1cfu/ml
exposure were examined for bacterial infection. Direct streaks of kidney and intestine
were spread on TSA plates plus DAP and polymixin-B. Fish from thei09cfu/ml
exposure were examined for bacterial infection at 1, 3, and 7 days post infection by the
same direct streak method.
Small-scale viral challenge
Two weeks post-vaccination 15 fish from each treatment in the i0 cfu/ml
exposure were challenged with 5 X I
4pflu/ml of IHNV strain 220-90. The fishwere
exposed to the virus suspension in 1 liter of static water fora period of 5 hours. Water
flow was restored after 5 hours and mortalitieswere recorded daily for 30 days after virus
exposure.
Large-scale vaccination experiment
DNA vaccines
For the DNA vaccination experiment, groups of 430 fishwere exposed to either
the 11 .29Adap single mutant or 11 .29AdapAaro doublemutant canying either the
vaccine plasmid pIHNV-G, or the luciferase reporter plasmid pLUC. Acontrol group of
430 fish was mock vaccinated.151
Protein vaccines
For the protein vaccination experiment, groups of 300 fish were exposed to
overnight cultures of 11 .29Adap(pXL3) or 11 .29Adap(pATH3) grown in M9 minimal
medium.
Vaccination protocol
For vaccination, fish were held in static water with aeration at a density of
approximately 0.04 kg/liter (300 to 430 ig fish per 10 liters). Stationary phase bacterial
culture was added to achieve a final0D600of 0.033, corresponding to approximately l0
cfulml. Fish were monitored for signs of stress throughout the exposure. Water flowwas
restored after 2 hours. After 21 days, 50 fish of each group were removed toa separate
tank. The remainder of the fish were vaccinated with a second dose of the bacterial
treatments at108 cfu/ml.After booster vaccination, the fish were held for a further 21
days. At various timepoints throughout the experiment, fish were sampled for
bacteriology and luciferase assays. Holding densities during immune development
period was approximately 0.0 1-0.02kg/rn3.
Luciferase Assays
To detect luciferase gene transfer, 3 sample fish from each treatmentwere
collected at various time points after 108 cfu/ml bacterial exposure. At 4 and 24 hours,
and 4, 7, 14 and 20 days post-exposure, fish were collected and frozen at -80° C. Positive
control fish that had each been injected with 500 ng of pLUC were also collected and152
frozen. In preparation for luciferase assay, the frozen fishwere weighed and
homogenized with dry ice in a coffee grinder (Toastmaster). Protease inhibitor cocktail
III (CaiBioChem, San Diego CA) was added before grinding (50tlper gram of fish).
Passive lysis buffer (Promega) was added to the homogenate (4 misper gram of fish) and
the suspension was frozen again at -80° C, thawed and centrifuged at 2000 Xg for 10
minutes. The clarified supernatant was assayed for luciferase activity with Promega's
luciferase assay reagent according to manufacturer's instructions inan EG&G/Berthold
Lumat LB9507 injection luminometer (EGG/Berthold)
Bacteriology
To detect infection of the fish with Y.ruckeri,3 sample fish from each treatment
were dissected at various time points after 108 cfu/ml bacterial exposure. At 0, 4, 24, and
72 hours, and 7, 14 and 20 days post-exposure, the kidney and large intestine from each
fish was homogenized separately in 300tlof LB + DAP + polymixin-B + ampicillin and
incubated with shaking at room temperature. After 18-24 hours incubation
approximately 10jtlof each culture was streaked on LB agar plates + DAP + polymixin-
B + ampicillin. Plates were incubated at room temperature for 72 hours. Putative Y.
ruckericolonies were identified by colony morphology. Identity of the colonieswas
confirmed by PCR for the dapA gene using primers ME680
(CCCGTGATAAGTTCCCTGTGG) and ME707 (ACGCCGATGGACGACAAAG).
PCR reactions were performed using Taq polymerase (Promega, Madison, WI) in 25 pA
volumes with 30 cycles of 94° C denaturation, annealing at 55° C, and extensionat 72° C.153
Samples for bacteriology were also collected at 4, 24, and 72 hours and 7, 14, and 20
days after the booster vaccination
Y. ruckerichallenge
After the immune development phase, the fish were distributed into individual
tanks of 50 fish each. Fish were then exposed to Y.ruckeriserotype 01 strain RS48 at
1.4 X 1 0 cfu/ml in static water with aeration for a period of 1 hour and 40 minutes, in 1
liter of water. Water flow was restored and mortalities were recorded daily for 14 days
after bacterial exposure. For challenge with the parental strain 11.29, ten fish from each
treatment group were injected intra-abdominally with serial dilutions of overnight broth
culture. Fish received iø, orcfu in 100d of Hank's balanced salt solution
(HBSS). Relative percent survival was calculated as described above.
Production of IHNV challenge virus
Chinook salmon embryo (CHSE-2 14) cells were maintained as previously
described (Engelking & Leong 1981) and used to propagate IHNV. The type 2 1HNV,
strain 220-90, used for challenge was obtained from Scott LaPatra of Clear Springs Foods
Inc. (Buhl, ID). CI-ISE-214 cells were infected with virus at a multiplicity of infection of
0.01 and incubated at 17°C for 7 days. The culture supernatant was collected and
centrifuged at 2500 x g for 10 mm at 4°C to remove cell debris. The clarified supernatant
was distributed into 5 ml tubes and frozen at -80° C. The viral titer was estimated by
determining the plaque titer for a tube of frozen virus (Burke and Mulcahy, 1980).154
IHNV Challenge
After the immune development phase, the fish were distributed into replicate
tanks of 50 fish each. Fish were then exposed to 1pfu IHNV per ml in static water for
a period of 5 h, at a density of 50 fish per liter of water. Water flow was restored after 5
h and mortalities were recorded daily for 30 days after virus exposure. Relative percent
survival was calculated using the following formula (Ellis, 1988a): RPS=
vaccinated mortality / % control mortality)] x 100.
Statistical methods
Cumulative mortality was recorded for each replicate tank at 30 days post
challenge. For the large-scale viral challenge, data from replicate tankswere first tested
for extra-binomial variation between replicates using Pearson's Chi-squared analysis
(Ramsey and Schafer, 1997) to determine if use of the standard binomial modelwas
adequate. Where appropriate, the replicates within each treatmentwere pooled for
calculation of a p-value with Fisher's exact test and pair-wise comparisonswere made
between all groups. For experiments with single tanks per treatment, the tankswere
examined collectively by Pearson's Chi-squared analysis to determine if the data fita
standard binomial distribution. If deviation from the binomial modelwas detected (p <
0.1) then pair-wise comparisons were made between each treatment. Statistical analyses
were performed using SPSS, version 9.0.0 (Chicago, IL)155
RESULTS
IHNV glycoprotein expressionby V. ruckeri
When 11 .29Adap(pXL3) was grown in M9 minimal medium supplemented with
DAP and 0.5 % casamino-acids, the bacteria formed elongated cells. Inclusion bodies
were observed in many of the elongated bacteria. These elongated bacteria with
inclusions were not observed in 11 .29Adap(pATH3)grown under the same conditions.
When 11 .29Adap(pXL3) was grown in rich media like LBor tryptic soy broth, inclusion
bodies and elongated cells did not develop. Bacterial pellets from 11 .29Adap
transformed with plasmid pXL3, pATH3, pIHNV-G,or pLUC were analyzed by SDS-
PAGE and western blot to evaluate glycoprotein expression in this strain. SDS-PAGE
gels show a heavy band of about 57 kDa in the pXL3 sample (Figure 5.la, b; lane 4).
This band is not prevalent in any of the other lanes. When similar protein samplesare
probed with antibody to THNV-glycoprotein in western blotting, the 57 kDa band in the
pXL3 lane reacts strongly with the antibody (Figure 5. lb. lane 4). The pIHNV-G lane
may have a very faint reactive band at approximately 6570 kDa (figure 5.lb lane 2).
This low level of expression from the eukaryotic expression vector isnot entirely
unexpected as we also detect luciferase activity from 11 .29Map carrying plasmid pLUC.156
Figure 5.1. SDS-PAGE and Western immunoblot analysis of 1'.ruckeri 11.29
expression of IHNV glycoprotein. Lanes: 1, pLUC; 2, pIHNV-G; 3, pATH3; 4,
pXL3. Ten to fifteen micrograms total protein was loaded per lane. MW molecular
weight marker. a. Colloidal coomassie total protein stain. b. Immunoblot. Primary
antibody was polyclonal rabbit anti-IHNV that had been pre-absorbed with lysed V.
ruckeri 11.29cells.Secondary antibody was FITC conjugated goat anti-rabbit. The
arrow indicates the 57 kDa trpE-glycoprotein fusion protein.MW
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Bacterial persistence and pathogenicity
In preliminary studies, no mortality was observed as a result of bacterial infection
in either the high or low dose bacterial exposure. Fourteen days post-vaccination,3 fish
from each treatment in the I O cfu/ml exposure were examined for bacterial infection.
Direct streaks of kidney and intestine were spread on TSA plates plus DAP and
polymixin-B. Y. ruckeri was not detected from any of the fish from the I6'cfu/ml
exposure at 14 days post-exposure. Fish from the iO cfu/ml exposure were examined for
bacterial infection at 1, 3, and 7 days post infection. Mutant 1'. ruckeriwas isolated from
fish exposed to 16' cfu/ml 11 .29LIdap at 1 and 3 days post-exposure, butnot 7 days post-
exposure. In contrast, the double mutant, 11 .29AdapAaro, was not detected (by direct
streak of the kidney and intestine) in any of the fish sampledon day 1, 3, or 7.It is
possible these fish were infected but below the detection limits of the direct streak
technique. Broth enrichment cultures will provide higher sensitivity to detect the
bacterial infection.
More thorough bacteriological screening was carried out in the large-scale
exposure. Bacterial infection was detected most frequently from fish exposed to
11 .29Adap(pIHNV-G) (Figure 5.2). Bacteria were isolated from all three fish sampledat
both 4 and 24 hours after primary exposure. Only one of the three samples from the
11 .29Adap(pIHNV-G) treatment tested positive for Y. ruckeri 3 days after primary
vaccination. Again, on day 7 post-vaccination, a single positive fishwas detected from
the 11 .29Adap(pIHNV-G) treatment. At 14 and 20 days post-vaccination, 11 .29Adap
was not cultured from any of the samples. Similarly, after the booster vaccination,159
11 .29Adapwas cultured from samples at 4 hours and 7 days after booster vaccination. In
this case, however, bacteria were not cultured from any of the three fish sampled 1 day or
3 days after the booster exposure. Strangely,1 1.29Adapwas not cultured out of any
sample from the11 .29Adap(pLUC)treatment group at any time point. In the treatment
groups exposed to11 .29AdapAaro(pIHNV-G)or11 .29AdapAaro(pLUC), Y ruckeriwas
only detected in a portion of the samples at 4 hours post-primary vaccination and then at
no other time point (Figure5.2).These data give some indication of the relative infection
levels between groups and at different time points. However, because of the small
sample size (3 fish per treatment per timepoint) it is possible, if infection rate was less
than 100%, that we randomly selected uninfected fish for dissection.
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Figure 5.2. Number of fish positive for V.ruckeriby broth enrichment at various
time-points post-vaccination. Three fish per treatment were sampled at each time-point.
Arrows indicate bath exposures to live attenuated bacteria.160
Luciferase assays
In preliminary experiments, luciferase assay measurements from homogenized
tissues were all negative. It is possible that luciferase activity from the digestive tract
samples was destroyed by proteases because, when homogenized viscerawere mixed
with luciferase positive bacterial suspensions, the luciferase activitywas abolished. This
elimination of luciferase activity did not occur in kidney tissue samples mixed with
luciferase positive bacteria. Addition of protease inhibitors (Protease inhibitor cocktail
III, CalBioChem, San Diego CA) prevented degradation of the luciferase activity in
homogenized viscera spiked with luciferase positive bacteria. The degradation of
luciferase activity was not examined for gill, muscle, skin, or liver tissue. No luciferase
activity was detected at 3 days post infection. The results from this portion of the study
indicated that tissue samples should be prepared with protease inhibitors.
For the large-scale bacterial exposure, a standard curve was constructed from ten-
fold serial dilutions of a saturated overnight culture of11 .29Adap(pLUC)(Figure 5.3a) to
determine the detection limit of the luminometer and to aid in estimation of the relative
luciferase activity of the samples. Each dilution was measured in duplicate. Plasmid
DNA injected fish did demonstrate luciferase activity at 4 and 7 days post injection. Two
plasmid-injected fish were tested from the 4 day time point and a single fishwas tested
from the 7 day timepoint. No luciferase activity was detected from bacterially exposed
fish 4 days or 7 days post-vaccination.Lowlevels of luciferase were detected from fish
exposed to11 .29Adap(pLUC)or11 .29Adapzaro(pLUC)at 4 hours post-vaccination
(Figure 5.3b). The levels of luciferase detected at 4 hours post-vaccinationwere near the161
lower detection limit of the assay and are consistent with an infection level of fewer than
5000 cfu/gram of fish tissue (Figure 5.3a).
1'. ruckerichallenge
A single tank of 50 fish from each treatment group was challenged by immersion
with a pathogenic strain of Y.ruckeri.The fish in this portion of the experiment were
bath vaccinated with a primary and booster vaccination 6 and 3 weeks prior to challenge.
Bacterial challenge with Y.ruckeriserotype 01 strain RS48 resulted in high mortalities in
all treatments (Figure 5.5). The peak of mortalities occurred 5 days post-challenge. The
unvaccinated control reached 92% CPM. The 11 .29Adap(pIHNV-G) treatmentgroup
had the lowest CPM (72%). Although this is not a large difference, it is significantly
different from the unvaccinated control (p = 0.009). CPM for the 11 .29Adap(pLUC)
treatment group was also lower than the unvaccinated control (p=O.OSO). In contrast, fish
vaccinated with 11 .29Adap(pXL3) may have been more susceptible to challenge
compared to unvaccinated fish (p0.041). Again, tank effects cannot be ruled out and
may have influenced the results of this challenge. We were unable to assess the level of
protection against serotype 02 strains in this study. Injection challenge of fish withup to
108 cfuwild-type 11.29 did not cause any mortality in either vaccinated or naïve fish.162
Figure 5.3: Luciferase assay. a) Tenfold serial dilutions of a saturated overnight culture
of 11.29Adap(pLUC). b)Homogenized fish samples from 4 hours, 4 days and 7 days
post exposure to108 cfu/ml11.29L\dap (pLUC)or 11.29AdapAaro (pLUC),or
unexposed fish (Neg). RLU = Relative luminescence units.a
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Figure 5.4. Challenge with serotype 01 1'.ruckeristrain RS48. Fish were challenged
in groups of 50 by immersion in 1.4 Xi09cfu/ml RS48. Mortalities were collected daily
for 14 days. a) Cumulative percent mortality (CPM) curves for the 14 day challenge. b)
Relative percent survival for each group compared to unvaccinated controls. Relative
percent survival was calculated using the following formula (Ellis 1988): RPS =
vaccinated mortality / % control mortality)] x 100.a 100
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Viral challenge
The unvaccinated fish in the preliminary trial reached cumulative percent
mortality (CPM) of 74%. With the exception of 11 .29Adap(pIHNV-G), all the
treatments exceeded 80% CPM (Figure 5.5a). Relative percent survival compared to the
unvaccinated control was also calculated (Figure 5.5b). The 11 .29Adap(pIHNV-G)
treatment appears at first glance to protect fish from viral challenge (47% CPM).
However, due to the small numbers of fish per treatment, chi-squared analysis of
cumulative percent mortality at 30 days post-challenge gives little statistical evidence of a
significant difference between 11 .29Adap(pIHNV-G) and the negative control (p-value =
0.14). Also, since this experiment did not have replicate tanks, tank effect cannot be
ruled out. The fish exposed to 11 .29AdapAaro(pIHNV-G) did not show any difference
from the negative control (Figure 5.5a), despite the higher gene transfer frequencies
observed in vitro for this strain (Chapter 4). Based on these results we decided to carry
out a larger scale experiment with replicate tanks, a higher dose of bacteria and to expose
the fish to a primary and booster dose.
As outlined in the materials and methods, the large-scale experiment was
designed with groups that had received either a single vaccination, or a primary and
booster vaccination. For each treatment, fish that received only the primary vaccination
were challenged in a single tank of 50 fish. The fish that received 2 doses of the vaccines
were divided into triplicate tanks of 50 fish for challenge. By 30 days post vaccination,
each treatment from the primary vaccination had reached CPM of 80% or greater (Figure
5.6a). The challenge results from the primary vaccination show no protective effect of
any vaccine. Statistical analysis did not reveal any significant differences between tanks167
in this challenge group. Relative percent survivalwas not calculated because
unchallenged control had the lowest cumulative mortality of theseven treatments,
In groups exposed to 2 doses of the bacterial vaccines, statistical analysis didnot
reveal evidence of extra-binomial variation between replicates,so the replicate tanks in
each treatment were pooled for calculation of CPM (Figure 5.7a) and RPS (Figure5.7b).
Fish receiving both a primary and booster vaccination also attained CPMgreater than
80% (Figure 5.7a). Pearson's chi-squared analysis did not detectany significant
differences between the treatment groups. If the replicatesare visually examined without
pooling, the 11 .29Adap group appears to have a slightly lower CPM at 30 dayspost
vaccination, however the range of the CPM between replicates overlaps for all the
treatments (Figure 5.7c).Figure 5.5. Small-scale IHNV challenge. Groups of 15 fishwere challenged with 5 X
1 0 pfu/ml IHNV strain 220-90, 2 weeks post vaccination. Mortalitieswere collected
daily for 30 days. a) Cumulative percent mortality (CPM)over the 30-day time course.
b) Relative percent survival (RPS) after 30 days. Relative percent survivalwas
calculated using the following formula (Ellis 1988): RPS= [1-(% vaccinated mortality /
% control mortality)] x 100.
Figure 5.6. IHNV challenge results from single bath vaccination. Cumulative
percent mortality curves for fish challenged 6 weeks after a single bath vaccination. Fish
were challenged in groups of 50 fish withpfu/ml IHNV strain 220-90. Mortalities
were monitored for 30 days post-challenge. Single tanks of 50 fish were used in this
challenge.
Figure 5.7. LHNV challenge results from booster vaccination. Fishwere challenged in
groups of 50 fish withi05pfu/ml IHNV strain 220-90. Mortalitieswere monitored for 30
days post-challenge. Triplicate tanks of 50 fishwere used for each treatment group. a)
Pooled cumulative percent mortality curves for triplicate tanks of fish challenged3 weeks
after booster vaccination (6 weeks after primary vaccination) b) Relativepercent survival
of the pooled treatments. Relative percent survivalwas calculated using the following
formula (Ellis 1988): RPS = [1-(% vaccinated mortality / % control mortality)]x 100. c)
Cumulative percent mortality at 30 days post-challenge for each replicate tank.a 100
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DISCUSSION
We have demonstrated that 11.29Adapis capable of producing high levels of
IHNV-G fusion protein from the prokaryotic expression plasmid pXL3. The fusion
protein made up approximately 15% of the total protein in the samples. Western blotting
indicated that 11.29L\dapalso produced a very small amount of full-length glycoprotein
from the eukaryotic expression plasmid pIHNV-G. This prokaryotic expression froma
eukaryotic vector was also observed in the luciferase assays. In fact, we routinely used
11.29Adap (pLUC)as a positive control for our luciferase assays. Both pIHNV-G and
pLUC were constructed with plasmid pcDNA3. This bacterial expression could
complicate the analysis of reporter gene activity and analyses might be required to
distinguish between bacterial expression andde novoexpression by the transfected
eukaryotic host. in our experiments, we correlated the luciferase assay results from
homogenized fish to the equivalent bacterial cfu/ml. In our study, luciferase activitywas
not detected from fish beyond 4 hours post-infection. This correlates well with the
bacterial persistence data. Viable 11.29Adap(pLUC) was not detected from fish kidneys
beyond 4 hours post-infection.
Clearly, fish were infected with the single mutant 11.29Adapand the double
mutant 11.29AdapAaro,however the 11.29AdapAarobacteria seemed to be cleared more
rapidly. The longer persistence, up to 7 days, of the 11.29Adapwas unexpected, since
the bacteria should have lysed when removed from a source of DAP. It is possible that
DAP could be supplied by other bacterial species in the fish, however, the 11.29Adap
was exclusively isolated from the kidney of the fish, and not from the intestine where the174
majority of resident bacteria would be found. Another possibility is the persistence of the
bacteria as cell wall-deficient "L-forms". McIntosh and Austin (1990) reported that
artificially induced cell wall deficient forms of Y. ruckeri persisted in Atlantic salmon for
8 days, and could be involved in mediation of an infectious carrier state. Cell wall-
deficient L-forms of bacteria have been implicated in disease processes (Pachas, 1986).
Neither of the mutants was pathogenic for rainbow trout by immersion exposure. The
LD50of strain 11.29 in rainbow trout has been previously reported to be 8 X I 0 to 6 X
l0 cfu per fish (Romalde 1993, O'Leary 1977). In this study, we observed no
mortalities in the fish challenged with strain 11.29 by injection of I 0, 1 0, or I 0 cfu per
fish. We also attempted to determine theLD50for the wild type and mutant strains.
Rainbow trout (12 g each) were injected with i07, 108, or 10 cfu of wild-type 11.29,
1l.29Adap, or I 1.29AdapAaro in 50 jil of HBSS. Mortalities were only observed in the
I 0 dose, and the level of mortality was similar for the wild type and 11 .29AdapAaro.
The dapA single mutant appeared to be slightly more pathogenic or toxic than the
parental type (8 of 10 fish injected with i0 cfu 11.29Adap died compared to 4 of 10 for
the wild-type and 11 .29AdapAaro. Direct injection of 11.29, 11 .29Lxdap, and
11 .29AdapAaro only caused mortality at extremely high doses (1 0 cfu/fish).
Additionally, these mortalities, occurring 24-48 hours post-injection, could have been
caused by acute toxicity of the bacteria rather than any infectious process. Essentially,
strain 11.29 and the mutants were completely non-pathogenic for the rainbow trout used
in this study.
The challenge with Y. ruckeri RS-48 did show some immune response in fish
exposed to 11 .29Adap (pIHINV-G) or 11 .29L\dap (pLUC). Fifteen to 20% relative175
survival of a vaccine group compared to unvaccinated controlmay not seem striking,
however the challenge conditions used were probably too stringent. Amore moderate
challenge dose that achieves 75% mortality in the unvaccinated controls (rather than 90-
100 %) would be preferable. The lack of protection afforded by 11.29Adap(pXL3) and
11.29Adap(pATH3) may be due to the fact that these two cultureswere grown inM9
minimal medium instead of a rich medium.
The results of the small-scale viral challenge were suggestive that the single
mutant 11.29Adapinduced some type of immune response, and thisresponse was unique
to the 11.29Adap(pII-INV-G)treatment group. However, the observations from the
small-scale viral challenge could be attributed to tank effect. The large-scale trial
attempted to answer this question by using replicate tanks and attemptedto enhance the
immune effect by increasing the dose of the bacterialexposure and adding a booster
immunization three weeks after primary vaccination. The results of the large-scale
challenge did not show the same differences that were observed in the small trial. A
single dose of I 0 cfu/ml did not give any protection against viral challenge. Ingroups
exposed to2doses, the total mortality for 11.29Adap(pIHNV-G) was slightly lower than
the unvaccinated control, but these groups were not statistically different. Perhaps this
was again due to the extremely harsh challenge conditions, which achieved over90%
mortality for all the groups except 11 .29Adap (pIHNV-G).
Although high levels of protection against viral challengewere not observed in
this study, these mutant strains may still be good vaccine carriers. The cultureor
exposure conditions may have been sub-optimal. As with the in vitro work reported in
chapter 4, this system has many variables that can be optimized andmay yet be an176
effective DNA delivery vehicle. Work by Fernandez-Alonso with E. co/i as a DNA
delivery vehicle indicated that there was an optimal dosage range, and exposure to too
may or too few bacteria reduced detection GFP fluorescence (Fernandez-Alonso et al.,
2001). This may have bee the case in our experiment as well considering that thei07
exposure gave borderline protection but the108exposure gave no protection from IHNV.
Perhaps 108 bacteria per ml overwhelmed the fishes' cells and all infected cells were
simply killed before expression of the transgene could be accomplished.
Since the parental strain 11.29 appears to be totally avirulent, perhaps a slightly
more pathogenic strain of Y. ruckeri could be attenuated with the mutagenic system
described in chapter 4. Since the mutagenic vectors are already constructed, new strains
could be generated with a minimum of effort.
Additionally, the avirulent mutant strains could be useful for identification of
virulence factors from other highly pathogenic strains of Y. ruckeri by transformation of
the mutants with genomic libraries derived from pathogenic strains to supply virulence
factors in trans. Also, the function of the resident plasmids of other Y. ruckeri strains
could be explored since 11.29 and its derivatives are free of resident plasmids.
Previously these studies would have been somewhat difficult as Y. ruckeri is transformed
relatively inefficiently 'Cutrin et al., 1994). The double and triple mutants appeared to be
much more efficiently transformed than the wild type or dapA single mutant (unpublished
observation) and this characteristic could be exploited in complementation studies.177
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Chapter 6. Summary
In this thesis, we have examined a several systems for the production and delivery
of recombinant vaccines for fish. C. crescentus was employed to produce and fragment
of the IHNV glycoprotein. Attenuated F. co/i and Y. ruckeri were exploited to deliver
plasmid DNA to fish cells in vitro, in addition, attenuated Y. ruckeri were examined in
vivo as bivalent vaccine delivery vehicles, either expressing a fragment of the IHNV
glycoprotein or carrying a plasmid DNA vaccine encoding the complete IHNV
glycoprotein.
The C. crescentus protein expression system generated very pure recombinant
fusion proteins. One of the fusion proteins we tested, 184 amino acids of IHNV
glycoprotein fused to the 242 amino acid C-terminus of the Caulobacter S-layer protein,
did show some protective effect when administered by injection. This vaccine represents
an improvement over F. co/i expression in that purification of the protein is rapid and
inexpensive, however, the vaccine must still be injected with an adjuvant. These studies
suggest C. crescentus mediated production of viral proteins for vaccines may be an
alternative to F. coil and yeast protein production.
Production of the recombinant protein fragment by invasive bacteria could
overcome the need for injection. Also, bacterial infection generally stimulates a broad
immune response, and this may eliminate the need for immunostimulantsor adjuvants.
In our experiments (Chapter 5), Y. ruckeri was able to produce the pXL3 glycoprotein
fusion at levels similar to E. co/i (Xu et al 1991). In vivo exposure of fish to live Y.
ruckeri producing the IHNV glycoprotein fusion did not appear to protect the fish from182
subsequent viral challenge, however, the exposure condition of the fish and growth
conditions of the bacteria were not optimized in our study.
Delivery of DNA vaccines by attenuated bacteria is an exciting approach to
generating an immersion or oral vaccine. We demonstrated an attenuated invasive E. co/i
strain, BM27 1 0(pGB2inv-hly), was able to mediate gene transfer to salmonid tissue
culture cells. The frequency of transfer we observed was somewhat lower than reported
in mammalian systems. However, in terms of vaccine development, the invasive E. co/i
system we used raises some biosafety concerns. Environmental release of engineered
bacteria carrying a plasmid with two virulence genes from human pathogens could be
cause for alarm, especially in food fish aquaculture. To avoid these concerns we
developed attenuated strains of the fish pathogen, Y. ruckeri.
We produced strains of Y ruckeri mutant for the dapA, aroA, and/or crp genes.
Strains with the dapA or aroA mutations grew normally in rich media and behaved
similarly to wild-type in invasion assays. Strains with crp mutations exhibited slow
growth and reduced ability to infect CHSE-2 14 tissue culture cells.
Mutant strains with a dapA mutation were also capable of inducing gene transfer
in a small portion (0.00 10 to 0.0085 %) of infected CHSE-214 cells. Optimization of
infection conditions could lead to greatly increased gene transfer efficiency. The highest
efficiency we observed in CHSE cells was comparable to that observed by Dietrich et
al.(Dietrich et al., 1998) for an attenuated Listeria nionocvtogenes in 1-leLa cells.
Two mutant strains of Y. ruckeri, 11 .29Adap and 11 .29AdapAaro, were tested in
vivo. Neither of the mutants was pathogenic for rainbow trout by immersion exposure.
We also attempted to determine the LD50 for the wild type and mutant strains. Rainbow183
trout (12 g each) were injected with i0, 108, ori09cfu of wild-type 11.29, 1 1.29Adap,
or 11.29AdapAaro in 50 p1 of HBSS. Mortalities were only observed in thei09dose,
and the level of mortality was similar for the wild type and 11 .29LdapAaro. The dapA
single mutant appeared to be slightly more pathogenic or toxic than the parental type,
however, these mortalities occurred 24-48 hours post-injection and could have been
caused by acute toxicity of the bacteria rather than any infectious process. Essentially,
strain 11.29 and the mutants were completely non-pathogenic for the rainbow trout used
in this study.
Exposure of rainbow trout to 11 .29Adap (pIHNV-G) or 11 .29Adap (pLUC) did
generate a protective response against challenge with RS48, a pathogenic strain of Y.
ruckeri. RS48 is a serotype 01 strain while 11.29 is serotype 02. The cross protection
we observed confirms previous work with cross protection between serotypes of Y.
ruckeri.
The results of a preliminary vaccination and viral challenge were suggestive that
the single mutant 11 .29Adap induced some type of immune response, and thisresponse
was unique to the 11 .29Adap(pIHNV-G) treatment group. A large-scale trial with
replicate tanks, higher vaccine dose and a booster exposure, was performed tomore fully
examine the immunogenicity of the attenuated mutants. The results of the large-scale
challenge did not show the same differences that were observed in the small trial. In
groups exposed to 2 doses of 11 .29Adap (pIHINV-G), the total mortality was slightly
lower than the unvaccinated control, but these groups were not statistically different.
Perhaps this was due to the extremely harsh challenge conditions that achievedover 90%
mortality for all the groups except 11 .29Adap (pIHNV-G).Although high levels of protection against viral challenge were not observed in
this study, these mutant strains may still be good vaccine carriers. The culture or
exposure conditions may have been sub-optimal. As with thein vitrowork, thisin vivo
system has many variables that can be optimized and may yet be an effective DNA or
protein delivery vehicle. Since the parental strain 11.29 appears to be totally avirulent,
perhaps a slightly more pathogenic strain of Y.ruckericould be attenuated with the
mutagenic system described in chapter 4. Since the mutagenic vectors are already
constructed, new strains could be generated with a minimum of effort. Additionally, the
avirulent mutant strains may have other applications including identification of virulence
factors from other highly pathogenic strains of Y. ruckeri by transformation of the
mutants with genomic libraries derived from pathogenic strains.
In all, our exploration of various vaccination methods has generated some
interesting results, useful tools, and many new questions. These vaccines were examined
in the most applied setting, using immunity to pathogenic challenge as the endpoint. The
immune response of fish clearly is more complex than the simple mortality/survival
situation we have emphasized here. Methods do exist or are in development by many
researchers to evaluate antibody or humoral response as well as cell-mediated immunity,
including lymphocyte proliferation assays. These vaccines and vaccination methodsmay
be useful in further exploration and understanding of the fish immune system.185
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